Nivolumab vs Pembrolizumab
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: PD-1 · full Non-Small Cell Lung Cancer pipeline
Nivolumab
Marketed by Bristol-Myers Squibb and partners
NCT01673867 · Phase 3 · completed
This was a large randomized trial comparing nivolumab with active treatment, but it was open-label rather than double-blinded. The prespecified primary endpoint, overall survival, favored nivolumab and was statistically significant; however, the lack of blinding limits the strength of the evidence.
Next expected readout: November 2026 · NCT02955290 (registry estimate)
Reported efficacy
Overall Survival (OS) Time in Months for All Randomized Participants at Primary Endpoint (Randomization until 413 deaths, up to March 2015 (approximately 29 months)): Overall Survival (OS) Time in Months for All Randomized Participants at Primary Endpoint (Randomization until 413 deaths, up to March 2015 (approximately 29 months)): Nivolumab 12.19 Months (95% CI 9.66 to 14.98) vs Docetaxel 9.36 Months (95% CI 8.05 to 10.68) (met)
Result source: NCT01673867
Pembrolizumab
Marketed by Merck & Co.
NCT02142738 · Phase 3 · completed
The trial randomized 305 participants to pembrolizumab or active platinum-based chemotherapy, but treatment was open-label rather than double-blinded. Its radiographically assessed primary endpoint, 6-month progression-free survival, was met: 62.1% with pembrolizumab versus 50.3% with chemotherapy, with p<0.001 and a hazard ratio of 0.50 (95% CI 0.37–0.68).
Next expected readout: November 2026 · NCT06545331 (registry estimate)
Reported efficacy
Progression Free Survival (PFS) Rate at Month 6: Progression Free Survival (PFS) Rate at Month 6 (Month 6): Pembrolizumab 62.1% (95% CI 53.8 to 69.4) vs SOC Chemotherapy 50.3% (95% CI 41.9 to 58.2) (met)
Result source: NCT02142738
Results for Non-Small Cell Lung Cancer
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Nivolumab | Pembrolizumab |
|---|---|---|
| PFS, median | 12.1 vs 8.1+4 vs placeboNCT0311704922 other results
| 8.8 vs 4.9+3.9 vs placeboNCT0257868017 other results
|
| OS, median | 12.2 vs 9.4vs DocetaxelNCT0167386720 other results
| 15.9 vs 11.3+4.6 vs placeboNCT0277543515 other results
|
| ORR | 61.5% vs 50.5%+11 vs placeboNCT0311704919 other results
| 47.6% vs 18.9%+28.7 vs placeboNCT0257868014 other results
|
| Duration of response, median | 11 vs 7+4 vs placeboNCT0311704912 other results
| 11.2 vs 7.8+3.4 vs placeboNCT025786808 other results
|
PFS, median
- Nivolumab
- 12.1 vs 8.1+4 vs placeboNCT03117049
22 other results
- 5.1 vs 5.5 NCT02477826
- 4.2 vs 5.5 NCT02477826
- 4.9 vs 5.5 NCT02477826
- 5.5 vs 5.5 NCT02477826
- 8.3 vs 5.5 NCT02477826
- 5.8 vs 5.5 NCT02477826
- 16.7 vs 15.6 NCT04026412
- 5.6 vs 5.5 NCT02864251
- 1.5 vs 5.5 NCT02864251
- 4.2 vs 5.9 NCT02041533
- 2.3 vs 4.4 NCT01673867
- 3.5 vs 2.8 NCT01642004
- 16.8 vs 15.7 NCT04026412
- 17.4 vs 15.7 NCT04026412
- 16.8 vs 16.5 NCT04026412
- 17.7 vs 16.5 NCT04026412
- 4.2 vs 5.8 NCT02041533
- 3.7 NCT03090737
- 5.2 NCT02659059
- 10.8 NCT02659059
- 2 NCT05061017
- 2 NCT05061017
- Pembrolizumab
- 8.8 vs 4.9+3.9 vs placeboNCT02578680
17 other results
- 6.4 vs 4.8 NCT02775435
- 5.6 vs 5.5 NCT03515837
- 5.6 vs 4.2 NCT03976375
- 4 vs 2.5 NCT02864394
- 3.3 vs 3 NCT02864394
- 7.1 NCT03976323
- 8.3 NCT03976323
- 6.5 vs 6.4 NCT02220894
- 6.2 vs 6.7 NCT02220894
- 5.4 vs 6.6 NCT02220894
- 2.5 vs 2.4 NCT04165096
- 4.5 vs 5.2 NCT03971474
- 29 NCT03631784
- 45.3 NCT03631784
- 7 NCT05077709
- 2.6 NCT02955758
- 4.4 NCT02733159
OS, median
- Nivolumab
- 12.2 vs 9.4vs DocetaxelNCT01673867
20 other results
- 9.2 vs 6.0 NCT01642004
- 17.1 vs 14.9 NCT02477826
- 15.7 vs 14.9 NCT02477826
- 17.4 vs 14.9 NCT02477826
- 15.2 vs 14.9 NCT02477826
- 18.3 vs 14.9 NCT02477826
- 21.0 vs 14.9 NCT02477826
- 12.0 vs 9.6 NCT02613507
- 25.4 vs 24.7 NCT03117049
- 12.2 vs 9.5 NCT01673867
- 9.2 vs 6.0 NCT01642004
- 34.6 vs 39.8 NCT04026412
- 39.5 vs 39.8 NCT04026412
- 19.4 vs 15.9 NCT02864251
- 17.1 vs 15.9 NCT02864251
- 14.4 vs 13.2 NCT02041533
- 13.7 vs 13.8 NCT02041533
- 10.6 NCT03090737
- 20.8 NCT02659059
- 19.4 NCT02659059
- Pembrolizumab
- 15.9 vs 11.3+4.6 vs placeboNCT02775435
15 other results
- 15.9 vs 14.7 NCT03515837
- 20 vs 12.2 NCT02220894
- 18 vs 13 NCT02220894
- 16.4 vs 12.1 NCT02220894
- 11.3 vs 12 NCT03976375
- 12.3 vs 10.9 NCT02864394
- 12.9 vs 10.6 NCT02864394
- 20.7 NCT03976323
- 23 NCT03976323
- 14.5 vs 11.6 NCT03971474
- 35.6 NCT03631784
- 56.7 NCT03631784
- 9.8 NCT02733159
- 22.3 NCT05077709
- 13.3 NCT02955758
ORR
- Nivolumab
- 61.5% vs 50.5%+11 vs placeboNCT03117049
19 other results
- 19.5% vs 12.8% NCT01673867
- 20% vs 8.8% NCT01642004
- 36.4% vs 29.7% NCT02477826
- 27.5% vs 29.7% NCT02477826
- 26.2% vs 29.7% NCT02477826
- 37.9% vs 29.7% NCT02477826
- 52.3% vs 29.7% NCT02477826
- 38.1% vs 29.7% NCT02477826
- 67.6% vs 64.5% NCT04026412
- 72.2% vs 64.5% NCT04026412
- 61.3% vs 57.9% NCT04026412
- 63.1% vs 57.9% NCT04026412
- 26.1% vs 33.5% NCT02041533
- 50.6% vs 43% NCT04623775
- 14.5% NCT01721759
- 17.1% NCT03090737
- 15.4% NCT01721759
- 32.3% NCT02659059
- 47.2% NCT02659059
- Pembrolizumab
- 47.6% vs 18.9%+28.7 vs placeboNCT02578680
14 other results
- 57.9% vs 38.4% NCT02775435
- 29% vs 27.1% NCT03515837
- 39.1% vs 32% NCT02220894
- 33.2% vs 28.9% NCT02220894
- 27.2% vs 26.5% NCT02220894
- 44.8% vs 27.8% NCT02142738
- 22.7% vs 14.3% NCT03976375
- 22.7% vs 12.5% NCT03976375
- 28.1% vs 7.1% NCT02864394
- 20.7% vs 5.7% NCT02864394
- 5.4% vs 11.1% NCT04165096
- 71.4% NCT03631784
- 75.5% NCT03631784
- 22% vs 28% NCT03971474
Duration of response, median
- Nivolumab
- 11 vs 7+4 vs placeboNCT03117049
12 other results
- 25.8 vs 25.2 NCT04026412
- 31.8 vs 25.2 NCT04026412
- 22.8 vs 27.9 NCT04026412
- 33.2 vs 27.9 NCT04026412
- 17.1 vs 5.5 NCT01673867
- 24.5 vs 8.4 NCT01642004
- 6.7 vs 5.5 NCT02864251
- 50.0 vs 5.5 NCT02864251
- 12 NCT01721759
- 8.4 vs 7.1 NCT04623775
- 35.5 NCT03090737
- 16 NCT01721759
- Pembrolizumab
- 11.2 vs 7.8+3.4 vs placeboNCT02578680
8 other results
- 7.7 vs 4.8 NCT02775435
- 6.3 vs 5.6 NCT03515837
- 6.9 vs 6.8 NCT03976375
- 16.6 vs 6.4 NCT02864394
- 16.6 vs 6.3 NCT02864394
- 12.9 vs 5.6 NCT03971474
- 14.6 NCT02733159
- 12.5 NCT05077709
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
5 other shared endpoints and safety
Coverage. Nivolumab: 9 of 9 rows · Pembrolizumab: 9 of 9 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Nivolumab Rows use multiple source trials | Pembrolizumab Rows use multiple source trials |
|---|---|---|
| Disease Control responder rate · % of participants | 87.3% (n=275) vs 89.8% (n=275) placeboa,b,c,d NCT03117049 · Phase 3 · registry result, not featured evidence | 75% (n=69) vs 73% (n=67) Standard of Care (Inv. Choice)a,b,c,d NCT03971474 · Phase 2 · registry result, not featured evidence · combination |
| Duration of Response time to event · months No placebo or comparator arm | 35.45 months480mg Q4We,c,d NCT03090737 · Phase 2 · registry result, not featured evidence 3 other source trials16 months3 mg/kg NCT01721759 · Phase 2 · registry result, not featured evidence 12 months3 mg/kg NCT01721759 · Phase 2 · registry result, not featured evidence NA months3 mg/kg NCT01721759 · Phase 2 · registry result, not featured evidence | 12.5 monthsf,e,c,d NCT05077709 · Phase 2 · registry result, not featured evidence · combination show 1 more doseNA months NCT05077709 · Phase 2 · registry result, not featured evidence · combination |
| ORR responder rate · % of participants No placebo or comparator arm | 17.1% (n=129)480mg Q4Wb,c,d NCT03090737 · Phase 2 · registry result, not featured evidence 4 other source trials32.3% (n=288) NCT02659059 · Phase 2 · registry result, not featured evidence · combination 47.2% (n=36) NCT02659059 · Phase 2 · registry result, not featured evidence · combination 14.5% (n=117)3 mg/kg NCT01721759 · Phase 2 · registry result, not featured evidence 15.4% (n=117)3 mg/kg NCT01721759 · Phase 2 · registry result, not featured evidence | 71.4% (n=112)f,b,c,d NCT03631784 · Phase 2 · registry result, not featured evidence · combination show 1 more dose75.5% (n=102) NCT03631784 · Phase 2 · registry result, not featured evidence · combination |
| Overall Survival time to event · months No placebo or comparator arm | NA monthsf,g,b,d NCT03158129 · Phase 2 · registry result, not featured evidence show 3 more dosesNA months NCT03158129 · Phase 2 · registry result, not featured evidence · combination NA months NCT03158129 · Phase 2 · registry result, not featured evidence · combination NA months NCT03158129 · Phase 2 · registry result, not featured evidence · combination | 20.7 monthsf,g,b,d NCT03976323 · Phase 3 · registry result, not featured evidence · combination show 1 more dose23 months NCT03976323 · Phase 3 · registry result, not featured evidence · combination |
| PFS time to event · months No placebo or comparator arm | 2 monthsf,g,e,d NCT05061017 · Phase 2 · registry result, not featured evidence · combination show 1 more dose2 months NCT05061017 · Phase 2 · registry result, not featured evidence · combination | 7.1 monthsf,g,e,d NCT03976323 · Phase 3 · registry result, not featured evidence · combination show 1 more dose8.3 months NCT03976323 · Phase 3 · registry result, not featured evidence · combination |
| Dropout rate | —480 mgh NCT01673867 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 show 43 more results—3 mg/kg NCT01673867 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 1.7%Nivolumab NCT01673867 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 —480 mg NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 —3 mg/kg NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 3%Nivolumab NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 1.7%360 mg NCT02998528 · Phase 3 · combination 0.9%3 mg/kg + 1 mg/kg NCT02998528 · Phase 3 · combination 1.3%Part 1-Arm A: Nivolumab NCT02477826 · Phase 3 1.3%Part 1-Arm B: Nivo + Ipi NCT02477826 · Phase 3 · combination 1.1%Part 1-Arm D: Nivo + Ipi NCT02477826 · Phase 3 · combination 2.8%Part 1-Arm G: Nivo + Chemo NCT02477826 · Phase 3 · combination 0.5%Part 2 - Arm H: Nivolumab + Chemot NCT02477826 · Phase 3 · combination 0%Part 3 -Arm J: Nivolumab + Ipilimu NCT02477826 · Phase 3 · combination 66% NCT03444766 · Phase 4 · registry result, not featured evidence 64.1%Arm A:Nivo + CCRT/Nivo + Ipi NCT04026412 · Phase 3 · registry result, not featured evidence · combination 56.9%Arm B: Nivo + CCRT/Nivo NCT04026412 · Phase 3 · registry result, not featured evidence · combination 73.1% NCT03117049 · Phase 3 · registry result, not featured evidence 0.3% NCT02613507 · Phase 3 · registry result, not featured evidence 2.1%Arm A: Nivolumab Plus Platinum-dou NCT02864251 · Phase 3 · registry result, not featured evidence · combination 2.7%Arm B: Nivolumab Plus Ipilimumab NCT02864251 · Phase 3 · registry result, not featured evidence · combination 1.5% NCT02041533 · Phase 3 · registry result, not featured evidence 1.1%480 mg every 4 weeks NCT02713867 · Phase 3 · registry result, not featured evidence 1.6%240 mg every 2 weeks NCT02713867 · Phase 3 · registry result, not featured evidence —Cohort A: Nivolumab Monotherapy (P NCT02066636 · Phase 3 · registry result, not featured evidence · monotherapy —Cohort B: Nivolumab Monotherapy (P NCT02066636 · Phase 3 · registry result, not featured evidence · monotherapy n/a: no completion milestoneNivolumab Monotherapy (Not Randomi NCT02066636 · Phase 3 · registry result, not featured evidence · monotherapy —Nivolumab Monotherapy (Pre-Randomi NCT02066636 · Phase 3 · registry result, not featured evidence · monotherapy 88.2%HBV Participants NCT03195491 · Phase 3 · registry result, not featured evidence 90.6%Non-HBV Participants NCT03195491 · Phase 3 · registry result, not featured evidence 2.5%Part 1: Treatment A NCT04623775 · Phase 2 · registry result, not featured evidence · combination 0%Part 2: Treatment C NCT04623775 · Phase 2 · registry result, not featured evidence · combination 8.7%Arm A - Nivolumab NCT03158129 · Phase 2 · registry result, not featured evidence 23.8%Arm B - Nivolumab + Ipilimumab NCT03158129 · Phase 2 · registry result, not featured evidence · combination 0%Arm C - Nivolumab + Chemotherapy NCT03158129 · Phase 2 · registry result, not featured evidence · combination 9.1%Arm D - Nivolumab + Ipilimumab + C NCT03158129 · Phase 2 · registry result, not featured evidence · combination —Pixatimod (PG545) + Nivolumab + Cy NCT05061017 · Phase 2 · registry result, not featured evidence · combination 0%Pixatimod (PG545) + Nivolumab - Co NCT05061017 · Phase 2 · registry result, not featured evidence · combination 37.9% NCT02350764 · Phase 2 · registry result, not featured evidence —600 mg NCT05005273 · Phase 2 · registry result, not featured evidence · combination n/a: no completion milestone480mg Q4W NCT03090737 · Phase 2 · registry result, not featured evidence 87.2%Nivolumab+Ipilimumab NCT02659059 · Phase 2 · registry result, not featured evidence · combination 88.9%Nivolumab+Ipilimumab+Chemotherapy NCT02659059 · Phase 2 · registry result, not featured evidence · combination n/a: no completion milestone3 mg/kg NCT01721759 · Phase 2 · registry result, not featured evidence | n/a: no completion milestonePembrolizumabi NCT02142738 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 show 48 more results—Pembrolizumab First Course NCT02142738 · Phase 3 · Non-Small Cell Lung Cancer · phase 3 —Pembrolizumab Second Course NCT02142738 · Phase 3 · Non-Small Cell Lung Cancer · phase 3 54%10 mg/kg NCT01905657 · Phase 2/3 · monotherapy · Non-Small Cell Lung Cancer · phase 2/3 —10 mg/kg NCT01905657 · Phase 2/3 · monotherapy · Non-Small Cell Lung Cancer · phase 2/3 58.8%2 mg/kg NCT01905657 · Phase 2/3 · monotherapy · Non-Small Cell Lung Cancer · phase 2/3 —2 mg/kg NCT01905657 · Phase 2/3 · monotherapy · Non-Small Cell Lung Cancer · phase 2/3 n/a: no completion milestonePembrolizumab+Pemetrexed+Platinum NCT02578680 · Phase 3 · combination —Pembrolizumab+Pemetrexed+Platinum NCT02578680 · Phase 3 · combination n/a: no completion milestone NCT02775435 · Phase 3 · combination n/a: no completion milestone NCT02220894 · Phase 3 n/a: no completion milestone NCT02504372 · Phase 3 89.3%200 mg IV Q3W NCT03715205 · Phase 4 · registry result, not featured evidence —Pembrolizumab (First Course) + Ola NCT03976323 · Phase 3 · registry result, not featured evidence · combination —Pembrolizumab (First Course) + Pem NCT03976323 · Phase 3 · registry result, not featured evidence · combination —Pembrolizumab (Second Course) + Ol NCT03976323 · Phase 3 · registry result, not featured evidence · combination —Pembrolizumab (Second Course) + Pe NCT03976323 · Phase 3 · registry result, not featured evidence · combination —Pembrolizumab + Olaparib (Maintena NCT03976323 · Phase 3 · registry result, not featured evidence · combination —Pembrolizumab + Pemetrexed (Mainte NCT03976323 · Phase 3 · registry result, not featured evidence · combination 33%Pembrolizumab + Pemetrexed + Plati NCT03976323 · Phase 3 · registry result, not featured evidence · combination 0%Arm 1 Stereotactic Body Radiation NCT03867175 · Phase 3 · registry result, not featured evidence · combination 0%Arm 2 Pembrolizumab Only NCT03867175 · Phase 3 · registry result, not featured evidence —Pembrolizumab + Lenvatinib NCT03976375 · Phase 3 · registry result, not featured evidence · combination n/a: no completion milestonePembrolizumab+Lenvatinib NCT03976375 · Phase 3 · registry result, not featured evidence · combination n/a: no completion milestone NCT03515837 · Phase 3 · registry result, not featured evidence · combination n/a: no completion milestone NCT03875092 · Phase 3 · registry result, not featured evidence · combination n/a: no completion milestone NCT03950674 · Phase 3 · registry result, not featured evidence · combination n/a: no completion milestone NCT02864394 · Phase 3 · registry result, not featured evidence n/a: no completion milestone NCT03850444 · Phase 3 · registry result, not featured evidence 2.5% NCT03634241 · Phase 2 · registry result, not featured evidence 90.5%Arm B (SCCHN) NCT05077709 · Phase 2 · registry result, not featured evidence · combination 60%Arm C (mUBC) NCT05077709 · Phase 2 · registry result, not featured evidence · combination n/a: no completion milestone800 mg NCT03516981 · Phase 2 · registry result, not featured evidence · combination n/a: no completion milestone200 mg NCT03516981 · Phase 2 · registry result, not featured evidence · combination n/a: no completion milestonePembrolizumab + Lenvatinib NCT03516981 · Phase 2 · registry result, not featured evidence · combination n/a: no completion milestonePembrolizumab + Quavonlimab NCT03516981 · Phase 2 · registry result, not featured evidence · combination n/a: no completion milestone NCT04165096 · Phase 2 · registry result, not featured evidence · combination 0%Untreated Brain Metastases From Me NCT02681549 · Phase 2 · registry result, not featured evidence 50%Untreated Brain Metastases From NS NCT02681549 · Phase 2 · registry result, not featured evidence 80.7%1st Line NSCLC NCT03625323 · Phase 2 · registry result, not featured evidence · combination 89.2%2nd Line HNSCC NCT03625323 · Phase 2 · registry result, not featured evidence · combination 94.4%2nd Line NSCLC NCT03625323 · Phase 2 · registry result, not featured evidence · combination 0% NCT02955758 · Phase 2 · registry result, not featured evidence n/a: no completion milestonePembrolizumab + cCRT + Paclitaxel NCT03631784 · Phase 2 · registry result, not featured evidence · combination n/a: no completion milestonePembrolizumab + cCRT + Pemetrexed NCT03631784 · Phase 2 · registry result, not featured evidence · combination 3.2% NCT02733159 · Phase 2 · registry result, not featured evidence 87.7% NCT03004183 · Phase 2 · registry result, not featured evidence n/a: no completion milestone NCT03971474 · Phase 2 · registry result, not featured evidence · combination 86.4% NCT03087760 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | —480 mgh NCT01673867 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 show 43 more results—3 mg/kg NCT01673867 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 0.3%Nivolumab NCT01673867 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 —480 mg NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 —3 mg/kg NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 0.7%Nivolumab NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 0.6%360 mg NCT02998528 · Phase 3 · combination 0%3 mg/kg + 1 mg/kg NCT02998528 · Phase 3 · combination 0.3%Part 1-Arm A: Nivolumab NCT02477826 · Phase 3 0%Part 1-Arm B: Nivo + Ipi NCT02477826 · Phase 3 · combination 0.5%Part 1-Arm D: Nivo + Ipi NCT02477826 · Phase 3 · combination 0%Part 1-Arm G: Nivo + Chemo NCT02477826 · Phase 3 · combination 0.3%Part 2 - Arm H: Nivolumab + Chemot NCT02477826 · Phase 3 · combination 0%Part 3 -Arm J: Nivolumab + Ipilimu NCT02477826 · Phase 3 · combination 6% NCT03444766 · Phase 4 · registry result, not featured evidence —Arm A:Nivo + CCRT/Nivo + Ipi NCT04026412 · Phase 3 · registry result, not featured evidence · combination —Arm B: Nivo + CCRT/Nivo NCT04026412 · Phase 3 · registry result, not featured evidence · combination — NCT03117049 · Phase 3 · registry result, not featured evidence — NCT02613507 · Phase 3 · registry result, not featured evidence 0.7%Arm A: Nivolumab Plus Platinum-dou NCT02864251 · Phase 3 · registry result, not featured evidence · combination 0%Arm B: Nivolumab Plus Ipilimumab NCT02864251 · Phase 3 · registry result, not featured evidence · combination — NCT02041533 · Phase 3 · registry result, not featured evidence —480 mg every 4 weeks NCT02713867 · Phase 3 · registry result, not featured evidence —240 mg every 2 weeks NCT02713867 · Phase 3 · registry result, not featured evidence —Cohort A: Nivolumab Monotherapy (P NCT02066636 · Phase 3 · registry result, not featured evidence · monotherapy —Cohort B: Nivolumab Monotherapy (P NCT02066636 · Phase 3 · registry result, not featured evidence · monotherapy 3.8%Nivolumab Monotherapy (Not Randomi NCT02066636 · Phase 3 · registry result, not featured evidence · monotherapy —Nivolumab Monotherapy (Pre-Randomi NCT02066636 · Phase 3 · registry result, not featured evidence · monotherapy 11.8%HBV Participants NCT03195491 · Phase 3 · registry result, not featured evidence 5%Non-HBV Participants NCT03195491 · Phase 3 · registry result, not featured evidence —Part 1: Treatment A NCT04623775 · Phase 2 · registry result, not featured evidence · combination —Part 2: Treatment C NCT04623775 · Phase 2 · registry result, not featured evidence · combination 0%Arm A - Nivolumab NCT03158129 · Phase 2 · registry result, not featured evidence 4.8%Arm B - Nivolumab + Ipilimumab NCT03158129 · Phase 2 · registry result, not featured evidence · combination 0%Arm C - Nivolumab + Chemotherapy NCT03158129 · Phase 2 · registry result, not featured evidence · combination 0%Arm D - Nivolumab + Ipilimumab + C NCT03158129 · Phase 2 · registry result, not featured evidence · combination —Pixatimod (PG545) + Nivolumab + Cy NCT05061017 · Phase 2 · registry result, not featured evidence · combination —Pixatimod (PG545) + Nivolumab - Co NCT05061017 · Phase 2 · registry result, not featured evidence · combination 13.8% NCT02350764 · Phase 2 · registry result, not featured evidence —600 mg NCT05005273 · Phase 2 · registry result, not featured evidence · combination 5.4%480mg Q4W NCT03090737 · Phase 2 · registry result, not featured evidence 11.1%Nivolumab+Ipilimumab NCT02659059 · Phase 2 · registry result, not featured evidence · combination 11.1%Nivolumab+Ipilimumab+Chemotherapy NCT02659059 · Phase 2 · registry result, not featured evidence · combination 9.4%3 mg/kg NCT01721759 · Phase 2 · registry result, not featured evidence | 8.4%Pembrolizumabi NCT02142738 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 show 48 more results—Pembrolizumab First Course NCT02142738 · Phase 3 · Non-Small Cell Lung Cancer · phase 3 —Pembrolizumab Second Course NCT02142738 · Phase 3 · Non-Small Cell Lung Cancer · phase 3 4.9%10 mg/kg NCT01905657 · Phase 2/3 · monotherapy · Non-Small Cell Lung Cancer · phase 2/3 —10 mg/kg NCT01905657 · Phase 2/3 · monotherapy · Non-Small Cell Lung Cancer · phase 2/3 6.7%2 mg/kg NCT01905657 · Phase 2/3 · monotherapy · Non-Small Cell Lung Cancer · phase 2/3 —2 mg/kg NCT01905657 · Phase 2/3 · monotherapy · Non-Small Cell Lung Cancer · phase 2/3 —Pembrolizumab+Pemetrexed+Platinum NCT02578680 · Phase 3 · combination —Pembrolizumab+Pemetrexed+Platinum NCT02578680 · Phase 3 · combination 11.5% NCT02775435 · Phase 3 · combination 19.9% NCT02220894 · Phase 3 — NCT02504372 · Phase 3 —200 mg IV Q3W NCT03715205 · Phase 4 · registry result, not featured evidence —Pembrolizumab (First Course) + Ola NCT03976323 · Phase 3 · registry result, not featured evidence · combination —Pembrolizumab (First Course) + Pem NCT03976323 · Phase 3 · registry result, not featured evidence · combination —Pembrolizumab (Second Course) + Ol NCT03976323 · Phase 3 · registry result, not featured evidence · combination —Pembrolizumab (Second Course) + Pe NCT03976323 · Phase 3 · registry result, not featured evidence · combination —Pembrolizumab + Olaparib (Maintena NCT03976323 · Phase 3 · registry result, not featured evidence · combination —Pembrolizumab + Pemetrexed (Mainte NCT03976323 · Phase 3 · registry result, not featured evidence · combination —Pembrolizumab + Pemetrexed + Plati NCT03976323 · Phase 3 · registry result, not featured evidence · combination —Arm 1 Stereotactic Body Radiation NCT03867175 · Phase 3 · registry result, not featured evidence · combination —Arm 2 Pembrolizumab Only NCT03867175 · Phase 3 · registry result, not featured evidence —Pembrolizumab + Lenvatinib NCT03976375 · Phase 3 · registry result, not featured evidence · combination —Pembrolizumab+Lenvatinib NCT03976375 · Phase 3 · registry result, not featured evidence · combination — NCT03515837 · Phase 3 · registry result, not featured evidence · combination 3.1% NCT03875092 · Phase 3 · registry result, not featured evidence · combination — NCT03950674 · Phase 3 · registry result, not featured evidence · combination — NCT02864394 · Phase 3 · registry result, not featured evidence 12.5% NCT03850444 · Phase 3 · registry result, not featured evidence — NCT03634241 · Phase 2 · registry result, not featured evidence —Arm B (SCCHN) NCT05077709 · Phase 2 · registry result, not featured evidence · combination —Arm C (mUBC) NCT05077709 · Phase 2 · registry result, not featured evidence · combination —800 mg NCT03516981 · Phase 2 · registry result, not featured evidence · combination —200 mg NCT03516981 · Phase 2 · registry result, not featured evidence · combination —Pembrolizumab + Lenvatinib NCT03516981 · Phase 2 · registry result, not featured evidence · combination —Pembrolizumab + Quavonlimab NCT03516981 · Phase 2 · registry result, not featured evidence · combination — NCT04165096 · Phase 2 · registry result, not featured evidence · combination —Untreated Brain Metastases From Me NCT02681549 · Phase 2 · registry result, not featured evidence —Untreated Brain Metastases From NS NCT02681549 · Phase 2 · registry result, not featured evidence —1st Line NSCLC NCT03625323 · Phase 2 · registry result, not featured evidence · combination —2nd Line HNSCC NCT03625323 · Phase 2 · registry result, not featured evidence · combination —2nd Line NSCLC NCT03625323 · Phase 2 · registry result, not featured evidence · combination — NCT02955758 · Phase 2 · registry result, not featured evidence —Pembrolizumab + cCRT + Paclitaxel NCT03631784 · Phase 2 · registry result, not featured evidence · combination —Pembrolizumab + cCRT + Pemetrexed NCT03631784 · Phase 2 · registry result, not featured evidence · combination 1.6% NCT02733159 · Phase 2 · registry result, not featured evidence 12.3% NCT03004183 · Phase 2 · registry result, not featured evidence 11.6% NCT03971474 · Phase 2 · registry result, not featured evidence · combination — NCT03087760 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 33.3%480 mgh NCT01673867 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 show 43 more results59.9%3 mg/kg NCT01673867 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 —Nivolumab NCT01673867 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 16.7%480 mg NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 64.9%3 mg/kg NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 —Nivolumab NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 30.1%360 mg NCT02998528 · Phase 3 · combination 27%3 mg/kg + 1 mg/kg NCT02998528 · Phase 3 · combination 61.1%Part 1-Arm A: Nivolumab NCT02477826 · Phase 3 70.3%Part 1-Arm B: Nivo + Ipi NCT02477826 · Phase 3 · combination 69.2%Part 1-Arm D: Nivo + Ipi NCT02477826 · Phase 3 · combination 65.1%Part 1-Arm G: Nivo + Chemo NCT02477826 · Phase 3 · combination 64%Part 2 - Arm H: Nivolumab + Chemot NCT02477826 · Phase 3 · combination 61.9%Part 3 -Arm J: Nivolumab + Ipilimu NCT02477826 · Phase 3 · combination 30% NCT03444766 · Phase 4 · registry result, not featured evidence 63.8%Arm A:Nivo + CCRT/Nivo + Ipi NCT04026412 · Phase 3 · registry result, not featured evidence · combination 56.9%Arm B: Nivo + CCRT/Nivo NCT04026412 · Phase 3 · registry result, not featured evidence · combination 56.4% NCT03117049 · Phase 3 · registry result, not featured evidence 54.3% NCT02613507 · Phase 3 · registry result, not featured evidence 54.6%Arm A: Nivolumab Plus Platinum-dou NCT02864251 · Phase 3 · registry result, not featured evidence · combination 64.8%Arm B: Nivolumab Plus Ipilimumab NCT02864251 · Phase 3 · registry result, not featured evidence · combination 73% NCT02041533 · Phase 3 · registry result, not featured evidence 34.8%480 mg every 4 weeks NCT02713867 · Phase 3 · registry result, not featured evidence 39.4%240 mg every 2 weeks NCT02713867 · Phase 3 · registry result, not featured evidence 44.9%Cohort A: Nivolumab Monotherapy (P NCT02066636 · Phase 3 · registry result, not featured evidence · monotherapy 41.6%Cohort B: Nivolumab Monotherapy (P NCT02066636 · Phase 3 · registry result, not featured evidence · monotherapy —Nivolumab Monotherapy (Not Randomi NCT02066636 · Phase 3 · registry result, not featured evidence · monotherapy 60.9%Nivolumab Monotherapy (Pre-Randomi NCT02066636 · Phase 3 · registry result, not featured evidence · monotherapy 70.6%HBV Participants NCT03195491 · Phase 3 · registry result, not featured evidence 41%Non-HBV Participants NCT03195491 · Phase 3 · registry result, not featured evidence 59.7%Part 1: Treatment A NCT04623775 · Phase 2 · registry result, not featured evidence · combination 65.2%Part 2: Treatment C NCT04623775 · Phase 2 · registry result, not featured evidence · combination 17.4%Arm A - Nivolumab NCT03158129 · Phase 2 · registry result, not featured evidence 14.3%Arm B - Nivolumab + Ipilimumab NCT03158129 · Phase 2 · registry result, not featured evidence · combination 31.8%Arm C - Nivolumab + Chemotherapy NCT03158129 · Phase 2 · registry result, not featured evidence · combination 13.6%Arm D - Nivolumab + Ipilimumab + C NCT03158129 · Phase 2 · registry result, not featured evidence · combination 37.5%Pixatimod (PG545) + Nivolumab + Cy NCT05061017 · Phase 2 · registry result, not featured evidence · combination 20%Pixatimod (PG545) + Nivolumab - Co NCT05061017 · Phase 2 · registry result, not featured evidence · combination 75.9% NCT02350764 · Phase 2 · registry result, not featured evidence 100%600 mg NCT05005273 · Phase 2 · registry result, not featured evidence · combination 43.4%480mg Q4W NCT03090737 · Phase 2 · registry result, not featured evidence 59.4%Nivolumab+Ipilimumab NCT02659059 · Phase 2 · registry result, not featured evidence · combination 72.2%Nivolumab+Ipilimumab+Chemotherapy NCT02659059 · Phase 2 · registry result, not featured evidence · combination 75.2%3 mg/kg NCT01721759 · Phase 2 · registry result, not featured evidence | —Pembrolizumabi NCT02142738 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 show 48 more results51.3%Pembrolizumab First Course NCT02142738 · Phase 3 · Non-Small Cell Lung Cancer · phase 3 16.7%Pembrolizumab Second Course NCT02142738 · Phase 3 · Non-Small Cell Lung Cancer · phase 3 —10 mg/kg NCT01905657 · Phase 2/3 · monotherapy · Non-Small Cell Lung Cancer · phase 2/3 38.8%10 mg/kg NCT01905657 · Phase 2/3 · monotherapy · Non-Small Cell Lung Cancer · phase 2/3 —2 mg/kg NCT01905657 · Phase 2/3 · monotherapy · Non-Small Cell Lung Cancer · phase 2/3 36.6%2 mg/kg NCT01905657 · Phase 2/3 · monotherapy · Non-Small Cell Lung Cancer · phase 2/3 57.5%Pembrolizumab+Pemetrexed+Platinum NCT02578680 · Phase 3 · combination 22.2%Pembrolizumab+Pemetrexed+Platinum NCT02578680 · Phase 3 · combination 46% NCT02775435 · Phase 3 · combination 41% NCT02220894 · Phase 3 24.5% NCT02504372 · Phase 3 20.7%200 mg IV Q3W NCT03715205 · Phase 4 · registry result, not featured evidence 35%Pembrolizumab (First Course) + Ola NCT03976323 · Phase 3 · registry result, not featured evidence · combination 37.7%Pembrolizumab (First Course) + Pem NCT03976323 · Phase 3 · registry result, not featured evidence · combination 0%Pembrolizumab (Second Course) + Ol NCT03976323 · Phase 3 · registry result, not featured evidence · combination 7.7%Pembrolizumab (Second Course) + Pe NCT03976323 · Phase 3 · registry result, not featured evidence · combination —Pembrolizumab + Olaparib (Maintena NCT03976323 · Phase 3 · registry result, not featured evidence · combination —Pembrolizumab + Pemetrexed (Mainte NCT03976323 · Phase 3 · registry result, not featured evidence · combination 23.4%Pembrolizumab + Pemetrexed + Plati NCT03976323 · Phase 3 · registry result, not featured evidence · combination 50%Arm 1 Stereotactic Body Radiation NCT03867175 · Phase 3 · registry result, not featured evidence · combination 100%Arm 2 Pembrolizumab Only NCT03867175 · Phase 3 · registry result, not featured evidence 54.7%Pembrolizumab + Lenvatinib NCT03976375 · Phase 3 · registry result, not featured evidence · combination —Pembrolizumab+Lenvatinib NCT03976375 · Phase 3 · registry result, not featured evidence · combination 35.1% NCT03515837 · Phase 3 · registry result, not featured evidence · combination 53.8% NCT03875092 · Phase 3 · registry result, not featured evidence · combination 36% NCT03950674 · Phase 3 · registry result, not featured evidence · combination 36.2% NCT02864394 · Phase 3 · registry result, not featured evidence 32.8% NCT03850444 · Phase 3 · registry result, not featured evidence 7.5% NCT03634241 · Phase 2 · registry result, not featured evidence 9.5%Arm B (SCCHN) NCT05077709 · Phase 2 · registry result, not featured evidence · combination 20%Arm C (mUBC) NCT05077709 · Phase 2 · registry result, not featured evidence · combination 60.8%800 mg NCT03516981 · Phase 2 · registry result, not featured evidence · combination 46.7%200 mg NCT03516981 · Phase 2 · registry result, not featured evidence · combination 52.5%Pembrolizumab + Lenvatinib NCT03516981 · Phase 2 · registry result, not featured evidence · combination 47.6%Pembrolizumab + Quavonlimab NCT03516981 · Phase 2 · registry result, not featured evidence · combination 37.8% NCT04165096 · Phase 2 · registry result, not featured evidence · combination 10.8%Untreated Brain Metastases From Me NCT02681549 · Phase 2 · registry result, not featured evidence 20%Untreated Brain Metastases From NS NCT02681549 · Phase 2 · registry result, not featured evidence 47.4%1st Line NSCLC NCT03625323 · Phase 2 · registry result, not featured evidence · combination 54.1%2nd Line HNSCC NCT03625323 · Phase 2 · registry result, not featured evidence · combination 25%2nd Line NSCLC NCT03625323 · Phase 2 · registry result, not featured evidence · combination 36% NCT02955758 · Phase 2 · registry result, not featured evidence 58.9%Pembrolizumab + cCRT + Paclitaxel NCT03631784 · Phase 2 · registry result, not featured evidence · combination 45.1%Pembrolizumab + cCRT + Pemetrexed NCT03631784 · Phase 2 · registry result, not featured evidence · combination 85% NCT02733159 · Phase 2 · registry result, not featured evidence 51.8% NCT03004183 · Phase 2 · registry result, not featured evidence 40.6% NCT03971474 · Phase 2 · registry result, not featured evidence · combination 45.5% NCT03087760 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | 480 mgh cough 33.3% arthralgia 20% rash 20% NCT01673867 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 show 40 more results3 mg/kg fatigue 33.4% decreased appetite 31.7% cough 28.9% NCT01673867 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 480 mg nausea 33.3% vomiting 33.3% abdominal pain 16.7% NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 3 mg/kg dyspnoea 35.9% cough 34.4% fatigue 32.1% NCT01642004 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 anaemia 50% hyponatraemia 37.3% aspartate aminotransferase increased 36.5% NCT02477826 · Phase 3 · combination anaemia 44% nausea 34.8% constipation 29.1% NCT04026412 · Phase 3 · registry result, not featured evidence · combination anaemia 41.5% nausea 32.7% cough 26.1% NCT04026412 · Phase 3 · registry result, not featured evidence · combination constipation 54.9% (placebo 48.7%) alopecia 52.4% (placebo 54.5%) peripheral sensory neuropathy 44.3% (placebo 42.2%) NCT03117049 · Phase 3 · registry result, not featured evidence anaemia 34.7% decreased appetite 31.5% fatigue 31.2% NCT02613507 · Phase 3 · registry result, not featured evidence anaemia 46.8% nausea 44.7% constipation 36.9% NCT02864251 · Phase 3 · registry result, not featured evidence · combination constipation 29.6% pruritus 25.4% diarrhoea 23.9% NCT02864251 · Phase 3 · registry result, not featured evidence · combination fatigue 40.4% decreased appetite 34.1% nausea 32.2% NCT02041533 · Phase 3 · registry result, not featured evidence 480 mg every 4 weeks diarrhoea 16.9% pruritus 16.9% fatigue 15.7% NCT02713867 · Phase 3 · registry result, not featured evidence 240 mg every 2 weeks pruritus 23.3% diarrhoea 22.8% fatigue 22.2% NCT02713867 · Phase 3 · registry result, not featured evidence diarrhoea 28.3% arthralgia 23.6% upper respiratory tract infection 22% NCT02066636 · Phase 3 · registry result, not featured evidence · monotherapy cough 17.6% weight decreased 16% arthralgia 14.4% NCT02066636 · Phase 3 · registry result, not featured evidence · monotherapy fatigue 36.1% dyspnoea 23.7% nausea 23.2% NCT02066636 · Phase 3 · registry result, not featured evidence · monotherapy anaemia 41.2% cough 41.2% hyponatraemia 35.3% NCT03195491 · Phase 3 · registry result, not featured evidence anaemia 40.5% decreased appetite 24.5% cough 22.2% NCT03195491 · Phase 3 · registry result, not featured evidence anaemia 66.2% fatigue 42.9% nausea 42.9% NCT04623775 · Phase 2 · registry result, not featured evidence · combination anaemia 69% nausea 34.8% thrombocytopenia 29.7% NCT04623775 · Phase 2 · registry result, not featured evidence · combination fatigue 34.8% anemia 30.4% rash acneiform 26.1% NCT03158129 · Phase 2 · registry result, not featured evidence rash acneiform 61.9% cough 38.1% fatigue 38.1% NCT03158129 · Phase 2 · registry result, not featured evidence · combination nausea 81.8% fatigue 72.7% anemia 54.5% NCT03158129 · Phase 2 · registry result, not featured evidence · combination anemia 50% diarrhea 40.9% nausea 40.9% NCT03158129 · Phase 2 · registry result, not featured evidence · combination anemia 62.5% fatigue 50% hyponatremia 50% NCT05061017 · Phase 2 · registry result, not featured evidence · combination activated partial thromboplastin time prolonged 80% hypertriglyceridemia 60% hyponatremia 60% NCT05061017 · Phase 2 · registry result, not featured evidence · combination hyperglycemia 100% hypoalbuminemia 93.1% anemia 75.9% NCT02350764 · Phase 2 · registry result, not featured evidence 600 mg blood alkaline phosphatase increased 100% blood lactate dehydrogenase increased 100% bronchitis 100% NCT05005273 · Phase 2 · registry result, not featured evidence · combination 480mg Q4W anaemia 28.7% blood alkaline phosphatase increased 24.8% rash 20.2% NCT03090737 · Phase 2 · registry result, not featured evidence fatigue 55.2% diarrhoea 38.5% nausea 38.2% NCT02659059 · Phase 2 · registry result, not featured evidence · combination fatigue 55.6% pruritus 47.2% nausea 44.4% NCT02659059 · Phase 2 · registry result, not featured evidence · combination 3 mg/kg fatigue 53% decreased appetite 39.3% dyspnoea 38.5% NCT01721759 · Phase 2 · registry result, not featured evidence | i diarrhoea 26.6% dyspnoea 26.6% fatigue 24% NCT02142738 · Phase 3 · Non-Small Cell Lung Cancer · phase 3 show 42 more resultsupper respiratory tract infection 33.3% constipation 16.7% decreased appetite 16.7% NCT02142738 · Phase 3 · Non-Small Cell Lung Cancer · phase 3 10 mg/kg fatigue 25.7% decreased appetite 23.3% dyspnoea 23% NCT01905657 · Phase 2/3 · monotherapy · Non-Small Cell Lung Cancer · phase 2/3 2 mg/kg decreased appetite 30.7% fatigue 30.1% nausea 25.7% NCT01905657 · Phase 2/3 · monotherapy · Non-Small Cell Lung Cancer · phase 2/3 nausea 57.3% (placebo 51%) anaemia 45.9% (placebo 45%) fatigue 42.7% (placebo 39.6%) NCT02578680 · Phase 3 · combination abdominal pain 22.2% (placebo 6.4%) cough 22.2% (placebo 30.7%) diarrhoea 22.2% (placebo 20.3%) NCT02578680 · Phase 3 · combination anaemia 53.2% (placebo 49.6%) alopecia 46% (placebo 37.5%) nausea 36.3% (placebo 32.1%) NCT02775435 · Phase 3 · combination weight increased 22.8% (placebo 28.9%) pruritus 21.6% (placebo 12.7%) hypothyroidism 20.7% (placebo 4.6%) NCT02504372 · Phase 3 200 mg IV Q3W hypothyroidism 17.3% anaemia 12.7% constipation 11.3% NCT03715205 · Phase 4 · registry result, not featured evidence anaemia 36.2% nausea 24% fatigue 17.2% NCT03976323 · Phase 3 · registry result, not featured evidence · combination anaemia 37.7% nausea 19% aspartate aminotransferase increased 16.6% NCT03976323 · Phase 3 · registry result, not featured evidence · combination anaemia 14.3% covid-19 14.3% headache 14.3% NCT03976323 · Phase 3 · registry result, not featured evidence · combination anaemia 15.4% cough 15.4% productive cough 15.4% NCT03976323 · Phase 3 · registry result, not featured evidence · combination anaemia 38.4% nausea 30.9% neutropenia 23.4% NCT03976323 · Phase 3 · registry result, not featured evidence · combination anemia 75% cough 75% abdominal pain 50% NCT03867175 · Phase 3 · registry result, not featured evidence · combination alanine aminotransferase increased 100% alkaline phosphatase increased 100% aspartate aminotransferase increased 100% NCT03867175 · Phase 3 · registry result, not featured evidence hypertension 41.4% diarrhoea 40.9% hypothyroidism 35.4% NCT03976375 · Phase 3 · registry result, not featured evidence · combination anaemia 40.4% (placebo 44.7%) nausea 39.2% (placebo 43.5%) neutrophil count decreased 36.7% (placebo 45.9%) NCT03515837 · Phase 3 · registry result, not featured evidence · combination alopecia 78.5% white blood cell count decreased 78.5% neutrophil count decreased 76.9% NCT03875092 · Phase 3 · registry result, not featured evidence · combination nausea 72% (placebo 53.3%) constipation 64% (placebo 73.3%) decreased appetite 56% (placebo 60%) NCT03950674 · Phase 3 · registry result, not featured evidence · combination anaemia 33.3% aspartate aminotransferase increased 21.6% cough 21.6% NCT02864394 · Phase 3 · registry result, not featured evidence fatigue 45% investigations 25% alanine aminotransferase increased 20% NCT03634241 · Phase 2 · registry result, not featured evidence anaemia 42.9% diarrhoea 33.3% fatigue 28.6% NCT05077709 · Phase 2 · registry result, not featured evidence · combination asthenia 40% blood creatinine increased 40% blood urea increased 40% NCT05077709 · Phase 2 · registry result, not featured evidence · combination 800 mg diarrhoea 29.4% fatigue 21.6% alanine aminotransferase increased 19.6% NCT03516981 · Phase 2 · registry result, not featured evidence · combination 200 mg pyrexia 23.3% constipation 20% decreased appetite 20% NCT03516981 · Phase 2 · registry result, not featured evidence · combination hypertension 52.5% diarrhoea 45% hypothyroidism 36.3% NCT03516981 · Phase 2 · registry result, not featured evidence · combination pruritus 29.3% cough 22% fatigue 20.7% NCT03516981 · Phase 2 · registry result, not featured evidence · combination fatigue 29.7% pruritus 29.7% nausea 24.3% NCT04165096 · Phase 2 · registry result, not featured evidence · combination anorexia 40% gastrointestinal disorders - other, specify 40% hypertension 40% NCT02681549 · Phase 2 · registry result, not featured evidence asthenia 34.2% dyspnoea 34.2% cough 29.8% NCT03625323 · Phase 2 · registry result, not featured evidence · combination asthenia 21.6% anaemia 18.9% cough 18.9% NCT03625323 · Phase 2 · registry result, not featured evidence · combination decreased appetite 36.1% dyspnoea 36.1% cough 30.6% NCT03625323 · Phase 2 · registry result, not featured evidence · combination nausea 24% decreased appetite 20% worsening abdominal pain 20% NCT02955758 · Phase 2 · registry result, not featured evidence anaemia 39.3% fatigue 34.8% alopecia 31.3% NCT03631784 · Phase 2 · registry result, not featured evidence · combination nausea 52% asthenia 40.2% anaemia 32.4% NCT03631784 · Phase 2 · registry result, not featured evidence · combination fatigue 21.4% nausea 12.5% back pain 10.7% NCT03004183 · Phase 2 · registry result, not featured evidence fatigue 56.5% hypoalbuminemia 44.9% hyponatremia 39.1% NCT03971474 · Phase 2 · registry result, not featured evidence · combination esophagitis 36.4% fatigue 36.4% hypothyroidism 22.7% NCT03087760 · Phase 2 · registry result, not featured evidence |
Notes
- aTrial phases differ: Phase 2 versus Phase 3.
- bPopulation comparability has not been reviewed for both studies.
- cTreatment context has not been resolved for both arms.
- dThe assessment timepoint is not available for both results.
- ePopulation context differs: registered conditions differ.
- fThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- gTrial phases differ: Phase 3 versus Phase 2.
- hPopulation comparability has not been reviewed for 38 of these studies.
- iPopulation comparability has not been reviewed for 42 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Nivolumab
show 5 more results
show 2 more results
show 11 more results
show 8 more results
show 1 more result
show 2 more results
show 5 more results
show 1 more result
+ 32 further endpoints in the CSV export.
Pembrolizumab
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 3 more results
show 1 more result
show 1 more result
show 3 more results
show 3 more results
show 1 more result
+ 39 further endpoints in the CSV export.
Urothelial Carcinoma
Shared mechanism: PD-1 · full Urothelial Carcinoma pipeline
Nivolumab
Marketed by Bristol-Myers Squibb and partners
NCT03036098 · Phase 3 · completed
This was a large randomized trial against standard chemotherapy, but it was open-label. Three of the four primary comparisons were statistically significant, while overall survival in PD-L1 positive patients given nivolumab plus ipilimumab has no posted significance test, so the overall result is mixed.
Next expected readout: December 2026 · NCT06682728 (registry estimate)
Reported efficacy
Overall Survival (OS) in Cisplatin-ineligible Randomized Participants for Primary Study (From the date of randomization to the date of death from any cause, or data cut-off date, whichever occurred first (up to approximately 89 months)); Overall Survival (OS) in Programmed Death-Ligand 1 (PD-L1) Positive (≥ 1%) Randomized Participants by Immunohistochemistry (IHC) for Primary Study (From the date of randomization to the date of death from any cause, or data cut-off date, whichever occurred first (up to approximately 89 months)); Progression-Free Survival (PFS) by Blinded Independent Central Review (BICR) [Using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1] in Cisplatin-eligible Participants for Sub-study (From the date of randomization to the date of first documented disease progression or death due to any cause, whichever occurs first (up to approximately 89 months)); Overall Survival (OS) in Cisplatin-eligible Participants for Sub-study (From the date of randomization to the date of death from any cause, or data cut-off date, whichever occurred first (up to approximately 89 months)): Sub-study (cisplatin-eligible), nivolumab + gemcitabine-cisplatin vs gemcitabine-cisplatin: PFS HR 0.72 (95% CI 0.59 to 0.88), p=0.0018; OS median 21.7 vs 18.9 months, HR 0.78 (95% CI 0.63 to 0.96), p=0.0171. Primary study, nivolumab + ipilimumab vs chemotherapy: OS in PD-L1 >=1% 16.3 vs 14.4 months, primary not met per BMS; OS in cisplatin-ineligible 19.1 vs 13.2 months, HR 0.79 (95% CI 0.64 to 0.97), posted p=0.0032 (CT.gov posted results). (mixed)
Result source: NCT03036098
Pembrolizumab
Marketed by Merck & Co.
NCT04223856 · Phase 3 · active, not recruiting
The trial was randomized and actively controlled, with 442 participants assigned to enfortumab vedotin plus pembrolizumab and 444 to chemotherapy, but treatment assignment was not blinded. Both primary endpoints were met in favor of the combination: independently reviewed progression-free survival and overall survival were significantly improved, but the open-label design and lack of a reported power calculation in the provided record support a moderate grade rather than a strong one.
Next expected readout: December 2026 · NCT04164082 (registry estimate)
Reported efficacy
Pembro Combo vs Chemo: Progression-free Survival (PFS) Using Response Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR) (Up to approximately 42 months); Pembro Combo vs Chemo: Overall Survival (OS) (Up to approximately 42 months); Pembro vs Chemo: OS in Participants With Programmed Cell Death Ligand 1 (PD-L1) Combined Positive Score (CPS) ≥10% (Up to approximately 42 months); Pembro vs Chemo: OS (Up to approximately 42 months): Pembrolizumab plus chemotherapy vs chemotherapy: PFS median 8.3 vs 7.1 months (HR 0.78, 95% CI 0.65 to 0.93; p=0.0033 against a boundary of 0.0019); OS median 17.0 vs 14.3 months (HR 0.86, 95% CI 0.72 to 1.02; p=0.0407 against a boundary of 0.0142). Pembrolizumab monotherapy OS comparisons were exploratory after the hierarchy stopped (KEYNOTE-361, Lancet Oncol 2021). (missed)
Result source: NCT02853305
Results for Urothelial Carcinoma
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
Coverage. Nivolumab: 3 of 4 rows · Pembrolizumab: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Nivolumab | Pembrolizumab |
|---|---|---|
| Dropout rate | 0%0.009 mg/kg q3w + 360 mg q3wa NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination show 9 more results0%0.006 mg/kg q3w + 240 mg q2w NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 33.3%0.006 mg/kg q2w + 240 mg q2w NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 20%0.006 mg/kg q3w + 360 mg q3w NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 17.2%0.006 mg/kg q3w + 360 mg q3w NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 0%0.003 mg/kg q2w + 240 mg q2w NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 0%Part 3 Schedule Finding (Schedule NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 0%Part 3 Schedule Finding (Schedule NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 0%Part 3 Schedule Finding (Schedule NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 10.5%Part 4 Dose Expansion of NKTR-214 NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination | 25%Experimental: Expansion 1a NCT04383938 · Phase 1/2 · registry result, not featured evidence · combination show 15 more results0%Experimental: Expansion 2 NCT04383938 · Phase 1/2 · registry result, not featured evidence · combination 4.8%Experimental: Expansion 3 NCT04383938 · Phase 1/2 · registry result, not featured evidence · combination 0%Experimental: Safety Lead In NCT04383938 · Phase 1/2 · registry result, not featured evidence · combination n/a: no completion milestone300 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination n/a: no completion milestone100 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination n/a: no completion milestone100 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination n/a: no completion milestone50 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination n/a: no completion milestone25 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination n/a: no completion milestone100 mg NCT02903914 · Phase 1 · registry result, not featured evidence · combination n/a: no completion milestone75 mg NCT02903914 · Phase 1 · registry result, not featured evidence · combination —50 mg NCT02903914 · Phase 1 · registry result, not featured evidence · combination n/a: no completion milestone50 mg NCT02903914 · Phase 1 · registry result, not featured evidence · combination n/a: no completion milestone50 mg NCT02903914 · Phase 1 · registry result, not featured evidence · combination 57.1%20 mg/kg NCT03236935 · Phase 1 · registry result, not featured evidence —12.5 mg/kg NCT03236935 · Phase 1 · registry result, not featured evidence |
| Discontinued due to AEs | —0.009 mg/kg q3w + 360 mg q3wa NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination show 9 more results—0.006 mg/kg q3w + 240 mg q2w NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination —0.006 mg/kg q2w + 240 mg q2w NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination —0.006 mg/kg q3w + 360 mg q3w NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination —0.006 mg/kg q3w + 360 mg q3w NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination —0.003 mg/kg q2w + 240 mg q2w NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination —Part 3 Schedule Finding (Schedule NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination —Part 3 Schedule Finding (Schedule NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination —Part 3 Schedule Finding (Schedule NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination —Part 4 Dose Expansion of NKTR-214 NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination | —Experimental: Expansion 1a NCT04383938 · Phase 1/2 · registry result, not featured evidence · combination show 15 more results—Experimental: Expansion 2 NCT04383938 · Phase 1/2 · registry result, not featured evidence · combination —Experimental: Expansion 3 NCT04383938 · Phase 1/2 · registry result, not featured evidence · combination —Experimental: Safety Lead In NCT04383938 · Phase 1/2 · registry result, not featured evidence · combination —300 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination —100 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination —100 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination —50 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination —25 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination 1.6%100 mg NCT02903914 · Phase 1 · registry result, not featured evidence · combination 0%75 mg NCT02903914 · Phase 1 · registry result, not featured evidence · combination —50 mg NCT02903914 · Phase 1 · registry result, not featured evidence · combination 0%50 mg NCT02903914 · Phase 1 · registry result, not featured evidence · combination 0%50 mg NCT02903914 · Phase 1 · registry result, not featured evidence · combination —20 mg/kg NCT03236935 · Phase 1 · registry result, not featured evidence —12.5 mg/kg NCT03236935 · Phase 1 · registry result, not featured evidence |
| Serious AEs | 66.7%0.009 mg/kg q3w + 360 mg q3wa NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination show 9 more results50%0.006 mg/kg q3w + 240 mg q2w NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 0%0.006 mg/kg q2w + 240 mg q2w NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 36%0.006 mg/kg q3w + 360 mg q3w NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 44.7%0.006 mg/kg q3w + 360 mg q3w NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 33.3%0.003 mg/kg q2w + 240 mg q2w NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 60%Part 3 Schedule Finding (Schedule NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 62.5%Part 3 Schedule Finding (Schedule NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 33.3%Part 3 Schedule Finding (Schedule NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 42.1%Part 4 Dose Expansion of NKTR-214 NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination | 66.7%Experimental: Expansion 1a NCT04383938 · Phase 1/2 · registry result, not featured evidence · combination show 15 more results60%Experimental: Expansion 2 NCT04383938 · Phase 1/2 · registry result, not featured evidence · combination 35%Experimental: Expansion 3 NCT04383938 · Phase 1/2 · registry result, not featured evidence · combination 16.7%Experimental: Safety Lead In NCT04383938 · Phase 1/2 · registry result, not featured evidence · combination 45%300 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination 50%100 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination 51%100 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination 40%50 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination 0%25 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination 38.2%100 mg NCT02903914 · Phase 1 · registry result, not featured evidence · combination 35.7%75 mg NCT02903914 · Phase 1 · registry result, not featured evidence · combination 37.5%50 mg NCT02903914 · Phase 1 · registry result, not featured evidence · combination —50 mg NCT02903914 · Phase 1 · registry result, not featured evidence · combination —50 mg NCT02903914 · Phase 1 · registry result, not featured evidence · combination 14.3%20 mg/kg NCT03236935 · Phase 1 · registry result, not featured evidence —12.5 mg/kg NCT03236935 · Phase 1 · registry result, not featured evidence |
| Most frequent reported AEs | 0.009 mg/kg q3w + 360 mg q3wa pyrexia 100% rash 100% chills 66.7% NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination show 9 more results0.006 mg/kg q3w + 240 mg q2w arthralgia 100% fatigue 100% headache 100% NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 0.006 mg/kg q2w + 240 mg q2w chills 100% pyrexia 100% back pain 66.7% NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 0.006 mg/kg q3w + 360 mg q3w fatigue 76% chills 64% cough 60% NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 0.006 mg/kg q3w + 360 mg q3w fatigue 50.6% pyrexia 47.9% nausea 40.1% NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 0.003 mg/kg q2w + 240 mg q2w chills 100% nasal congestion 100% arthralgia 66.7% NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination fatigue 90% diarrhoea 80% nausea 80% NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination diarrhoea 75% influenza like illness 75% pruritus 75% NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination decreased appetite 100% fatigue 100% influenza like illness 100% NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination fatigue 78.9% influenza like illness 68.4% nausea 57.9% NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination | a decreased appetite 50% alanine aminotransferase increased 33.3% diarrhea 33.3% NCT04383938 · Phase 1/2 · registry result, not featured evidence · combination show 12 more resultsanaemia 80% dizziness 80% fatigue 80% NCT04383938 · Phase 1/2 · registry result, not featured evidence · combination dizziness 45% decreased appetite 30% dyspnea 30% NCT04383938 · Phase 1/2 · registry result, not featured evidence · combination abdominal pain 66.7% blood alkaline phosphatase increased 66.7% fatigue 66.7% NCT04383938 · Phase 1/2 · registry result, not featured evidence · combination 300 mg BID + 200 mg Q3W fatigue 65% nausea 55% vomiting 50% NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination 100 mg BID + 200 mg Q3W fatigue 50% back pain 38.9% diarrhoea 38.9% NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination 100 mg BID + 200 mg Q3W fatigue 48.4% nausea 30.1% cough 26.2% NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination 50 mg BID + 200 mg Q3W fatigue 65% arthralgia 45% nausea 45% NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination 25 mg BID + 200 mg Q3W arthralgia 100% constipation 75% cough 75% NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination 100 mg diarrhoea 25.2% constipation 23.6% fatigue 23.6% NCT02903914 · Phase 1 · registry result, not featured evidence · combination 75 mg aspartate aminotransferase increased 21.4% back pain 21.4% fatigue 21.4% NCT02903914 · Phase 1 · registry result, not featured evidence · combination 50 mg fatigue 37.5% diarrhoea 25% decreased appetite 18.8% NCT02903914 · Phase 1 · registry result, not featured evidence · combination 20 mg/kg hypertension 28.6% anemia 14.3% arthralgia 14.3% NCT03236935 · Phase 1 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Nivolumab
show 1 more result
Pembrolizumab
show 3 more results
show 3 more results
show 3 more results
show 2 more results
show 3 more results
Hepatocellular Carcinoma
Shared mechanism: PD-1 · full Hepatocellular Carcinoma pipeline
Nivolumab
Marketed by Bristol-Myers Squibb and partners
NCT04039607 · Phase 3 · completed
This was a large randomized phase 3 trial against an active comparator, and its primary endpoint, overall survival, was met with statistical significance. Patients and doctors knew which treatment was given, but survival is an objective outcome that this knowledge cannot change; an open-label design still keeps the evidence below the top level.
Next expected readout: December 2026 · NCT07176650 (registry estimate)
No aligned efficacy figure on record for this race.
Pembrolizumab
Marketed by Merck & Co.
NCT03062358 · Phase 3 · completed
Patients were randomly assigned 2:1 to pembrolizumab or placebo, with patients and investigators blinded. Overall survival, the primary endpoint, was significantly longer with pembrolizumab (hazard ratio 0.79, 95% CI 0.63 to 0.99, one-sided p=0.0180). The protocol reports a power calculation for overall survival and 453 patients were enrolled against a planned 450.
Next expected readout: December 2026 · NCT03419481 (registry estimate)
Reported efficacy
Overall Survival (OS) (Up to approximately 4 years): Overall Survival (OS) (Up to approximately 4 years): Pembrolizumab + BSC 14.6 Months (95% CI 12.6 to 18) | Placebo + BSC 13 Months (95% CI 10.5 to 15.1) (met)
Result source: NCT03062358
Results for Hepatocellular Carcinoma
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
Coverage. Nivolumab: 4 of 4 rows · Pembrolizumab: 2 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Nivolumab | Pembrolizumab |
|---|---|---|
| Dropout rate | 0%Galunisertib + Nivolumab (Cohort 1a NCT02423343 · Phase 1/2 · registry result, not featured evidence · combination show 5 more results20%Galunisertib + Nivolumab (Cohort 2 NCT02423343 · Phase 1/2 · registry result, not featured evidence · combination 0%Galunisertib + Nivolumab (Cohort 3 NCT02423343 · Phase 1/2 · registry result, not featured evidence · combination 0%Galunisertib + Nivolumab (Cohort 4 NCT02423343 · Phase 1/2 · registry result, not featured evidence · combination —Galunisertib + Nivolumab (HCC) Pha NCT02423343 · Phase 1/2 · registry result, not featured evidence · combination —Galunisertib + Nivolumab (NSCLC) P NCT02423343 · Phase 1/2 · registry result, not featured evidence · combination | n/a: no completion milestone300 mg BID + 200 mg Q3Wa NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination show 4 more resultsn/a: no completion milestone100 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination n/a: no completion milestone100 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination n/a: no completion milestone50 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination n/a: no completion milestone25 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination |
| Discontinued due to AEs | 0%Galunisertib + Nivolumab (Cohort 1a NCT02423343 · Phase 1/2 · registry result, not featured evidence · combination show 5 more results0%Galunisertib + Nivolumab (Cohort 2 NCT02423343 · Phase 1/2 · registry result, not featured evidence · combination 0%Galunisertib + Nivolumab (Cohort 3 NCT02423343 · Phase 1/2 · registry result, not featured evidence · combination 0%Galunisertib + Nivolumab (Cohort 4 NCT02423343 · Phase 1/2 · registry result, not featured evidence · combination —Galunisertib + Nivolumab (HCC) Pha NCT02423343 · Phase 1/2 · registry result, not featured evidence · combination —Galunisertib + Nivolumab (NSCLC) P NCT02423343 · Phase 1/2 · registry result, not featured evidence · combination | —300 mg BID + 200 mg Q3Wa NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination show 4 more results—100 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination —100 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination —50 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination —25 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination |
| Serious AEs | 33.3%Galunisertib + Nivolumab (Cohort 1a NCT02423343 · Phase 1/2 · registry result, not featured evidence · combination show 5 more results40%Galunisertib + Nivolumab (Cohort 2 NCT02423343 · Phase 1/2 · registry result, not featured evidence · combination 33.3%Galunisertib + Nivolumab (Cohort 3 NCT02423343 · Phase 1/2 · registry result, not featured evidence · combination 50%Galunisertib + Nivolumab (Cohort 4 NCT02423343 · Phase 1/2 · registry result, not featured evidence · combination 0%Galunisertib + Nivolumab (HCC) Pha NCT02423343 · Phase 1/2 · registry result, not featured evidence · combination 52%Galunisertib + Nivolumab (NSCLC) P NCT02423343 · Phase 1/2 · registry result, not featured evidence · combination | 45%300 mg BID + 200 mg Q3Wa NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination show 4 more results50%100 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination 51%100 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination 40%50 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination 0%25 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination |
| Most frequent reported AEs | a vomiting 66.7% dehydration 33.3% depression 33.3% NCT02423343 · Phase 1/2 · registry result, not featured evidence · combination show 5 more resultsdiarrhoea 40% pulmonary embolism 40% abdominal pain 20% NCT02423343 · Phase 1/2 · registry result, not featured evidence · combination dyspnoea 33.3% headache 33.3% hyperglycaemia 33.3% NCT02423343 · Phase 1/2 · registry result, not featured evidence · combination amylase increased 75% aspartate aminotransferase increased 50% blood alkaline phosphatase increased 50% NCT02423343 · Phase 1/2 · registry result, not featured evidence · combination gingivitis 100% rhinorrhoea 100% abdominal distension 0% NCT02423343 · Phase 1/2 · registry result, not featured evidence · combination pruritus 36% decreased appetite 28% diarrhoea 28% NCT02423343 · Phase 1/2 · registry result, not featured evidence · combination | 300 mg BID + 200 mg Q3Wa fatigue 65% nausea 55% vomiting 50% NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination show 4 more results100 mg BID + 200 mg Q3W fatigue 50% back pain 38.9% diarrhoea 38.9% NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination 100 mg BID + 200 mg Q3W fatigue 48.4% nausea 30.1% cough 26.2% NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination 50 mg BID + 200 mg Q3W fatigue 65% arthralgia 45% nausea 45% NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination 25 mg BID + 200 mg Q3W arthralgia 100% constipation 75% cough 75% NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Nivolumab
show 1 more result
show 1 more result
show 1 more result
Gastric Cancer
Shared mechanism: PD-1 · full Gastric Cancer pipeline
Nivolumab
Marketed by Bristol-Myers Squibb and partners
NCT02872116 · Phase 3 · completed
The trial randomized 2,031 participants to nivolumab plus chemotherapy or active chemotherapy control, but treatment assignment was open-label rather than double-blinded. Its clinical primary endpoints were met, with statistically significant improvements in both overall survival and progression-free survival; however, the available record does not report a power calculation, so the evidence is graded moderate.
Next expected readout: December 2026 · NCT04900818 (registry estimate)
No aligned efficacy figure on record for this race.
Pembrolizumab
Marketed by Merck & Co.
NCT03615326 · Phase 3 · completed
This was a randomized, quadruple-blind, placebo-controlled phase 3 trial; 698 participants were randomized in its main cohort, more than the approximately 692 its published sample-size calculation required. Both primary endpoints were met: progression-free survival by blinded central review (hazard ratio 0.73) and overall survival (hazard ratio 0.80) were significantly better with pembrolizumab.
Next expected readout: December 2026 · NCT05041153 (registry estimate)
No aligned efficacy figure on record for this race.
Results for Gastric Cancer
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
Coverage. Nivolumab: 3 of 4 rows · Pembrolizumab: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Nivolumab | Pembrolizumab |
|---|---|---|
| Dropout rate | 0%0.009 mg/kg q3w + 360 mg q3wa NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination show 9 more results0%0.006 mg/kg q3w + 240 mg q2w NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 33.3%0.006 mg/kg q2w + 240 mg q2w NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 20%0.006 mg/kg q3w + 360 mg q3w NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 17.2%0.006 mg/kg q3w + 360 mg q3w NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 0%0.003 mg/kg q2w + 240 mg q2w NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 0%Part 3 Schedule Finding (Schedule NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 0%Part 3 Schedule Finding (Schedule NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 0%Part 3 Schedule Finding (Schedule NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 10.5%Part 4 Dose Expansion of NKTR-214 NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination | n/a: no completion milestoneCohort A: Triple Negative Breast Ca NCT03797326 · Phase 2 · registry result, not featured evidence · combination show 27 more resultsn/a: no completion milestoneCohort B: Ovarian Cancer (Lenva + NCT03797326 · Phase 2 · registry result, not featured evidence · combination n/a: no completion milestoneCohort C: Gastric Cancer (Lenva + NCT03797326 · Phase 2 · registry result, not featured evidence · combination n/a: no completion milestoneCohort D1: Colorectal Cancer (Lenv NCT03797326 · Phase 2 · registry result, not featured evidence · combination n/a: no completion milestoneCohort D2: Colorectal Cancer (Lenv NCT03797326 · Phase 2 · registry result, not featured evidence n/a: no completion milestoneCohort E: Glioblastoma Multiforma NCT03797326 · Phase 2 · registry result, not featured evidence · combination n/a: no completion milestoneCohort F: Biliary Tract Cancer (Le NCT03797326 · Phase 2 · registry result, not featured evidence · combination n/a: no completion milestoneCohort G: Pancreatic Cancer (Lenva NCT03797326 · Phase 2 · registry result, not featured evidence · combination 25%Experimental: Expansion 1 NCT04383938 · Phase 1/2 · registry result, not featured evidence · combination 0%Experimental: Expansion 2 NCT04383938 · Phase 1/2 · registry result, not featured evidence · combination 4.8%Experimental: Expansion 3 NCT04383938 · Phase 1/2 · registry result, not featured evidence · combination 0%Experimental: Safety Lead In NCT04383938 · Phase 1/2 · registry result, not featured evidence · combination n/a: no completion milestone300 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination n/a: no completion milestone100 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination n/a: no completion milestone100 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination n/a: no completion milestone50 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination n/a: no completion milestone25 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination n/a: no completion milestone100 mg NCT02903914 · Phase 1 · registry result, not featured evidence · combination n/a: no completion milestone75 mg NCT02903914 · Phase 1 · registry result, not featured evidence · combination —50 mg NCT02903914 · Phase 1 · registry result, not featured evidence · combination n/a: no completion milestone50 mg NCT02903914 · Phase 1 · registry result, not featured evidence · combination n/a: no completion milestone50 mg NCT02903914 · Phase 1 · registry result, not featured evidence · combination n/a: no completion milestone2.2 µg/kg NCT02563548 · Phase 1 · registry result, not featured evidence · combination n/a: no completion milestone2.2 µg/kg NCT02563548 · Phase 1 · registry result, not featured evidence · combination —2.2 µg/kg NCT02563548 · Phase 1 · registry result, not featured evidence · combination —2.2 µg/kg NCT02563548 · Phase 1 · registry result, not featured evidence · combination n/a: no completion milestone1.6 µg/kg NCT02563548 · Phase 1 · registry result, not featured evidence · combination n/a: no completion milestone1.6 µg/kg NCT02563548 · Phase 1 · registry result, not featured evidence · combination |
| Discontinued due to AEs | —0.009 mg/kg q3w + 360 mg q3wa NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination show 9 more results—0.006 mg/kg q3w + 240 mg q2w NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination —0.006 mg/kg q2w + 240 mg q2w NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination —0.006 mg/kg q3w + 360 mg q3w NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination —0.006 mg/kg q3w + 360 mg q3w NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination —0.003 mg/kg q2w + 240 mg q2w NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination —Part 3 Schedule Finding (Schedule NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination —Part 3 Schedule Finding (Schedule NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination —Part 3 Schedule Finding (Schedule NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination —Part 4 Dose Expansion of NKTR-214 NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination | —Cohort A: Triple Negative Breast Ca NCT03797326 · Phase 2 · registry result, not featured evidence · combination show 27 more results—Cohort B: Ovarian Cancer (Lenva + NCT03797326 · Phase 2 · registry result, not featured evidence · combination —Cohort C: Gastric Cancer (Lenva + NCT03797326 · Phase 2 · registry result, not featured evidence · combination —Cohort D1: Colorectal Cancer (Lenv NCT03797326 · Phase 2 · registry result, not featured evidence · combination —Cohort D2: Colorectal Cancer (Lenv NCT03797326 · Phase 2 · registry result, not featured evidence —Cohort E: Glioblastoma Multiforma NCT03797326 · Phase 2 · registry result, not featured evidence · combination —Cohort F: Biliary Tract Cancer (Le NCT03797326 · Phase 2 · registry result, not featured evidence · combination —Cohort G: Pancreatic Cancer (Lenva NCT03797326 · Phase 2 · registry result, not featured evidence · combination —Experimental: Expansion 1 NCT04383938 · Phase 1/2 · registry result, not featured evidence · combination —Experimental: Expansion 2 NCT04383938 · Phase 1/2 · registry result, not featured evidence · combination —Experimental: Expansion 3 NCT04383938 · Phase 1/2 · registry result, not featured evidence · combination —Experimental: Safety Lead In NCT04383938 · Phase 1/2 · registry result, not featured evidence · combination —300 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination —100 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination —100 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination —50 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination —25 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination 1.6%100 mg NCT02903914 · Phase 1 · registry result, not featured evidence · combination 0%75 mg NCT02903914 · Phase 1 · registry result, not featured evidence · combination —50 mg NCT02903914 · Phase 1 · registry result, not featured evidence · combination 0%50 mg NCT02903914 · Phase 1 · registry result, not featured evidence · combination 0%50 mg NCT02903914 · Phase 1 · registry result, not featured evidence · combination 0%2.2 µg/kg NCT02563548 · Phase 1 · registry result, not featured evidence · combination 50%2.2 µg/kg NCT02563548 · Phase 1 · registry result, not featured evidence · combination —2.2 µg/kg NCT02563548 · Phase 1 · registry result, not featured evidence · combination —2.2 µg/kg NCT02563548 · Phase 1 · registry result, not featured evidence · combination 66.7%1.6 µg/kg NCT02563548 · Phase 1 · registry result, not featured evidence · combination 0%1.6 µg/kg NCT02563548 · Phase 1 · registry result, not featured evidence · combination |
| Serious AEs | 66.7%0.009 mg/kg q3w + 360 mg q3wa NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination show 9 more results50%0.006 mg/kg q3w + 240 mg q2w NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 0%0.006 mg/kg q2w + 240 mg q2w NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 36%0.006 mg/kg q3w + 360 mg q3w NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 44.7%0.006 mg/kg q3w + 360 mg q3w NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 33.3%0.003 mg/kg q2w + 240 mg q2w NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 60%Part 3 Schedule Finding (Schedule NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 62.5%Part 3 Schedule Finding (Schedule NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 33.3%Part 3 Schedule Finding (Schedule NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 42.1%Part 4 Dose Expansion of NKTR-214 NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination | 51.6%Cohort A: Triple Negative Breast Ca NCT03797326 · Phase 2 · registry result, not featured evidence · combination show 27 more results61.3%Cohort B: Ovarian Cancer (Lenva + NCT03797326 · Phase 2 · registry result, not featured evidence · combination 57.6%Cohort C: Gastric Cancer (Lenva + NCT03797326 · Phase 2 · registry result, not featured evidence · combination 52.4%Cohort D1: Colorectal Cancer (Lenv NCT03797326 · Phase 2 · registry result, not featured evidence · combination 40%Cohort D2: Colorectal Cancer (Lenv NCT03797326 · Phase 2 · registry result, not featured evidence 29.7%Cohort E: Glioblastoma Multiforma NCT03797326 · Phase 2 · registry result, not featured evidence · combination 60.8%Cohort F: Biliary Tract Cancer (Le NCT03797326 · Phase 2 · registry result, not featured evidence · combination 47.6%Cohort G: Pancreatic Cancer (Lenva NCT03797326 · Phase 2 · registry result, not featured evidence · combination 66.7%Experimental: Expansion 1 NCT04383938 · Phase 1/2 · registry result, not featured evidence · combination 60%Experimental: Expansion 2 NCT04383938 · Phase 1/2 · registry result, not featured evidence · combination 35%Experimental: Expansion 3 NCT04383938 · Phase 1/2 · registry result, not featured evidence · combination 16.7%Experimental: Safety Lead In NCT04383938 · Phase 1/2 · registry result, not featured evidence · combination 45%300 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination 50%100 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination 51%100 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination 40%50 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination 0%25 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination 38.2%100 mg NCT02903914 · Phase 1 · registry result, not featured evidence · combination 35.7%75 mg NCT02903914 · Phase 1 · registry result, not featured evidence · combination 37.5%50 mg NCT02903914 · Phase 1 · registry result, not featured evidence · combination —50 mg NCT02903914 · Phase 1 · registry result, not featured evidence · combination —50 mg NCT02903914 · Phase 1 · registry result, not featured evidence · combination —2.2 µg/kg NCT02563548 · Phase 1 · registry result, not featured evidence · combination —2.2 µg/kg NCT02563548 · Phase 1 · registry result, not featured evidence · combination —2.2 µg/kg NCT02563548 · Phase 1 · registry result, not featured evidence · combination —2.2 µg/kg NCT02563548 · Phase 1 · registry result, not featured evidence · combination —1.6 µg/kg NCT02563548 · Phase 1 · registry result, not featured evidence · combination —1.6 µg/kg NCT02563548 · Phase 1 · registry result, not featured evidence · combination |
| Most frequent reported AEs | 0.009 mg/kg q3w + 360 mg q3wa pyrexia 100% rash 100% chills 66.7% NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination show 9 more results0.006 mg/kg q3w + 240 mg q2w arthralgia 100% fatigue 100% headache 100% NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 0.006 mg/kg q2w + 240 mg q2w chills 100% pyrexia 100% back pain 66.7% NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 0.006 mg/kg q3w + 360 mg q3w fatigue 76% chills 64% cough 60% NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 0.006 mg/kg q3w + 360 mg q3w fatigue 50.6% pyrexia 47.9% nausea 40.1% NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 0.003 mg/kg q2w + 240 mg q2w chills 100% nasal congestion 100% arthralgia 66.7% NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination fatigue 90% diarrhoea 80% nausea 80% NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination diarrhoea 75% influenza like illness 75% pruritus 75% NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination decreased appetite 100% fatigue 100% influenza like illness 100% NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination fatigue 78.9% influenza like illness 68.4% nausea 57.9% NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination | a hypertension 51.6% diarrhoea 45.2% hypothyroidism 45.2% NCT03797326 · Phase 2 · registry result, not featured evidence · combination show 19 more resultshypertension 67.7% diarrhoea 61.3% decreased appetite 48.4% NCT03797326 · Phase 2 · registry result, not featured evidence · combination hypertension 37.4% nausea 31.3% asthenia 30.3% NCT03797326 · Phase 2 · registry result, not featured evidence · combination hypertension 56.2% diarrhoea 44.8% decreased appetite 43.8% NCT03797326 · Phase 2 · registry result, not featured evidence · combination hypertension 56.7% diarrhoea 53.3% dysphonia 40% NCT03797326 · Phase 2 · registry result, not featured evidence hypertension 50.5% asthenia 28.7% hypothyroidism 27.7% NCT03797326 · Phase 2 · registry result, not featured evidence · combination hypertension 56.9% diarrhoea 41.2% fatigue 39.2% NCT03797326 · Phase 2 · registry result, not featured evidence · combination hypertension 53.4% nausea 35.9% decreased appetite 32% NCT03797326 · Phase 2 · registry result, not featured evidence · combination decreased appetite 50% alanine aminotransferase increased 33.3% diarrhea 33.3% NCT04383938 · Phase 1/2 · registry result, not featured evidence · combination anaemia 80% dizziness 80% fatigue 80% NCT04383938 · Phase 1/2 · registry result, not featured evidence · combination dizziness 45% decreased appetite 30% dyspnea 30% NCT04383938 · Phase 1/2 · registry result, not featured evidence · combination abdominal pain 66.7% blood alkaline phosphatase increased 66.7% fatigue 66.7% NCT04383938 · Phase 1/2 · registry result, not featured evidence · combination 300 mg BID + 200 mg Q3W fatigue 65% nausea 55% vomiting 50% NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination 100 mg BID + 200 mg Q3W fatigue 50% back pain 38.9% diarrhoea 38.9% NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination 100 mg BID + 200 mg Q3W fatigue 48.4% nausea 30.1% cough 26.2% NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination 50 mg BID + 200 mg Q3W fatigue 65% arthralgia 45% nausea 45% NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination 25 mg BID + 200 mg Q3W arthralgia 100% constipation 75% cough 75% NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination 100 mg diarrhoea 25.2% constipation 23.6% fatigue 23.6% NCT02903914 · Phase 1 · registry result, not featured evidence · combination 75 mg aspartate aminotransferase increased 21.4% back pain 21.4% fatigue 21.4% NCT02903914 · Phase 1 · registry result, not featured evidence · combination 50 mg fatigue 37.5% diarrhoea 25% decreased appetite 18.8% NCT02903914 · Phase 1 · registry result, not featured evidence · combination |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Nivolumab
show 1 more result
Pembrolizumab
show 11 more results
show 14 more results
show 15 more results
show 9 more results
show 5 more results
show 3 more results
show 3 more results
Melanoma
Shared mechanism: PD-1 · full Melanoma pipeline
Nivolumab
Marketed by Bristol-Myers Squibb and partners
NCT01721746 · Phase 3 · completed
This was a large randomized trial against chemotherapy, but it was open-label. Overall survival, an objective outcome, was not significantly better with nivolumab, although more patients had a tumour response.
Next expected readout: November 2026 · NCT06712927 (registry estimate)
Reported efficacy
Recurrence-free Survival (RFS) (up to 36 months): Recurrence-free Survival (RFS) (up to 36 months): Nivolumab 3 mg/kg 52.37 Months | Ipilimumab 10 mg/kg 24.08 Months (95% CI 16.56 to 35.09) (met)
Result source: NCT02388906
Pembrolizumab
Marketed by Merck & Co.
NCT01866319 · Phase 3 · completed
The trial randomized 834 participants to two pembrolizumab schedules or active-control ipilimumab, with progression assessed by blinded independent radiology review and statistically significant improvements in progression-free survival and overall survival for both pembrolizumab schedules versus ipilimumab. However, treatment assignment was open-label rather than double-blinded, so the evidence is rated moderate despite the objective clinical endpoints and favorable results.
Next expected readout: December 2026 · NCT02644369 (registry estimate)
No aligned efficacy figure on record for this race.
Results for Melanoma
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
Coverage. Nivolumab: 9 of 10 rows · Pembrolizumab: 10 of 10 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Nivolumab Rows use multiple source trials | Pembrolizumab Rows use multiple source trials |
|---|---|---|
| Duration of Response time to event · months No placebo or comparator arm | NA months30 mga,b,c NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination show 2 more doses7.38 months*30 mg NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination · converted to months from 32 weeks as posted 20.63 months*30 mg NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination · converted to months from 89.4 weeks as posted | 15.61 months5 mg weeklya,b,c NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination show 6 more dosesNA months5 mg weekly NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination 10.1 months5 mg weekly NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination 10.14 months5 mg weekly NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination 25.49 months5 mg weekly NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination 25.49 months5 mg weekly NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination 7.33 months5 mg weekly NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination |
| ORR event count · % of participants No placebo or comparator arm | 14.9% (n=429)*0.006 mg/kg q3w + 360 mg q3wa,d,b,c NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination · converted to % from 64 Participants as posted show 1 more dose17.6% (n=17)* NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination · converted to % from 3 Participants as posted | 20% (n=5)*3.2/4 mga,d,b,c NCT02009449 · Phase 1 · registry result, not featured evidence · converted to % from 1 Participants as posted show 19 more doses20% (n=5)*3.2/4 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination · converted to % from 1 Participants as posted 6.3% (n=95)*1.6/2 mg NCT02009449 · Phase 1 · registry result, not featured evidence · converted to % from 6 Participants as posted 10.7% (n=28)*1.6/2 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination · converted to % from 3 Participants as posted 39.6% (n=48)*1.6/2 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination · converted to % from 19 Participants as posted 0% (n=5)*0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · converted to % from 0 Participants as posted 46.7% (n=15)*0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination · converted to % from 7 Participants as posted 0% (n=6)*0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination · converted to % from 0 Participants as posted 16.7% (n=6)*0.8/ 1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination · converted to % from 1 Participants as posted 20% (n=5)*0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination · converted to % from 1 Participants as posted 35.7% (n=14)*0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination · converted to % from 5 Participants as posted 100% (n=1)*0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination · converted to % from 1 Participants as posted 0% (n=5)*0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination · converted to % from 0 Participants as posted 0% (n=6)*0.4/0.5 mg NCT02009449 · Phase 1 · registry result, not featured evidence · converted to % from 0 Participants as posted 33.3% (n=3)*0.4/0.5 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination · converted to % from 1 Participants as posted 20% (n=5)*0.4/ 0.5 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination · converted to % from 1 Participants as posted 0% (n=4)*0.4/0.5 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination · converted to % from 0 Participants as posted 0% (n=5)*0.2/0.25 mg NCT02009449 · Phase 1 · registry result, not featured evidence · converted to % from 0 Participants as posted 25% (n=4)*0.2/0.25 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination · converted to % from 1 Participants as posted 0% (n=4)*0.08/0.1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · converted to % from 0 Participants as posted |
| ORR responder rate · % of participants No placebo or comparator arm | 0% (n=1)400 mga,b,c NCT02658890 · Phase 1/2 · registry result, not featured evidence show 15 more doses0% (n=6)BMS-986205 400 mg + nivolumab 240 mg NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination 5.6% (n=18)BMS-986205 200 mg + nivolumab 240 mg NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination 31.3% (n=16)BMS-986205 200 mg NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination 23.5% (n=17)BMS-986205 200 mg NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination 28.6% (n=14)BMS-986205 200 mg NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination 0% (n=12)BMS-986205 100 mg + nivolumab 240 mg NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination 42.9% (n=14)BMS-986205 100 mg NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination 0% (n=18)BMS-986205 100 mg NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination 13.3% (n=15)BMS-986205 100 mg NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination 0% (n=1)50 mg NCT02658890 · Phase 1/2 · registry result, not featured evidence 10% (n=10)BMS-986205 50 mg + nivolumab 240 mg NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination 0% (n=7)BMS-986205 25 mg + nivolumab 240 mg NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination 14.3% (n=14) NCT02658890 · Phase 1/2 · registry result, not featured evidence 11.8% (n=17) NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination 50% (n=6) NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination | 22.2% (n=18)5 mg weeklya,b,c NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination show 3 more doses9.2% (n=76)5 mg weekly NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination 18.9% (n=53)5 mg weekly NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination 5.4% (n=37)5 mg weekly NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination |
| PFS time to event · months No placebo or comparator arm | 2 monthsa,e,b,c NCT05061017 · Phase 2 · registry result, not featured evidence · combination show 1 more dose2 months NCT05061017 · Phase 2 · registry result, not featured evidence · combination | 2.76 months5 mg weeklya,e,b,c NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination show 7 more doses2.76 months5 mg weekly NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination 2.83 months5 mg weekly NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination 2.69 months5 mg weekly NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination 4.4 months5 mg weekly NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination 2.96 months5 mg weekly NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination 1.91 months5 mg weekly NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination 1.91 months5 mg weekly NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination |
| Progressive Disease event count · % of participants No placebo or comparator arm Progressive disease (PD) | 0% (n=1)*400 mga,f,c NCT02658890 · Phase 1/2 · registry result, not featured evidence · converted to % from 0 Participants as posted show 15 more doses66.7% (n=6)*BMS-986205 400 mg + nivolumab 240 mg NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination · converted to % from 4 Participants as posted 50% (n=18)*BMS-986205 200 mg + nivolumab 240 mg NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination · converted to % from 9 Participants as posted 37.5% (n=16)*BMS-986205 200 mg NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination · converted to % from 6 Participants as posted 17.6% (n=17)*BMS-986205 200 mg NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination · converted to % from 3 Participants as posted 14.3% (n=14)*BMS-986205 200 mg NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination · converted to % from 2 Participants as posted 58.3% (n=12)*BMS-986205 100 mg + nivolumab 240 mg NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination · converted to % from 7 Participants as posted 57.1% (n=14)*BMS-986205 100 mg NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination · converted to % from 8 Participants as posted 55.6% (n=18)*BMS-986205 100 mg NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination · converted to % from 10 Participants as posted 20% (n=15)*BMS-986205 100 mg NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination · converted to % from 3 Participants as posted 0% (n=1)*50 mg NCT02658890 · Phase 1/2 · registry result, not featured evidence · converted to % from 0 Participants as posted 50% (n=10)*BMS-986205 50 mg + nivolumab 240 mg NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination · converted to % from 5 Participants as posted 71.4% (n=7)*BMS-986205 25 mg + nivolumab 240 mg NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination · converted to % from 5 Participants as posted 50% (n=14)* NCT02658890 · Phase 1/2 · registry result, not featured evidence · converted to % from 7 Participants as posted 52.9% (n=17)* NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination · converted to % from 9 Participants as posted 33.3% (n=6)* NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination · converted to % from 2 Participants as posted | 50% (n=10) @ 52wk*a,f,c NCT02407171 · Phase 1/2 · registry result, not featured evidence · combination · converted to % from 5 Participants as posted show 1 more dose20% (n=5) @ 52wk* NCT02407171 · Phase 1/2 · registry result, not featured evidence · combination · converted to % from 1 Participants as posted |
| Stable Disease event count · % of participants No placebo or comparator arm Stable disease (SD) | 0% (n=1)*400 mga,f,c NCT02658890 · Phase 1/2 · registry result, not featured evidence · converted to % from 0 Participants as posted show 15 more doses33.3% (n=6)*BMS-986205 400 mg + nivolumab 240 mg NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination · converted to % from 2 Participants as posted 22.2% (n=18)*BMS-986205 200 mg + nivolumab 240 mg NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination · converted to % from 4 Participants as posted 25% (n=16)*BMS-986205 200 mg NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination · converted to % from 4 Participants as posted 47.1% (n=17)*BMS-986205 200 mg NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination · converted to % from 8 Participants as posted 28.6% (n=14)*BMS-986205 200 mg NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination · converted to % from 4 Participants as posted 33.3% (n=12)*BMS-986205 100 mg + nivolumab 240 mg NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination · converted to % from 4 Participants as posted 0% (n=14)*BMS-986205 100 mg NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination · converted to % from 0 Participants as posted 33.3% (n=18)*BMS-986205 100 mg NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination · converted to % from 6 Participants as posted 40% (n=15)*BMS-986205 100 mg NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination · converted to % from 6 Participants as posted 0% (n=1)*50 mg NCT02658890 · Phase 1/2 · registry result, not featured evidence · converted to % from 0 Participants as posted 30% (n=10)*BMS-986205 50 mg + nivolumab 240 mg NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination · converted to % from 3 Participants as posted 28.6% (n=7)*BMS-986205 25 mg + nivolumab 240 mg NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination · converted to % from 2 Participants as posted 21.4% (n=14)* NCT02658890 · Phase 1/2 · registry result, not featured evidence · converted to % from 3 Participants as posted 17.6% (n=17)* NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination · converted to % from 3 Participants as posted 16.7% (n=6)* NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination · converted to % from 1 Participants as posted | 40% (n=10) @ 52wk*a,f,c NCT02407171 · Phase 1/2 · registry result, not featured evidence · combination · converted to % from 4 Participants as posted show 1 more dose40% (n=5) @ 52wk* NCT02407171 · Phase 1/2 · registry result, not featured evidence · combination · converted to % from 2 Participants as posted |
| Dropout rate | —Pixatimod (PG545) + Nivolumab + Cyg NCT05061017 · Phase 2 · registry result, not featured evidence · combination show 66 more results0%Pixatimod (PG545) + Nivolumab - Co NCT05061017 · Phase 2 · registry result, not featured evidence · combination 100%40 mg NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination 100%30 mg NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination 97.5%30 mg NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination 100%20 mg NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination 0%0.009 mg/kg q3w + 360 mg q3w NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 0%0.006 mg/kg q3w + 240 mg q2w NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 33.3%0.006 mg/kg q2w + 240 mg q2w NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 20%0.006 mg/kg q3w + 360 mg q3w NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 17.2%0.006 mg/kg q3w + 360 mg q3w NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 0%0.003 mg/kg q2w + 240 mg q2w NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 0%Part 3 Schedule Finding (Schedule NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 0%Part 3 Schedule Finding (Schedule NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 0%Part 3 Schedule Finding (Schedule NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 10.5%Part 4 Dose Expansion of NKTR-214 NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination —400 mg NCT02658890 · Phase 1/2 · registry result, not featured evidence —BMS-986205 400 mg + nivolumab 240 mg NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination 0%BMS-986205 400 mg + nivolumab 240 mg NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination 0%BMS-986205 200 mg + nivolumab 240 mg NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination 0%BMS-986205 200 mg NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination 0%BMS-986205 200 mg NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination 0%BMS-986205 200 mg NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination 0%BMS-986205 100 mg + nivolumab 240 mg NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination 0%BMS-986205 100 mg NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination 0%BMS-986205 100 mg NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination 0%BMS-986205 100 mg NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination —50 mg NCT02658890 · Phase 1/2 · registry result, not featured evidence 0%BMS-986205 50 mg + nivolumab 240 mg NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination 0%50 mg NCT02658890 · Phase 1/2 · registry result, not featured evidence 0%BMS-986205 25 mg + nivolumab 240 mg NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination 0%Food Effect/ Relative BA (FE BA) S NCT02658890 · Phase 1/2 · registry result, not featured evidence 0%Part 2: Exp ML Anti-PDL1+CTLA4 NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination 0%Part 2: Exp ML BRAF-MT- NIVO NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination —0.3 mg/kg + Nivolumab NCT03123783 · Phase 1/2 · registry result, not featured evidence · combination —0.1 mg/kg + Nivolumab NCT03123783 · Phase 1/2 · registry result, not featured evidence · combination —0.03 mg/kg + Nivolumab NCT03123783 · Phase 1/2 · registry result, not featured evidence · combination —Cohort 1(Arm)/ inNSCLC (Phase 2) - NCT03123783 · Phase 1/2 · registry result, not featured evidence · combination —Cohort 2(Arm)/ PD1-MM (Phase 2) - NCT03123783 · Phase 1/2 · registry result, not featured evidence · combination —Cohort 3A(Arm)/ PD1-NSCLC (Phase 2 NCT03123783 · Phase 1/2 · registry result, not featured evidence · combination —Cohort 3B(Arm)/ PD1-NSCLC (Phase 2 NCT03123783 · Phase 1/2 · registry result, not featured evidence · combination 100%3.2/4 mg NCT02009449 · Phase 1 · registry result, not featured evidence 100%3.2/4 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 99.1%1.6/2 mg NCT02009449 · Phase 1 · registry result, not featured evidence 100%1.6/2 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 96.5%1.6/2 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 100%0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence 100%0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 100%0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 100%0.8/ 1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination —0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 100%0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 85.7%0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 100%0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 100%0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 100%0.4/0.5 mg NCT02009449 · Phase 1 · registry result, not featured evidence 100%0.4/0.5 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 100%0.4/ 0.5 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination —0.4/0.5 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 100%0.4/0.5 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 100%0.2/0.25 mg NCT02009449 · Phase 1 · registry result, not featured evidence 100%0.2/0.25 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 100%0.08/0.1 mg NCT02009449 · Phase 1 · registry result, not featured evidence 0%280 mg PO BID NCT03229278 · Phase 1 · registry result, not featured evidence · combination 0%140 mg / 280 mg NCT03229278 · Phase 1 · registry result, not featured evidence · combination 0%140 mg PO BID NCT03229278 · Phase 1 · registry result, not featured evidence · combination 0%140 mg PO daily NCT03229278 · Phase 1 · registry result, not featured evidence · combination | 89.3%200 mg IV Q3Wg NCT03715205 · Phase 4 · registry result, not featured evidence show 59 more results0%Untreated Brain Metastases From Me NCT02681549 · Phase 2 · registry result, not featured evidence 50%Untreated Brain Metastases From NS NCT02681549 · Phase 2 · registry result, not featured evidence 0%5 mg weekly NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination 0%5 mg weekly NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination —5 mg weekly NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination —5 mg weekly NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination —5 mg weekly NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination —5 mg weekly NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination 66.7%3 mg weekly NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination n/a: no completion milestone300 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination n/a: no completion milestone100 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination n/a: no completion milestone100 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination n/a: no completion milestone50 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination n/a: no completion milestone25 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination 0%Phase 1: Lung Targets + MK-3475 / NCT02407171 · Phase 1/2 · registry result, not featured evidence · combination 0%Phase 1: Non-Lung Target + MK-3475 NCT02407171 · Phase 1/2 · registry result, not featured evidence · combination 0%30 Gy over 5 fractions NCT02858869 · Phase 1 · registry result, not featured evidence · combination 0%27 Gy over 3 fractions NCT02858869 · Phase 1 · registry result, not featured evidence · combination 0%18-21 Gy in one fraction NCT02858869 · Phase 1 · registry result, not featured evidence · combination 100%3.2/4 mg NCT02009449 · Phase 1 · registry result, not featured evidence 100%3.2/4 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 99.1%1.6/2 mg NCT02009449 · Phase 1 · registry result, not featured evidence 100%1.6/2 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 96.5%1.6/2 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 100%0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence 100%0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 100%0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 100%0.8/ 1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination —0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 100%0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 85.7%0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 100%0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 100%0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 100%0.4/0.5 mg NCT02009449 · Phase 1 · registry result, not featured evidence 100%0.4/0.5 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 100%0.4/ 0.5 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination —0.4/0.5 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 100%0.4/0.5 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 100%0.2/0.25 mg NCT02009449 · Phase 1 · registry result, not featured evidence 100%0.2/0.25 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 100%0.08/0.1 mg NCT02009449 · Phase 1 · registry result, not featured evidence 0%280 mg PO BID NCT03229278 · Phase 1 · registry result, not featured evidence · combination 0%140 mg / 280 mg NCT03229278 · Phase 1 · registry result, not featured evidence · combination 0%140 mg PO BID NCT03229278 · Phase 1 · registry result, not featured evidence · combination 0%140 mg PO daily NCT03229278 · Phase 1 · registry result, not featured evidence · combination 57.1%20 mg/kg NCT03236935 · Phase 1 · registry result, not featured evidence —12.5 mg/kg NCT03236935 · Phase 1 · registry result, not featured evidence 92.3%10 mg/kg Q2W NCT01295827 · Phase 1 · registry result, not featured evidence 92.5%10 mg/kg Q3W NCT01295827 · Phase 1 · registry result, not featured evidence · combination 91.6%10 mg/kg Q2W NCT01295827 · Phase 1 · registry result, not featured evidence 93.2%10 mg/kg Q3W NCT01295827 · Phase 1 · registry result, not featured evidence · combination 100%10 mg/kg Q2W NCT01295827 · Phase 1 · registry result, not featured evidence · combination 100%3 mg/kg Q2W NCT01295827 · Phase 1 · registry result, not featured evidence 89%2 mg/kg Q3W NCT01295827 · Phase 1 · registry result, not featured evidence · combination 90.2%2 mg/kg Q3W NCT01295827 · Phase 1 · registry result, not featured evidence 100%1 mg/kg Q2W NCT01295827 · Phase 1 · registry result, not featured evidence 100%Solid Tumors: Pembrolizumab Titrat NCT01295827 · Phase 1 · registry result, not featured evidence 66.7%Solid Tumors: Pembrolizumab Titrat NCT01295827 · Phase 1 · registry result, not featured evidence 100%Solid Tumors: Pembrolizumab Titrat NCT01295827 · Phase 1 · registry result, not featured evidence |
| Discontinued due to AEs | —Pixatimod (PG545) + Nivolumab + Cyg NCT05061017 · Phase 2 · registry result, not featured evidence · combination show 66 more results—Pixatimod (PG545) + Nivolumab - Co NCT05061017 · Phase 2 · registry result, not featured evidence · combination —40 mg NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination —30 mg NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination —30 mg NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination —20 mg NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination —0.009 mg/kg q3w + 360 mg q3w NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination —0.006 mg/kg q3w + 240 mg q2w NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination —0.006 mg/kg q2w + 240 mg q2w NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination —0.006 mg/kg q3w + 360 mg q3w NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination —0.006 mg/kg q3w + 360 mg q3w NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination —0.003 mg/kg q2w + 240 mg q2w NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination —Part 3 Schedule Finding (Schedule NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination —Part 3 Schedule Finding (Schedule NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination —Part 3 Schedule Finding (Schedule NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination —Part 4 Dose Expansion of NKTR-214 NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination —400 mg NCT02658890 · Phase 1/2 · registry result, not featured evidence —BMS-986205 400 mg + nivolumab 240 mg NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination —BMS-986205 400 mg + nivolumab 240 mg NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination —BMS-986205 200 mg + nivolumab 240 mg NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination —BMS-986205 200 mg NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination —BMS-986205 200 mg NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination —BMS-986205 200 mg NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination —BMS-986205 100 mg + nivolumab 240 mg NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination —BMS-986205 100 mg NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination —BMS-986205 100 mg NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination —BMS-986205 100 mg NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination —50 mg NCT02658890 · Phase 1/2 · registry result, not featured evidence —BMS-986205 50 mg + nivolumab 240 mg NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination —50 mg NCT02658890 · Phase 1/2 · registry result, not featured evidence —BMS-986205 25 mg + nivolumab 240 mg NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination —Food Effect/ Relative BA (FE BA) S NCT02658890 · Phase 1/2 · registry result, not featured evidence —Part 2: Exp ML Anti-PDL1+CTLA4 NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination —Part 2: Exp ML BRAF-MT- NIVO NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination —0.3 mg/kg + Nivolumab NCT03123783 · Phase 1/2 · registry result, not featured evidence · combination —0.1 mg/kg + Nivolumab NCT03123783 · Phase 1/2 · registry result, not featured evidence · combination —0.03 mg/kg + Nivolumab NCT03123783 · Phase 1/2 · registry result, not featured evidence · combination —Cohort 1(Arm)/ inNSCLC (Phase 2) - NCT03123783 · Phase 1/2 · registry result, not featured evidence · combination —Cohort 2(Arm)/ PD1-MM (Phase 2) - NCT03123783 · Phase 1/2 · registry result, not featured evidence · combination —Cohort 3A(Arm)/ PD1-NSCLC (Phase 2 NCT03123783 · Phase 1/2 · registry result, not featured evidence · combination —Cohort 3B(Arm)/ PD1-NSCLC (Phase 2 NCT03123783 · Phase 1/2 · registry result, not featured evidence · combination —3.2/4 mg NCT02009449 · Phase 1 · registry result, not featured evidence —3.2/4 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination —1.6/2 mg NCT02009449 · Phase 1 · registry result, not featured evidence —1.6/2 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination —1.6/2 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination —0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence —0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination —0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination —0.8/ 1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination —0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination —0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination —0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination —0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination —0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination —0.4/0.5 mg NCT02009449 · Phase 1 · registry result, not featured evidence —0.4/0.5 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination —0.4/ 0.5 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination —0.4/0.5 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination —0.4/0.5 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination —0.2/0.25 mg NCT02009449 · Phase 1 · registry result, not featured evidence —0.2/0.25 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination —0.08/0.1 mg NCT02009449 · Phase 1 · registry result, not featured evidence —280 mg PO BID NCT03229278 · Phase 1 · registry result, not featured evidence · combination —140 mg / 280 mg NCT03229278 · Phase 1 · registry result, not featured evidence · combination —140 mg PO BID NCT03229278 · Phase 1 · registry result, not featured evidence · combination —140 mg PO daily NCT03229278 · Phase 1 · registry result, not featured evidence · combination | —200 mg IV Q3Wg NCT03715205 · Phase 4 · registry result, not featured evidence show 59 more results—Untreated Brain Metastases From Me NCT02681549 · Phase 2 · registry result, not featured evidence —Untreated Brain Metastases From NS NCT02681549 · Phase 2 · registry result, not featured evidence —5 mg weekly NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination —5 mg weekly NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination —5 mg weekly NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination —5 mg weekly NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination —5 mg weekly NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination —5 mg weekly NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination —3 mg weekly NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination —300 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination —100 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination —100 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination —50 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination —25 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination —Phase 1: Lung Targets + MK-3475 / NCT02407171 · Phase 1/2 · registry result, not featured evidence · combination —Phase 1: Non-Lung Target + MK-3475 NCT02407171 · Phase 1/2 · registry result, not featured evidence · combination —30 Gy over 5 fractions NCT02858869 · Phase 1 · registry result, not featured evidence · combination —27 Gy over 3 fractions NCT02858869 · Phase 1 · registry result, not featured evidence · combination —18-21 Gy in one fraction NCT02858869 · Phase 1 · registry result, not featured evidence · combination —3.2/4 mg NCT02009449 · Phase 1 · registry result, not featured evidence —3.2/4 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination —1.6/2 mg NCT02009449 · Phase 1 · registry result, not featured evidence —1.6/2 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination —1.6/2 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination —0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence —0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination —0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination —0.8/ 1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination —0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination —0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination —0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination —0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination —0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination —0.4/0.5 mg NCT02009449 · Phase 1 · registry result, not featured evidence —0.4/0.5 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination —0.4/ 0.5 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination —0.4/0.5 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination —0.4/0.5 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination —0.2/0.25 mg NCT02009449 · Phase 1 · registry result, not featured evidence —0.2/0.25 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination —0.08/0.1 mg NCT02009449 · Phase 1 · registry result, not featured evidence —280 mg PO BID NCT03229278 · Phase 1 · registry result, not featured evidence · combination —140 mg / 280 mg NCT03229278 · Phase 1 · registry result, not featured evidence · combination —140 mg PO BID NCT03229278 · Phase 1 · registry result, not featured evidence · combination —140 mg PO daily NCT03229278 · Phase 1 · registry result, not featured evidence · combination —20 mg/kg NCT03236935 · Phase 1 · registry result, not featured evidence —12.5 mg/kg NCT03236935 · Phase 1 · registry result, not featured evidence 12%10 mg/kg Q2W NCT01295827 · Phase 1 · registry result, not featured evidence 15.3%10 mg/kg Q3W NCT01295827 · Phase 1 · registry result, not featured evidence · combination 10.3%10 mg/kg Q2W NCT01295827 · Phase 1 · registry result, not featured evidence 16.9%10 mg/kg Q3W NCT01295827 · Phase 1 · registry result, not featured evidence · combination 16.7%10 mg/kg Q2W NCT01295827 · Phase 1 · registry result, not featured evidence · combination 66.7%3 mg/kg Q2W NCT01295827 · Phase 1 · registry result, not featured evidence 9.1%2 mg/kg Q3W NCT01295827 · Phase 1 · registry result, not featured evidence · combination 11.5%2 mg/kg Q3W NCT01295827 · Phase 1 · registry result, not featured evidence 25%1 mg/kg Q2W NCT01295827 · Phase 1 · registry result, not featured evidence 25%Solid Tumors: Pembrolizumab Titrat NCT01295827 · Phase 1 · registry result, not featured evidence 33.3%Solid Tumors: Pembrolizumab Titrat NCT01295827 · Phase 1 · registry result, not featured evidence 66.7%Solid Tumors: Pembrolizumab Titrat NCT01295827 · Phase 1 · registry result, not featured evidence |
| Serious AEs | 37.5%Pixatimod (PG545) + Nivolumab + Cyg NCT05061017 · Phase 2 · registry result, not featured evidence · combination show 66 more results20%Pixatimod (PG545) + Nivolumab - Co NCT05061017 · Phase 2 · registry result, not featured evidence · combination 57.1%40 mg NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination 85.7%30 mg NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination 49.4%30 mg NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination 33.3%20 mg NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination 66.7%0.009 mg/kg q3w + 360 mg q3w NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 50%0.006 mg/kg q3w + 240 mg q2w NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 0%0.006 mg/kg q2w + 240 mg q2w NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 36%0.006 mg/kg q3w + 360 mg q3w NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 44.7%0.006 mg/kg q3w + 360 mg q3w NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 33.3%0.003 mg/kg q2w + 240 mg q2w NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 60%Part 3 Schedule Finding (Schedule NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 62.5%Part 3 Schedule Finding (Schedule NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 33.3%Part 3 Schedule Finding (Schedule NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 42.1%Part 4 Dose Expansion of NKTR-214 NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 100%400 mg NCT02658890 · Phase 1/2 · registry result, not featured evidence 83.3%BMS-986205 400 mg + nivolumab 240 mg NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination —BMS-986205 400 mg + nivolumab 240 mg NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination 66.7%BMS-986205 200 mg + nivolumab 240 mg NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination 68.8%BMS-986205 200 mg NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination 82.4%BMS-986205 200 mg NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination 64.3%BMS-986205 200 mg NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination 66.7%BMS-986205 100 mg + nivolumab 240 mg NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination 85.7%BMS-986205 100 mg NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination 83.3%BMS-986205 100 mg NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination 80%BMS-986205 100 mg NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination 100%50 mg NCT02658890 · Phase 1/2 · registry result, not featured evidence 60%BMS-986205 50 mg + nivolumab 240 mg NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination 0%50 mg NCT02658890 · Phase 1/2 · registry result, not featured evidence 71.4%BMS-986205 25 mg + nivolumab 240 mg NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination 50%Food Effect/ Relative BA (FE BA) S NCT02658890 · Phase 1/2 · registry result, not featured evidence 58.8%Part 2: Exp ML Anti-PDL1+CTLA4 NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination 16.7%Part 2: Exp ML BRAF-MT- NIVO NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination 0%0.3 mg/kg + Nivolumab NCT03123783 · Phase 1/2 · registry result, not featured evidence · combination 33.3%0.1 mg/kg + Nivolumab NCT03123783 · Phase 1/2 · registry result, not featured evidence · combination 33.3%0.03 mg/kg + Nivolumab NCT03123783 · Phase 1/2 · registry result, not featured evidence · combination 47.2%Cohort 1(Arm)/ inNSCLC (Phase 2) - NCT03123783 · Phase 1/2 · registry result, not featured evidence · combination 15.8%Cohort 2(Arm)/ PD1-MM (Phase 2) - NCT03123783 · Phase 1/2 · registry result, not featured evidence · combination 42.9%Cohort 3A(Arm)/ PD1-NSCLC (Phase 2 NCT03123783 · Phase 1/2 · registry result, not featured evidence · combination 46.4%Cohort 3B(Arm)/ PD1-NSCLC (Phase 2 NCT03123783 · Phase 1/2 · registry result, not featured evidence · combination 40%3.2/4 mg NCT02009449 · Phase 1 · registry result, not featured evidence 60%3.2/4 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 51.3%1.6/2 mg NCT02009449 · Phase 1 · registry result, not featured evidence 47.1%1.6/2 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 56.1%1.6/2 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 33.3%0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence 55.6%0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 66.7%0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination —0.8/ 1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 66.7%0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 16.7%0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 57.1%0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 100%0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 20%0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 33.3%0.4/0.5 mg NCT02009449 · Phase 1 · registry result, not featured evidence 33.3%0.4/0.5 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination —0.4/ 0.5 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 33.3%0.4/0.5 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 40%0.4/0.5 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 33.3%0.2/0.25 mg NCT02009449 · Phase 1 · registry result, not featured evidence 0%0.2/0.25 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 75%0.08/0.1 mg NCT02009449 · Phase 1 · registry result, not featured evidence 14.3%280 mg PO BID NCT03229278 · Phase 1 · registry result, not featured evidence · combination 0%140 mg / 280 mg NCT03229278 · Phase 1 · registry result, not featured evidence · combination 66.7%140 mg PO BID NCT03229278 · Phase 1 · registry result, not featured evidence · combination 100%140 mg PO daily NCT03229278 · Phase 1 · registry result, not featured evidence · combination | 20.7%200 mg IV Q3Wg NCT03715205 · Phase 4 · registry result, not featured evidence show 59 more results10.8%Untreated Brain Metastases From Me NCT02681549 · Phase 2 · registry result, not featured evidence 20%Untreated Brain Metastases From NS NCT02681549 · Phase 2 · registry result, not featured evidence 22.2%5 mg weekly NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination 57.1%5 mg weekly NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination 55.6%5 mg weekly NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination 43.4%5 mg weekly NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination 45.3%5 mg weekly NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination 36.8%5 mg weekly NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination 66.7%3 mg weekly NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination 45%300 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination 50%100 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination 51%100 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination 40%50 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination 0%25 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination 50%Phase 1: Lung Targets + MK-3475 / NCT02407171 · Phase 1/2 · registry result, not featured evidence · combination 20%Phase 1: Non-Lung Target + MK-3475 NCT02407171 · Phase 1/2 · registry result, not featured evidence · combination 33.3%30 Gy over 5 fractions NCT02858869 · Phase 1 · registry result, not featured evidence · combination 41.7%27 Gy over 3 fractions NCT02858869 · Phase 1 · registry result, not featured evidence · combination 14.3%18-21 Gy in one fraction NCT02858869 · Phase 1 · registry result, not featured evidence · combination 40%3.2/4 mg NCT02009449 · Phase 1 · registry result, not featured evidence 60%3.2/4 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 51.3%1.6/2 mg NCT02009449 · Phase 1 · registry result, not featured evidence 47.1%1.6/2 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 56.1%1.6/2 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 33.3%0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence 55.6%0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 66.7%0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination —0.8/ 1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 66.7%0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 16.7%0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 57.1%0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 100%0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 20%0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 33.3%0.4/0.5 mg NCT02009449 · Phase 1 · registry result, not featured evidence 33.3%0.4/0.5 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination —0.4/ 0.5 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 33.3%0.4/0.5 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 40%0.4/0.5 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 33.3%0.2/0.25 mg NCT02009449 · Phase 1 · registry result, not featured evidence 0%0.2/0.25 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 75%0.08/0.1 mg NCT02009449 · Phase 1 · registry result, not featured evidence 14.3%280 mg PO BID NCT03229278 · Phase 1 · registry result, not featured evidence · combination 0%140 mg / 280 mg NCT03229278 · Phase 1 · registry result, not featured evidence · combination 66.7%140 mg PO BID NCT03229278 · Phase 1 · registry result, not featured evidence · combination 100%140 mg PO daily NCT03229278 · Phase 1 · registry result, not featured evidence · combination 14.3%20 mg/kg NCT03236935 · Phase 1 · registry result, not featured evidence —12.5 mg/kg NCT03236935 · Phase 1 · registry result, not featured evidence 43.9%10 mg/kg Q2W NCT01295827 · Phase 1 · registry result, not featured evidence 41.2%10 mg/kg Q3W NCT01295827 · Phase 1 · registry result, not featured evidence · combination 42.6%10 mg/kg Q2W NCT01295827 · Phase 1 · registry result, not featured evidence 41.5%10 mg/kg Q3W NCT01295827 · Phase 1 · registry result, not featured evidence · combination 30%10 mg/kg Q2W NCT01295827 · Phase 1 · registry result, not featured evidence · combination 33.3%3 mg/kg Q2W NCT01295827 · Phase 1 · registry result, not featured evidence 42.6%2 mg/kg Q3W NCT01295827 · Phase 1 · registry result, not featured evidence · combination 55.7%2 mg/kg Q3W NCT01295827 · Phase 1 · registry result, not featured evidence 25%1 mg/kg Q2W NCT01295827 · Phase 1 · registry result, not featured evidence 0%Solid Tumors: Pembrolizumab Titrat NCT01295827 · Phase 1 · registry result, not featured evidence 66.7%Solid Tumors: Pembrolizumab Titrat NCT01295827 · Phase 1 · registry result, not featured evidence 33.3%Solid Tumors: Pembrolizumab Titrat NCT01295827 · Phase 1 · registry result, not featured evidence |
| Most frequent reported AEs | g anemia 62.5% fatigue 50% hyponatremia 50% NCT05061017 · Phase 2 · registry result, not featured evidence · combination show 63 more resultsactivated partial thromboplastin time prolonged 80% hypertriglyceridemia 60% hyponatremia 60% NCT05061017 · Phase 2 · registry result, not featured evidence · combination 40 mg anaemia 57.1% decreased appetite 57.1% contusion 42.9% NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination 30 mg fatigue 71.4% weight decreased 71.4% anaemia 57.1% NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination 30 mg fatigue 65.8% nausea 55.7% diarrhoea 53.2% NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination 20 mg diarrhoea 66.7% dyspnoea 66.7% fatigue 66.7% NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination 0.009 mg/kg q3w + 360 mg q3w pyrexia 100% rash 100% chills 66.7% NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 0.006 mg/kg q3w + 240 mg q2w arthralgia 100% fatigue 100% headache 100% NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 0.006 mg/kg q2w + 240 mg q2w chills 100% pyrexia 100% back pain 66.7% NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 0.006 mg/kg q3w + 360 mg q3w fatigue 76% chills 64% cough 60% NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 0.006 mg/kg q3w + 360 mg q3w fatigue 50.6% pyrexia 47.9% nausea 40.1% NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 0.003 mg/kg q2w + 240 mg q2w chills 100% nasal congestion 100% arthralgia 66.7% NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination fatigue 90% diarrhoea 80% nausea 80% NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination diarrhoea 75% influenza like illness 75% pruritus 75% NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination decreased appetite 100% fatigue 100% influenza like illness 100% NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination fatigue 78.9% influenza like illness 68.4% nausea 57.9% NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 400 mg abdominal discomfort 0% abdominal distension 0% abdominal hernia 0% NCT02658890 · Phase 1/2 · registry result, not featured evidence BMS-986205 400 mg + nivolumab 240 mg constipation 66.7% fatigue 66.7% vomiting 66.7% NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination BMS-986205 200 mg + nivolumab 240 mg fatigue 66.7% nausea 44.4% vomiting 44.4% NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination BMS-986205 200 mg decreased appetite 43.8% fatigue 43.8% nausea 43.8% NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination BMS-986205 200 mg fatigue 52.9% alanine aminotransferase increased 35.3% urinary tract infection 35.3% NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination BMS-986205 200 mg fatigue 42.9% constipation 28.6% nausea 28.6% NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination BMS-986205 100 mg + nivolumab 240 mg fatigue 58.3% anaemia 50% decreased appetite 50% NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination BMS-986205 100 mg asthenia 28.6% decreased appetite 28.6% nausea 28.6% NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination BMS-986205 100 mg decreased appetite 55.6% nausea 50% vomiting 38.9% NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination BMS-986205 100 mg decreased appetite 33.3% asthenia 26.7% constipation 26.7% NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination 50 mg headache 100% oedema peripheral 100% vomiting 100% NCT02658890 · Phase 1/2 · registry result, not featured evidence BMS-986205 50 mg + nivolumab 240 mg fatigue 70% vomiting 60% decreased appetite 50% NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination 50 mg abdominal discomfort 0% abdominal distension 0% abdominal hernia 0% NCT02658890 · Phase 1/2 · registry result, not featured evidence BMS-986205 25 mg + nivolumab 240 mg fatigue 57.1% nausea 57.1% vomiting 57.1% NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination fatigue 64.3% nausea 42.9% diarrhoea 35.7% NCT02658890 · Phase 1/2 · registry result, not featured evidence constipation 29.4% fatigue 29.4% nausea 29.4% NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination diarrhoea 50% fatigue 50% headache 50% NCT02658890 · Phase 1/2 · registry result, not featured evidence · combination 0.3 mg/kg + Nivolumab chills 100% nausea 100% pruritus 100% NCT03123783 · Phase 1/2 · registry result, not featured evidence · combination 0.1 mg/kg + Nivolumab anaemia 66.7% chills 66.7% decreased appetite 66.7% NCT03123783 · Phase 1/2 · registry result, not featured evidence · combination 0.03 mg/kg + Nivolumab fatigue 100% anxiety 33.3% arthralgia 33.3% NCT03123783 · Phase 1/2 · registry result, not featured evidence · combination chills 56.6% pyrexia 52.8% nausea 45.3% NCT03123783 · Phase 1/2 · registry result, not featured evidence · combination pyrexia 68.4% chills 50% nausea 47.4% NCT03123783 · Phase 1/2 · registry result, not featured evidence · combination nausea 50% pyrexia 50% dyspnoea 42.9% NCT03123783 · Phase 1/2 · registry result, not featured evidence · combination chills 46.4% asthenia 42.9% pyrexia 42.9% NCT03123783 · Phase 1/2 · registry result, not featured evidence · combination 3.2/4 mg anaemia 80% decreased appetite 80% fatigue 80% NCT02009449 · Phase 1 · registry result, not featured evidence 3.2/4 mg fatigue 100% anaemia 80% headache 60% NCT02009449 · Phase 1 · registry result, not featured evidence · combination 1.6/2 mg anaemia 75.2% fatigue 59% thrombocytopenia 59% NCT02009449 · Phase 1 · registry result, not featured evidence 1.6/2 mg fatigue 85.3% anaemia 76.5% thrombocytopenia 58.8% NCT02009449 · Phase 1 · registry result, not featured evidence · combination 1.6/2 mg anaemia 68.4% fatigue 59.6% cough 42.1% NCT02009449 · Phase 1 · registry result, not featured evidence · combination 0.8/1 mg anaemia 83.3% constipation 66.7% decreased appetite 66.7% NCT02009449 · Phase 1 · registry result, not featured evidence 0.8/1 mg fatigue 88.9% nausea 83.3% anaemia 77.8% NCT02009449 · Phase 1 · registry result, not featured evidence · combination 0.8/1 mg anaemia 83.3% thrombocytopenia 66.7% fatigue 50% NCT02009449 · Phase 1 · registry result, not featured evidence · combination 0.8/1 mg anaemia 83.3% fatigue 66.7% thrombocytopenia 66.7% NCT02009449 · Phase 1 · registry result, not featured evidence · combination 0.8/1 mg fatigue 100% decreased appetite 66.7% lipase increased 50% NCT02009449 · Phase 1 · registry result, not featured evidence · combination 0.8/1 mg fatigue 85.7% thrombocytopenia 71.4% anaemia 57.1% NCT02009449 · Phase 1 · registry result, not featured evidence · combination 0.8/1 mg activated partial thromboplastin time prolonged 100% alanine aminotransferase increased 100% anaemia 100% NCT02009449 · Phase 1 · registry result, not featured evidence · combination 0.8/1 mg anaemia 100% fatigue 100% thrombocytopenia 100% NCT02009449 · Phase 1 · registry result, not featured evidence · combination 0.4/0.5 mg anaemia 83.3% fatigue 83.3% nausea 83.3% NCT02009449 · Phase 1 · registry result, not featured evidence 0.4/0.5 mg anaemia 100% dyspnoea 66.7% fatigue 66.7% NCT02009449 · Phase 1 · registry result, not featured evidence · combination 0.4/0.5 mg thrombocytopenia 100% fatigue 66.7% anaemia 33.3% NCT02009449 · Phase 1 · registry result, not featured evidence · combination 0.4/0.5 mg fatigue 100% anaemia 80% hypokalaemia 60% NCT02009449 · Phase 1 · registry result, not featured evidence · combination 0.2/0.25 mg anaemia 50% fatigue 50% injection site erythema 50% NCT02009449 · Phase 1 · registry result, not featured evidence 0.2/0.25 mg asthenia 100% neutropenia 100% spermatic cord disorder 100% NCT02009449 · Phase 1 · registry result, not featured evidence · combination 0.08/0.1 mg injection site erythema 75% abdominal distension 50% abdominal pain 50% NCT02009449 · Phase 1 · registry result, not featured evidence 280 mg PO BID aspartate aminotransferase increased 14.3% cough 14.3% fatigue 14.3% NCT03229278 · Phase 1 · registry result, not featured evidence · combination 140 mg / 280 mg anemia 66.7% back pain 66.7% diarrhea 66.7% NCT03229278 · Phase 1 · registry result, not featured evidence · combination 140 mg PO BID lipase increased 66.7% alkaline phosphatase increased 33.3% anorexia 33.3% NCT03229278 · Phase 1 · registry result, not featured evidence · combination 140 mg PO daily hepatobiliary disorders - other, specify 100% abdominal pain 66.7% back pain 66.7% NCT03229278 · Phase 1 · registry result, not featured evidence · combination | 200 mg IV Q3Wg hypothyroidism 17.3% anaemia 12.7% constipation 11.3% NCT03715205 · Phase 4 · registry result, not featured evidence show 56 more resultsanorexia 40% gastrointestinal disorders - other, specify 40% hypertension 40% NCT02681549 · Phase 2 · registry result, not featured evidence 5 mg weekly fatigue 66.7% decreased appetite 55.6% cough 33.3% NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination 5 mg weekly fatigue 85.7% cough 42.9% hypophosphataemia 42.9% NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination 5 mg weekly fatigue 77.8% musculoskeletal and connective tissue disorders 55.6% cough 38.9% NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination 5 mg weekly fatigue 47.4% musculoskeletal and connective tissue disorders 44.7% decreased appetite 35.5% NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination 5 mg weekly nausea 56.6% fatigue 54.7% musculoskeletal and connective tissue disorders 45.3% NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination 5 mg weekly fatigue 57.9% musculoskeletal and connective tissue disorders 44.7% blood alkaline phosphatase increased 36.8% NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination 3 mg weekly decreased appetite 50% cough 33.3% diarrhoea 33.3% NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination 300 mg BID + 200 mg Q3W fatigue 65% nausea 55% vomiting 50% NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination 100 mg BID + 200 mg Q3W fatigue 50% back pain 38.9% diarrhoea 38.9% NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination 100 mg BID + 200 mg Q3W fatigue 48.4% nausea 30.1% cough 26.2% NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination 50 mg BID + 200 mg Q3W fatigue 65% arthralgia 45% nausea 45% NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination 25 mg BID + 200 mg Q3W arthralgia 100% constipation 75% cough 75% NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination dyspnea 90% fatigue 90% pain 70% NCT02407171 · Phase 1/2 · registry result, not featured evidence · combination fatigue 100% cough 80% pain 60% NCT02407171 · Phase 1/2 · registry result, not featured evidence · combination 30 Gy over 5 fractions headache 33.3% agitation 16.7% dermatitis, other 16.7% NCT02858869 · Phase 1 · registry result, not featured evidence · combination 27 Gy over 3 fractions symptomatic radionecrosis 16.7% constipation 8.3% dermatitis, other 8.3% NCT02858869 · Phase 1 · registry result, not featured evidence · combination 18-21 Gy in one fraction symptomatic radionecrosis 14.3% agitation 0% constipation 0% NCT02858869 · Phase 1 · registry result, not featured evidence · combination 3.2/4 mg anaemia 80% decreased appetite 80% fatigue 80% NCT02009449 · Phase 1 · registry result, not featured evidence 3.2/4 mg fatigue 100% anaemia 80% headache 60% NCT02009449 · Phase 1 · registry result, not featured evidence · combination 1.6/2 mg anaemia 75.2% fatigue 59% thrombocytopenia 59% NCT02009449 · Phase 1 · registry result, not featured evidence 1.6/2 mg fatigue 85.3% anaemia 76.5% thrombocytopenia 58.8% NCT02009449 · Phase 1 · registry result, not featured evidence · combination 1.6/2 mg anaemia 68.4% fatigue 59.6% cough 42.1% NCT02009449 · Phase 1 · registry result, not featured evidence · combination 0.8/1 mg anaemia 83.3% constipation 66.7% decreased appetite 66.7% NCT02009449 · Phase 1 · registry result, not featured evidence 0.8/1 mg fatigue 88.9% nausea 83.3% anaemia 77.8% NCT02009449 · Phase 1 · registry result, not featured evidence · combination 0.8/1 mg anaemia 83.3% thrombocytopenia 66.7% fatigue 50% NCT02009449 · Phase 1 · registry result, not featured evidence · combination 0.8/1 mg anaemia 83.3% fatigue 66.7% thrombocytopenia 66.7% NCT02009449 · Phase 1 · registry result, not featured evidence · combination 0.8/1 mg fatigue 100% decreased appetite 66.7% lipase increased 50% NCT02009449 · Phase 1 · registry result, not featured evidence · combination 0.8/1 mg fatigue 85.7% thrombocytopenia 71.4% anaemia 57.1% NCT02009449 · Phase 1 · registry result, not featured evidence · combination 0.8/1 mg activated partial thromboplastin time prolonged 100% alanine aminotransferase increased 100% anaemia 100% NCT02009449 · Phase 1 · registry result, not featured evidence · combination 0.8/1 mg anaemia 100% fatigue 100% thrombocytopenia 100% NCT02009449 · Phase 1 · registry result, not featured evidence · combination 0.4/0.5 mg anaemia 83.3% fatigue 83.3% nausea 83.3% NCT02009449 · Phase 1 · registry result, not featured evidence 0.4/0.5 mg anaemia 100% dyspnoea 66.7% fatigue 66.7% NCT02009449 · Phase 1 · registry result, not featured evidence · combination 0.4/0.5 mg thrombocytopenia 100% fatigue 66.7% anaemia 33.3% NCT02009449 · Phase 1 · registry result, not featured evidence · combination 0.4/0.5 mg fatigue 100% anaemia 80% hypokalaemia 60% NCT02009449 · Phase 1 · registry result, not featured evidence · combination 0.2/0.25 mg anaemia 50% fatigue 50% injection site erythema 50% NCT02009449 · Phase 1 · registry result, not featured evidence 0.2/0.25 mg asthenia 100% neutropenia 100% spermatic cord disorder 100% NCT02009449 · Phase 1 · registry result, not featured evidence · combination 0.08/0.1 mg injection site erythema 75% abdominal distension 50% abdominal pain 50% NCT02009449 · Phase 1 · registry result, not featured evidence 280 mg PO BID aspartate aminotransferase increased 14.3% cough 14.3% fatigue 14.3% NCT03229278 · Phase 1 · registry result, not featured evidence · combination 140 mg / 280 mg anemia 66.7% back pain 66.7% diarrhea 66.7% NCT03229278 · Phase 1 · registry result, not featured evidence · combination 140 mg PO BID lipase increased 66.7% alkaline phosphatase increased 33.3% anorexia 33.3% NCT03229278 · Phase 1 · registry result, not featured evidence · combination 140 mg PO daily hepatobiliary disorders - other, specify 100% abdominal pain 66.7% back pain 66.7% NCT03229278 · Phase 1 · registry result, not featured evidence · combination 20 mg/kg hypertension 28.6% anemia 14.3% arthralgia 14.3% NCT03236935 · Phase 1 · registry result, not featured evidence 10 mg/kg Q2W fatigue 58.9% diarrhoea 38.9% nausea 38.3% NCT01295827 · Phase 1 · registry result, not featured evidence 10 mg/kg Q3W fatigue 52.1% diarrhoea 35.5% nausea 34.5% NCT01295827 · Phase 1 · registry result, not featured evidence · combination 10 mg/kg Q2W fatigue 38.6% decreased appetite 27.2% dyspnoea 25.7% NCT01295827 · Phase 1 · registry result, not featured evidence 10 mg/kg Q3W fatigue 42.5% decreased appetite 30.7% cough 30% NCT01295827 · Phase 1 · registry result, not featured evidence · combination 10 mg/kg Q2W fatigue 50% decreased appetite 30% constipation 20% NCT01295827 · Phase 1 · registry result, not featured evidence · combination 3 mg/kg Q2W back pain 66.7% nausea 66.7% breast pain 33.3% NCT01295827 · Phase 1 · registry result, not featured evidence 2 mg/kg Q3W fatigue 47.5% nausea 34.6% diarrhoea 33.3% NCT01295827 · Phase 1 · registry result, not featured evidence · combination 2 mg/kg Q3W fatigue 27.9% diarrhoea 19.7% constipation 16.4% NCT01295827 · Phase 1 · registry result, not featured evidence 1 mg/kg Q2W pruritus 75% abdominal pain upper 25% anaemia 25% NCT01295827 · Phase 1 · registry result, not featured evidence bradycardia 25% diarrhoea 25% fatigue 25% NCT01295827 · Phase 1 · registry result, not featured evidence diarrhoea 66.7% fatigue 66.7% pruritus 66.7% NCT01295827 · Phase 1 · registry result, not featured evidence decreased appetite 66.7% fatigue 50% depression 33.3% NCT01295827 · Phase 1 · registry result, not featured evidence |
Notes
- aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- bPopulation context differs: registered conditions differ.
- cThe assessment timepoint is not available for both results.
- dTrial phases differ: Phase 1 versus Phase 1/2.
- eTrial phases differ: Phase 1/2 versus Phase 2.
- fPopulation comparability has not been reviewed for both studies.
- gPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Nivolumab
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 2 more results
show 2 more results
show 19 more results
show 15 more results
+ 1 further endpoint in the CSV export.
Pembrolizumab
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 7 more results
show 7 more results
show 12 more results
show 6 more results
show 1 more result
show 1 more result
show 2 more results
show 2 more results
+ 1 further endpoint in the CSV export.
Colorectal Cancer
Shared mechanism: PD-1 · full Colorectal Cancer pipeline
Nivolumab
Marketed by Bristol-Myers Squibb and partners
NCT02060188 · Phase 2 · completed
The study was non-randomized, unblinded, and had no comparator arm; its 385 participants were distributed across multiple treatment cohorts, including small cohorts. The primary endpoint was investigator-assessed tumor response, and although results were posted, there was no controlled primary comparison to determine whether nivolumab improved outcomes.
Next expected readout: December 2026 · NCT04912765 (registry estimate)
No aligned efficacy figure on record for this race.
Pembrolizumab
Marketed by Merck & Co.
NCT02460198 · Phase 2 · completed
The study treated 124 participants with pembrolizumab in a non-randomized, open-label, single-group design without a placebo or active comparator. Although the primary endpoint was an objective tumor response measure assessed by central imaging, the study had no formal between-group comparison and therefore provides limited evidence of pembrolizumab’s comparative benefit.
Next expected readout: December 2026 · NCT05784688 (registry estimate)
Reported efficacy
Objective Response Rate (ORR) - Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1) Assessed by Central Imaging Vendor (Up to approximately 48 months): Objective Response Rate (ORR) - Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1) Assessed by Central Imaging Vendor (Up to approximately 48 months): Cohort A - Pembrolizumab 200 mg 32.8 Percentage of participants (95% CI 21.3 to 46) | Cohort B - Pembrolizumab 200 mg 34.9 Percentage of participants (95% CI 23.3 to 48) (not_applicable)
Result source: NCT02460198
Results for Colorectal Cancer
There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.
Nivolumab: registry results are on file for Colorectal Cancer, but their comparison mappings are not yet available.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Pembrolizumab
show 7 more results
show 17 more results
show 19 more results
show 22 more results
show 7 more results
show 7 more results
show 5 more results
show 10 more results
show 10 more results
show 7 more results
show 7 more results
show 7 more results
+ 6 further endpoints in the CSV export.
Available safety results
Pembrolizumab
| Dropout rate | n/a: no completion milestoneCohort A: Triple Negative Breast C NCT03797326 · Phase 2 · registry result, not featured evidence · combination show 44 more resultsn/a: no completion milestoneCohort B: Ovarian Cancer (Lenva + NCT03797326 · Phase 2 · registry result, not featured evidence · combination n/a: no completion milestoneCohort C: Gastric Cancer (Lenva + NCT03797326 · Phase 2 · registry result, not featured evidence · combination n/a: no completion milestoneCohort D1: Colorectal Cancer (Lenv NCT03797326 · Phase 2 · registry result, not featured evidence · combination n/a: no completion milestoneCohort D2: Colorectal Cancer (Lenv NCT03797326 · Phase 2 · registry result, not featured evidence n/a: no completion milestoneCohort E: Glioblastoma Multiforma NCT03797326 · Phase 2 · registry result, not featured evidence · combination n/a: no completion milestoneCohort F: Biliary Tract Cancer (Le NCT03797326 · Phase 2 · registry result, not featured evidence · combination n/a: no completion milestoneCohort G: Pancreatic Cancer (Lenva NCT03797326 · Phase 2 · registry result, not featured evidence · combination n/a: no completion milestone100 mg + 200 mg NCT03473925 · Phase 2 · registry result, not featured evidence · combination n/a: no completion milestone30 mg + 200 mg NCT03473925 · Phase 2 · registry result, not featured evidence · combination 100%1200 ug/kg NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination 100%960 ug/kg NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination 66.7%480 ug/kg NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination —Phase 2a: Arm I NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination —Phase 2a: Arm II NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination —Phase 2a: Arm III NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination —Phase 2a: Arm IV NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination —Phase 2a: Arm IVa NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination —Phase 2a: Arm V NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination —Phase 2a: Arm Va NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination —Phase 2a: Biomarker Cohort NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination 0%5 mg weekly NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination 0%5 mg weekly NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination —5 mg weekly NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination —5 mg weekly NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination —5 mg weekly NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination —5 mg weekly NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination 66.7%3 mg weekly NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination n/a: no completion milestone300 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination n/a: no completion milestone100 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination n/a: no completion milestone100 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination n/a: no completion milestone50 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination n/a: no completion milestone25 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination 57.1%1400 mg + 200 mg NCT02713529 · Phase 1/2 · registry result, not featured evidence · combination 87.5%1100 mg + 200 mg NCT02713529 · Phase 1/2 · registry result, not featured evidence · combination 73.8%Part 2, Group 1: CRC MMR-proficien NCT02713529 · Phase 1/2 · registry result, not featured evidence · combination 93.5%Part 2, Group 2: Pancreatic Cancer NCT02713529 · Phase 1/2 · registry result, not featured evidence · combination 75%Part 2, Group 3: NSCLC PD-L1 Low, NCT02713529 · Phase 1/2 · registry result, not featured evidence · combination 73.7%Part 2, Group 4a: Refractory / Rel NCT02713529 · Phase 1/2 · registry result, not featured evidence · combination 66.7%Part 2, Group 4b: Refractory/Relap NCT02713529 · Phase 1/2 · registry result, not featured evidence · combination n/a: no completion milestone100 mg NCT02903914 · Phase 1 · registry result, not featured evidence · combination n/a: no completion milestone75 mg NCT02903914 · Phase 1 · registry result, not featured evidence · combination —50 mg NCT02903914 · Phase 1 · registry result, not featured evidence · combination n/a: no completion milestone50 mg NCT02903914 · Phase 1 · registry result, not featured evidence · combination n/a: no completion milestone50 mg NCT02903914 · Phase 1 · registry result, not featured evidence · combination |
|---|---|
| Discontinued due to AEs | —Cohort A: Triple Negative Breast C NCT03797326 · Phase 2 · registry result, not featured evidence · combination show 44 more results—Cohort B: Ovarian Cancer (Lenva + NCT03797326 · Phase 2 · registry result, not featured evidence · combination —Cohort C: Gastric Cancer (Lenva + NCT03797326 · Phase 2 · registry result, not featured evidence · combination —Cohort D1: Colorectal Cancer (Lenv NCT03797326 · Phase 2 · registry result, not featured evidence · combination —Cohort D2: Colorectal Cancer (Lenv NCT03797326 · Phase 2 · registry result, not featured evidence —Cohort E: Glioblastoma Multiforma NCT03797326 · Phase 2 · registry result, not featured evidence · combination —Cohort F: Biliary Tract Cancer (Le NCT03797326 · Phase 2 · registry result, not featured evidence · combination —Cohort G: Pancreatic Cancer (Lenva NCT03797326 · Phase 2 · registry result, not featured evidence · combination —100 mg + 200 mg NCT03473925 · Phase 2 · registry result, not featured evidence · combination —30 mg + 200 mg NCT03473925 · Phase 2 · registry result, not featured evidence · combination —1200 ug/kg NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination —960 ug/kg NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination —480 ug/kg NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination —Phase 2a: Arm I NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination —Phase 2a: Arm II NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination —Phase 2a: Arm III NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination —Phase 2a: Arm IV NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination —Phase 2a: Arm IVa NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination —Phase 2a: Arm V NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination —Phase 2a: Arm Va NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination —Phase 2a: Biomarker Cohort NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination —5 mg weekly NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination —5 mg weekly NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination —5 mg weekly NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination —5 mg weekly NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination —5 mg weekly NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination —5 mg weekly NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination —3 mg weekly NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination —300 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination —100 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination —100 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination —50 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination —25 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination —1400 mg + 200 mg NCT02713529 · Phase 1/2 · registry result, not featured evidence · combination —1100 mg + 200 mg NCT02713529 · Phase 1/2 · registry result, not featured evidence · combination —Part 2, Group 1: CRC MMR-proficien NCT02713529 · Phase 1/2 · registry result, not featured evidence · combination —Part 2, Group 2: Pancreatic Cancer NCT02713529 · Phase 1/2 · registry result, not featured evidence · combination —Part 2, Group 3: NSCLC PD-L1 Low, NCT02713529 · Phase 1/2 · registry result, not featured evidence · combination —Part 2, Group 4a: Refractory / Rel NCT02713529 · Phase 1/2 · registry result, not featured evidence · combination —Part 2, Group 4b: Refractory/Relap NCT02713529 · Phase 1/2 · registry result, not featured evidence · combination 1.6%100 mg NCT02903914 · Phase 1 · registry result, not featured evidence · combination 0%75 mg NCT02903914 · Phase 1 · registry result, not featured evidence · combination —50 mg NCT02903914 · Phase 1 · registry result, not featured evidence · combination 0%50 mg NCT02903914 · Phase 1 · registry result, not featured evidence · combination 0%50 mg NCT02903914 · Phase 1 · registry result, not featured evidence · combination |
| Serious AEs | 51.6%Cohort A: Triple Negative Breast C NCT03797326 · Phase 2 · registry result, not featured evidence · combination show 44 more results61.3%Cohort B: Ovarian Cancer (Lenva + NCT03797326 · Phase 2 · registry result, not featured evidence · combination 57.6%Cohort C: Gastric Cancer (Lenva + NCT03797326 · Phase 2 · registry result, not featured evidence · combination 52.4%Cohort D1: Colorectal Cancer (Lenv NCT03797326 · Phase 2 · registry result, not featured evidence · combination 40%Cohort D2: Colorectal Cancer (Lenv NCT03797326 · Phase 2 · registry result, not featured evidence 29.7%Cohort E: Glioblastoma Multiforma NCT03797326 · Phase 2 · registry result, not featured evidence · combination 60.8%Cohort F: Biliary Tract Cancer (Le NCT03797326 · Phase 2 · registry result, not featured evidence · combination 47.6%Cohort G: Pancreatic Cancer (Lenva NCT03797326 · Phase 2 · registry result, not featured evidence · combination 27.8%100 mg + 200 mg NCT03473925 · Phase 2 · registry result, not featured evidence · combination 33.3%30 mg + 200 mg NCT03473925 · Phase 2 · registry result, not featured evidence · combination 16.7%1200 ug/kg NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination 33.3%960 ug/kg NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination 66.7%480 ug/kg NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination 25%Phase 2a: Arm I NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination 82.4%Phase 2a: Arm II NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination 64.7%Phase 2a: Arm III NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination 51.7%Phase 2a: Arm IV NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination 71.4%Phase 2a: Arm IVa NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination 56.3%Phase 2a: Arm V NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination 79.4%Phase 2a: Arm Va NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination 69.2%Phase 2a: Biomarker Cohort NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination 22.2%5 mg weekly NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination 57.1%5 mg weekly NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination 55.6%5 mg weekly NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination 43.4%5 mg weekly NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination 45.3%5 mg weekly NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination 36.8%5 mg weekly NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination 66.7%3 mg weekly NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination 45%300 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination 50%100 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination 51%100 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination 40%50 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination 0%25 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination —1400 mg + 200 mg NCT02713529 · Phase 1/2 · registry result, not featured evidence · combination —1100 mg + 200 mg NCT02713529 · Phase 1/2 · registry result, not featured evidence · combination —Part 2, Group 1: CRC MMR-proficien NCT02713529 · Phase 1/2 · registry result, not featured evidence · combination —Part 2, Group 2: Pancreatic Cancer NCT02713529 · Phase 1/2 · registry result, not featured evidence · combination —Part 2, Group 3: NSCLC PD-L1 Low, NCT02713529 · Phase 1/2 · registry result, not featured evidence · combination —Part 2, Group 4a: Refractory / Rel NCT02713529 · Phase 1/2 · registry result, not featured evidence · combination —Part 2, Group 4b: Refractory/Relap NCT02713529 · Phase 1/2 · registry result, not featured evidence · combination 38.2%100 mg NCT02903914 · Phase 1 · registry result, not featured evidence · combination 35.7%75 mg NCT02903914 · Phase 1 · registry result, not featured evidence · combination 37.5%50 mg NCT02903914 · Phase 1 · registry result, not featured evidence · combination —50 mg NCT02903914 · Phase 1 · registry result, not featured evidence · combination —50 mg NCT02903914 · Phase 1 · registry result, not featured evidence · combination |
| Most frequent reported AEs | hypertension 51.6% diarrhoea 45.2% hypothyroidism 45.2% NCT03797326 · Phase 2 · registry result, not featured evidence · combination show 35 more resultshypertension 67.7% diarrhoea 61.3% decreased appetite 48.4% NCT03797326 · Phase 2 · registry result, not featured evidence · combination hypertension 37.4% nausea 31.3% asthenia 30.3% NCT03797326 · Phase 2 · registry result, not featured evidence · combination hypertension 56.2% diarrhoea 44.8% decreased appetite 43.8% NCT03797326 · Phase 2 · registry result, not featured evidence · combination hypertension 56.7% diarrhoea 53.3% dysphonia 40% NCT03797326 · Phase 2 · registry result, not featured evidence hypertension 50.5% asthenia 28.7% hypothyroidism 27.7% NCT03797326 · Phase 2 · registry result, not featured evidence · combination hypertension 56.9% diarrhoea 41.2% fatigue 39.2% NCT03797326 · Phase 2 · registry result, not featured evidence · combination hypertension 53.4% nausea 35.9% decreased appetite 32% NCT03797326 · Phase 2 · registry result, not featured evidence · combination 100 mg + 200 mg nausea 29.6% fatigue 25.9% pyrexia 22.2% NCT03473925 · Phase 2 · registry result, not featured evidence · combination 30 mg + 200 mg fatigue 33.3% decreased appetite 27.5% pyrexia 23.5% NCT03473925 · Phase 2 · registry result, not featured evidence · combination 1200 ug/kg chills 83.3% fatigue 66.7% injection site erythema 66.7% NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination 960 ug/kg oedema peripheral 66.7% anaemia 33.3% blood bilirubin increased 33.3% NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination 480 ug/kg headache 100% pyrexia 100% chills 66.7% NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination alanine aminotransferase increased 31.3% cough 31.3% oedema peripheral 31.3% NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination fatigue 41.2% nausea 29.4% oedema peripheral 23.5% NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination fatigue 47.1% decreased appetite 35.3% pruritus 23.5% NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination nausea 48.3% fatigue 44.8% pyrexia 41.4% NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination fatigue 42.9% pyrexia 42.9% decreased appetite 35.7% NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination pyrexia 43.8% fatigue 37.5% nausea 31.3% NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination fatigue 47.1% anaemia 32.4% decreased appetite 26.5% NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination aspartate aminotransferase increased 38.5% anaemia 30.8% fatigue 30.8% NCT04332653 · Phase 1/2 · registry result, not featured evidence · combination 5 mg weekly fatigue 66.7% decreased appetite 55.6% cough 33.3% NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination 5 mg weekly fatigue 85.7% cough 42.9% hypophosphataemia 42.9% NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination 5 mg weekly fatigue 77.8% musculoskeletal and connective tissue disorders 55.6% cough 38.9% NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination 5 mg weekly fatigue 47.4% musculoskeletal and connective tissue disorders 44.7% decreased appetite 35.5% NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination 5 mg weekly nausea 56.6% fatigue 54.7% musculoskeletal and connective tissue disorders 45.3% NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination 5 mg weekly fatigue 57.9% musculoskeletal and connective tissue disorders 44.7% blood alkaline phosphatase increased 36.8% NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination 3 mg weekly decreased appetite 50% cough 33.3% diarrhoea 33.3% NCT02437136 · Phase 1/2 · registry result, not featured evidence · combination 300 mg BID + 200 mg Q3W fatigue 65% nausea 55% vomiting 50% NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination 100 mg BID + 200 mg Q3W fatigue 50% back pain 38.9% diarrhoea 38.9% NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination 100 mg BID + 200 mg Q3W fatigue 48.4% nausea 30.1% cough 26.2% NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination 50 mg BID + 200 mg Q3W fatigue 65% arthralgia 45% nausea 45% NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination 25 mg BID + 200 mg Q3W arthralgia 100% constipation 75% cough 75% NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination 100 mg diarrhoea 25.2% constipation 23.6% fatigue 23.6% NCT02903914 · Phase 1 · registry result, not featured evidence · combination 75 mg aspartate aminotransferase increased 21.4% back pain 21.4% fatigue 21.4% NCT02903914 · Phase 1 · registry result, not featured evidence · combination 50 mg fatigue 37.5% diarrhoea 25% decreased appetite 18.8% NCT02903914 · Phase 1 · registry result, not featured evidence · combination |
Head and Neck Squamous Cell Carcinoma
Shared mechanism: PD-1 · full Head and Neck Squamous Cell Carcinoma pipeline
Nivolumab
Marketed by Bristol-Myers Squibb and partners
NCT02105636 · Phase 3 · completed
The trial randomly assigned 361 participants to open-label nivolumab or active comparator therapy, so treatment assignment was not blinded. Its objective primary endpoint, overall survival, was statistically significantly better with nivolumab, but the available record does not report a power calculation; these design limitations support a moderate grade rather than the highest grade.
Next expected readout: November 2026 · NCT02955290 (registry estimate)
Reported efficacy
Overall Survival (OS) (From date of randomization to date of death (Up to approximately 18 months)): Overall Survival (OS) (From date of randomization to date of death (Up to approximately 18 months)): Nivolumab 3mg/kg 7.49 Months (95% CI 5.49 to 9.1) | Investigators Choice 5.06 Months (95% CI 4.04 to 6.05) (met)
Result source: NCT02105636
Pembrolizumab
Marketed by Merck & Co.
NCT02358031 · Phase 3 · completed
KEYNOTE-048 was a randomized, open-label, active-controlled Phase 3 in 882 patients with recurrent or metastatic HNSCC. Its primary endpoint, overall survival, is a clinical outcome and was met at a pre-specified interim analysis. An open-label trial is never graded strong under the rubric.
Next expected readout: November 2026 · NCT02955290 (registry estimate)
Reported efficacy
Pembro Combo vs Control: Progression Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by Blinded Independent Central Review (BICR) in All Participants (Up to approximately 47 months); Pembro Combo vs Control: PFS Per RECIST 1.1 by BICR in Participants With Programmed Cell Death Ligand 1 (PD-L1) Combined Positive Score (CPS) ≥1 (Up to approximately 47 months); Pembro Combo vs Control: PFS Per RECIST 1.1 by BICR in Participants With PD-L1 CPS ≥20 (Up to approximately 47 months); Pembro Combo vs Control: Overall Survival (OS) in All Participants (Up to approximately 47 months); Pembro Combo vs Control: OS in Participants With PD-L1 CPS ≥1 (Up to approximately 47 months); Pembro Combo vs Control: OS in Participants With PD-L1 CPS ≥20 (Up to approximately 47 months); Pembro Mono vs Control: PFS Per RECIST 1.1 by BICR in All Participants (Up to approximately 47 months); Pembro Mono vs Control: PFS Per RECIST 1.1 by BICR in Participants With PD-L1 CPS ≥1 (Up to approximately 47 months); Pembro Mono vs Control: PFS Per RECIST 1.1 by BICR in Participants With PD-L1 CPS ≥20 (Up to approximately 47 months); Pembro Mono vs Control: OS in All Participants (Up to approximately 47 months); Pembro Mono vs Control: OS in Participants With PD-L1 CPS ≥1 (Up to approximately 47 months); Pembro Mono vs Control: OS in Participants With PD-L1 CPS ≥20 (Up to approximately 47 months): Primary endpoint, overall survival at a pre-specified interim analysis: pembrolizumab plus platinum/fluorouracil vs cetuximab plus platinum/fluorouracil, median 13.0 vs 10.7 months, HR 0.77; pembrolizumab alone vs cetuximab-chemotherapy in PD-L1 CPS >=1, HR 0.65 (95% CI 0.53 to 0.80) (KEYTRUDA label, KEYNOTE-048). (met)
Result source: NCT02358031
Results for Head and Neck Squamous Cell Carcinoma
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
Coverage. Nivolumab: 6 of 7 rows · Pembrolizumab: 7 of 7 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Nivolumab Rows use multiple source trials | Pembrolizumab Rows use multiple source trials |
|---|---|---|
| Duration of Response time to event · months No placebo or comparator arm | NA months4 mg/kg + 3 mg/kg Q2Wa,b,c NCT02526017 · Phase 1 · registry result, not featured evidence · combination show 6 more doses8.9 months4 mg/kg + 3 mg/kg Q2W NCT02526017 · Phase 1 · registry result, not featured evidence · combination 16.2 months4 mg/kg + 3 mg/kg Q2W NCT02526017 · Phase 1 · registry result, not featured evidence · combination 7.3 months4 mg/kg + 3 mg/kg Q2W NCT02526017 · Phase 1 · registry result, not featured evidence · combination 12.7 months4 mg/kg + 3 mg/kg Q2W NCT02526017 · Phase 1 · registry result, not featured evidence · combination NA months4 mg/kg + 3 mg/kg Q2W NCT02526017 · Phase 1 · registry result, not featured evidence · combination NA months4 mg/kg + 3 mg/kg Q2W NCT02526017 · Phase 1 · registry result, not featured evidence · combination | NA months5.0 mga,b,c NCT04879849 · Phase 1 · registry result, not featured evidence · combination show 6 more dosesNA months5.0 mg NCT04879849 · Phase 1 · registry result, not featured evidence · combination NA months3.5 mg NCT04879849 · Phase 1 · registry result, not featured evidence · combination 9.26 months2.5 mg NCT04879849 · Phase 1 · registry result, not featured evidence · combination NA months2.5 mg NCT04879849 · Phase 1 · registry result, not featured evidence · combination NA months2.5 mg NCT04879849 · Phase 1 · registry result, not featured evidence · combination NA months0.2 mg NCT04879849 · Phase 1 · registry result, not featured evidence · combination |
| ORR responder rate · % of participants No placebo or comparator arm | 7% (n=14)280 mg PO BIDb,c NCT03229278 · Phase 1 · registry result, not featured evidence · combination 16 other source trials0% (n=30)4 mg/kg + 3 mg/kg Q2W NCT02526017 · Phase 1 · registry result, not featured evidence · combination 0% (n=30)4 mg/kg + 3 mg/kg Q2W NCT02526017 · Phase 1 · registry result, not featured evidence · combination 9.1% (n=11)4 mg/kg + 3 mg/kg Q2W NCT02526017 · Phase 1 · registry result, not featured evidence · combination 9.1% (n=11)4 mg/kg + 3 mg/kg Q2W NCT02526017 · Phase 1 · registry result, not featured evidence · combination 6.9% (n=29)4 mg/kg + 3 mg/kg Q2W NCT02526017 · Phase 1 · registry result, not featured evidence · combination 3.4% (n=29)4 mg/kg + 3 mg/kg Q2W NCT02526017 · Phase 1 · registry result, not featured evidence · combination 3.2% (n=31)4 mg/kg + 3 mg/kg Q2W NCT02526017 · Phase 1 · registry result, not featured evidence · combination 0% (n=31)4 mg/kg + 3 mg/kg Q2W NCT02526017 · Phase 1 · registry result, not featured evidence · combination 13.3% (n=30)4 mg/kg + 3 mg/kg Q2W NCT02526017 · Phase 1 · registry result, not featured evidence · combination 6.7% (n=30)4 mg/kg + 3 mg/kg Q2W NCT02526017 · Phase 1 · registry result, not featured evidence · combination 5.9% (n=68)4 mg/kg + 3 mg/kg Q2W NCT02526017 · Phase 1 · registry result, not featured evidence · combination 6% (n=67)4 mg/kg + 3 mg/kg Q2W NCT02526017 · Phase 1 · registry result, not featured evidence · combination 6.7% (n=30)4 mg/kg + 3 mg/kg Q2W NCT02526017 · Phase 1 · registry result, not featured evidence · combination 16.7% (n=30)4 mg/kg + 3 mg/kg Q2W NCT02526017 · Phase 1 · registry result, not featured evidence · combination 13.8% (n=29)4 mg/kg + 3 mg/kg Q2W NCT02526017 · Phase 1 · registry result, not featured evidence · combination 10.7% (n=28)4 mg/kg + 3 mg/kg Q2W NCT02526017 · Phase 1 · registry result, not featured evidence · combination | 25% (n=4)5.0 mga,b,c NCT04879849 · Phase 1 · registry result, not featured evidence · combination show 27 more doses0% (n=4)5.0 mg NCT04879849 · Phase 1 · registry result, not featured evidence · combination 0% (n=4)5.0 mg NCT04879849 · Phase 1 · registry result, not featured evidence · combination 25% (n=4)5.0 mg NCT04879849 · Phase 1 · registry result, not featured evidence · combination 0% (n=6)3.5 mg NCT04879849 · Phase 1 · registry result, not featured evidence · combination 0% (n=6)3.5 mg NCT04879849 · Phase 1 · registry result, not featured evidence · combination 16.7% (n=6)3.5 mg NCT04879849 · Phase 1 · registry result, not featured evidence · combination 0% (n=6)3.5 mg NCT04879849 · Phase 1 · registry result, not featured evidence · combination 14.3% (n=7)2.5 mg NCT04879849 · Phase 1 · registry result, not featured evidence · combination 14.3% (n=7)2.5 mg NCT04879849 · Phase 1 · registry result, not featured evidence · combination 14.3% (n=7)2.5 mg NCT04879849 · Phase 1 · registry result, not featured evidence · combination 14.3% (n=7)2.5 mg NCT04879849 · Phase 1 · registry result, not featured evidence · combination 0% (n=3)1.6 mg NCT04879849 · Phase 1 · registry result, not featured evidence · combination 0% (n=3)1.6 mg NCT04879849 · Phase 1 · registry result, not featured evidence · combination 0% (n=3)1.6 mg NCT04879849 · Phase 1 · registry result, not featured evidence · combination 0% (n=3)1.6 mg NCT04879849 · Phase 1 · registry result, not featured evidence · combination 0% (n=4)0.8 mg NCT04879849 · Phase 1 · registry result, not featured evidence · combination 0% (n=4)0.8 mg NCT04879849 · Phase 1 · registry result, not featured evidence · combination 0% (n=4)0.8 mg NCT04879849 · Phase 1 · registry result, not featured evidence · combination 0% (n=4)0.8 mg NCT04879849 · Phase 1 · registry result, not featured evidence · combination 0% (n=2)0.4 mg NCT04879849 · Phase 1 · registry result, not featured evidence · combination 0% (n=2)0.4 mg NCT04879849 · Phase 1 · registry result, not featured evidence · combination 0% (n=2)0.4 mg NCT04879849 · Phase 1 · registry result, not featured evidence · combination 0% (n=2)0.4 mg NCT04879849 · Phase 1 · registry result, not featured evidence · combination 0% (n=2)0.2 mg NCT04879849 · Phase 1 · registry result, not featured evidence · combination 0% (n=2)0.2 mg NCT04879849 · Phase 1 · registry result, not featured evidence · combination 50% (n=2)0.2 mg NCT04879849 · Phase 1 · registry result, not featured evidence · combination 0% (n=2)0.2 mg NCT04879849 · Phase 1 · registry result, not featured evidence · combination |
| PFS time to event · months No placebo or comparator arm | 1.8 months4 mg/kg + 3 mg/kg Q2Wa,b,c NCT02526017 · Phase 1 · registry result, not featured evidence · combination show 7 more doses1.8 months4 mg/kg + 3 mg/kg Q2W NCT02526017 · Phase 1 · registry result, not featured evidence · combination 2.8 months4 mg/kg + 3 mg/kg Q2W NCT02526017 · Phase 1 · registry result, not featured evidence · combination 1.9 months4 mg/kg + 3 mg/kg Q2W NCT02526017 · Phase 1 · registry result, not featured evidence · combination 2 months4 mg/kg + 3 mg/kg Q2W NCT02526017 · Phase 1 · registry result, not featured evidence · combination 1.7 months4 mg/kg + 3 mg/kg Q2W NCT02526017 · Phase 1 · registry result, not featured evidence · combination 2.9 months4 mg/kg + 3 mg/kg Q2W NCT02526017 · Phase 1 · registry result, not featured evidence · combination 1.8 months4 mg/kg + 3 mg/kg Q2W NCT02526017 · Phase 1 · registry result, not featured evidence · combination | 2.1 months100 mga,b,c NCT02903914 · Phase 1 · registry result, not featured evidence · combination show 3 more doses3 months100 mg NCT02903914 · Phase 1 · registry result, not featured evidence · combination 2.6 months75 mg NCT02903914 · Phase 1 · registry result, not featured evidence · combination 2.1 months50 mg NCT02903914 · Phase 1 · registry result, not featured evidence · combination |
| Dropout rate | 0%280 mg PO BIDd NCT03229278 · Phase 1 · registry result, not featured evidence · combination show 11 more results0%140 mg / 280 mg NCT03229278 · Phase 1 · registry result, not featured evidence · combination 0%140 mg PO BID NCT03229278 · Phase 1 · registry result, not featured evidence · combination 0%140 mg PO daily NCT03229278 · Phase 1 · registry result, not featured evidence · combination 0%6 mg/kg + 3 mg/kg Q2W NCT02526017 · Phase 1 · registry result, not featured evidence · combination 0%6 mg/kg Q2W NCT02526017 · Phase 1 · registry result, not featured evidence —4 mg/kg + 3 mg/kg Q2W NCT02526017 · Phase 1 · registry result, not featured evidence · combination 0%4 mg/kg + 3 mg/kg Q3W NCT02526017 · Phase 1 · registry result, not featured evidence · combination 0%4 mg/kg Q2W NCT02526017 · Phase 1 · registry result, not featured evidence 25%2 mg/kg + 3 mg/kg Q2W NCT02526017 · Phase 1 · registry result, not featured evidence · combination 0%2 mg/kg Q2W NCT02526017 · Phase 1 · registry result, not featured evidence —1 mg/kg + 3 mg/kg Q2W NCT02526017 · Phase 1 · registry result, not featured evidence · combination | n/a: no completion milestone300 mg BID + 200 mg Q3Wd NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination show 28 more resultsn/a: no completion milestone100 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination n/a: no completion milestone100 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination n/a: no completion milestone50 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination n/a: no completion milestone25 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination —5.0 mg NCT04879849 · Phase 1 · registry result, not featured evidence · combination n/a: no completion milestone5.0 mg NCT04879849 · Phase 1 · registry result, not featured evidence · combination —3.5 mg NCT04879849 · Phase 1 · registry result, not featured evidence · combination n/a: no completion milestone3.5 mg NCT04879849 · Phase 1 · registry result, not featured evidence · combination —2.5 mg NCT04879849 · Phase 1 · registry result, not featured evidence · combination n/a: no completion milestone2.5 mg NCT04879849 · Phase 1 · registry result, not featured evidence · combination —1.6 mg NCT04879849 · Phase 1 · registry result, not featured evidence · combination n/a: no completion milestone1.6 mg NCT04879849 · Phase 1 · registry result, not featured evidence · combination —0.8 mg NCT04879849 · Phase 1 · registry result, not featured evidence · combination n/a: no completion milestone0.8 mg NCT04879849 · Phase 1 · registry result, not featured evidence · combination —0.4 mg NCT04879849 · Phase 1 · registry result, not featured evidence · combination n/a: no completion milestone0.4 mg NCT04879849 · Phase 1 · registry result, not featured evidence · combination —0.2 mg NCT04879849 · Phase 1 · registry result, not featured evidence · combination 0%280 mg PO BID NCT03229278 · Phase 1 · registry result, not featured evidence · combination 0%140 mg / 280 mg NCT03229278 · Phase 1 · registry result, not featured evidence · combination 0%140 mg PO BID NCT03229278 · Phase 1 · registry result, not featured evidence · combination 0%140 mg PO daily NCT03229278 · Phase 1 · registry result, not featured evidence · combination n/a: no completion milestone100 mg NCT02903914 · Phase 1 · registry result, not featured evidence · combination n/a: no completion milestone75 mg NCT02903914 · Phase 1 · registry result, not featured evidence · combination —50 mg NCT02903914 · Phase 1 · registry result, not featured evidence · combination n/a: no completion milestone50 mg NCT02903914 · Phase 1 · registry result, not featured evidence · combination n/a: no completion milestone50 mg NCT02903914 · Phase 1 · registry result, not featured evidence · combination 57.1%20 mg/kg NCT03236935 · Phase 1 · registry result, not featured evidence —12.5 mg/kg NCT03236935 · Phase 1 · registry result, not featured evidence |
| Discontinued due to AEs | —280 mg PO BIDd NCT03229278 · Phase 1 · registry result, not featured evidence · combination show 11 more results—140 mg / 280 mg NCT03229278 · Phase 1 · registry result, not featured evidence · combination —140 mg PO BID NCT03229278 · Phase 1 · registry result, not featured evidence · combination —140 mg PO daily NCT03229278 · Phase 1 · registry result, not featured evidence · combination —6 mg/kg + 3 mg/kg Q2W NCT02526017 · Phase 1 · registry result, not featured evidence · combination —6 mg/kg Q2W NCT02526017 · Phase 1 · registry result, not featured evidence —4 mg/kg + 3 mg/kg Q2W NCT02526017 · Phase 1 · registry result, not featured evidence · combination —4 mg/kg + 3 mg/kg Q3W NCT02526017 · Phase 1 · registry result, not featured evidence · combination —4 mg/kg Q2W NCT02526017 · Phase 1 · registry result, not featured evidence —2 mg/kg + 3 mg/kg Q2W NCT02526017 · Phase 1 · registry result, not featured evidence · combination —2 mg/kg Q2W NCT02526017 · Phase 1 · registry result, not featured evidence —1 mg/kg + 3 mg/kg Q2W NCT02526017 · Phase 1 · registry result, not featured evidence · combination | —300 mg BID + 200 mg Q3Wd NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination show 28 more results—100 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination —100 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination —50 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination —25 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination —5.0 mg NCT04879849 · Phase 1 · registry result, not featured evidence · combination —5.0 mg NCT04879849 · Phase 1 · registry result, not featured evidence · combination —3.5 mg NCT04879849 · Phase 1 · registry result, not featured evidence · combination —3.5 mg NCT04879849 · Phase 1 · registry result, not featured evidence · combination —2.5 mg NCT04879849 · Phase 1 · registry result, not featured evidence · combination —2.5 mg NCT04879849 · Phase 1 · registry result, not featured evidence · combination —1.6 mg NCT04879849 · Phase 1 · registry result, not featured evidence · combination —1.6 mg NCT04879849 · Phase 1 · registry result, not featured evidence · combination —0.8 mg NCT04879849 · Phase 1 · registry result, not featured evidence · combination —0.8 mg NCT04879849 · Phase 1 · registry result, not featured evidence · combination —0.4 mg NCT04879849 · Phase 1 · registry result, not featured evidence · combination —0.4 mg NCT04879849 · Phase 1 · registry result, not featured evidence · combination —0.2 mg NCT04879849 · Phase 1 · registry result, not featured evidence · combination —280 mg PO BID NCT03229278 · Phase 1 · registry result, not featured evidence · combination —140 mg / 280 mg NCT03229278 · Phase 1 · registry result, not featured evidence · combination —140 mg PO BID NCT03229278 · Phase 1 · registry result, not featured evidence · combination —140 mg PO daily NCT03229278 · Phase 1 · registry result, not featured evidence · combination 1.6%100 mg NCT02903914 · Phase 1 · registry result, not featured evidence · combination 0%75 mg NCT02903914 · Phase 1 · registry result, not featured evidence · combination —50 mg NCT02903914 · Phase 1 · registry result, not featured evidence · combination 0%50 mg NCT02903914 · Phase 1 · registry result, not featured evidence · combination 0%50 mg NCT02903914 · Phase 1 · registry result, not featured evidence · combination —20 mg/kg NCT03236935 · Phase 1 · registry result, not featured evidence —12.5 mg/kg NCT03236935 · Phase 1 · registry result, not featured evidence |
| Serious AEs | 14.3%280 mg PO BIDd NCT03229278 · Phase 1 · registry result, not featured evidence · combination show 11 more results0%140 mg / 280 mg NCT03229278 · Phase 1 · registry result, not featured evidence · combination 66.7%140 mg PO BID NCT03229278 · Phase 1 · registry result, not featured evidence · combination 100%140 mg PO daily NCT03229278 · Phase 1 · registry result, not featured evidence · combination 50%6 mg/kg + 3 mg/kg Q2W NCT02526017 · Phase 1 · registry result, not featured evidence · combination 54.5%6 mg/kg Q2W NCT02526017 · Phase 1 · registry result, not featured evidence 52.1%4 mg/kg + 3 mg/kg Q2W NCT02526017 · Phase 1 · registry result, not featured evidence · combination 50%4 mg/kg + 3 mg/kg Q3W NCT02526017 · Phase 1 · registry result, not featured evidence · combination 10%4 mg/kg Q2W NCT02526017 · Phase 1 · registry result, not featured evidence 33.3%2 mg/kg + 3 mg/kg Q2W NCT02526017 · Phase 1 · registry result, not featured evidence · combination 33.3%2 mg/kg Q2W NCT02526017 · Phase 1 · registry result, not featured evidence 50%1 mg/kg + 3 mg/kg Q2W NCT02526017 · Phase 1 · registry result, not featured evidence · combination | 45%300 mg BID + 200 mg Q3Wd NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination show 28 more results50%100 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination 51%100 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination 40%50 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination 0%25 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination 50%5.0 mg NCT04879849 · Phase 1 · registry result, not featured evidence · combination —5.0 mg NCT04879849 · Phase 1 · registry result, not featured evidence · combination 0%3.5 mg NCT04879849 · Phase 1 · registry result, not featured evidence · combination —3.5 mg NCT04879849 · Phase 1 · registry result, not featured evidence · combination 42.9%2.5 mg NCT04879849 · Phase 1 · registry result, not featured evidence · combination —2.5 mg NCT04879849 · Phase 1 · registry result, not featured evidence · combination 33.3%1.6 mg NCT04879849 · Phase 1 · registry result, not featured evidence · combination —1.6 mg NCT04879849 · Phase 1 · registry result, not featured evidence · combination 75%0.8 mg NCT04879849 · Phase 1 · registry result, not featured evidence · combination —0.8 mg NCT04879849 · Phase 1 · registry result, not featured evidence · combination 50%0.4 mg NCT04879849 · Phase 1 · registry result, not featured evidence · combination —0.4 mg NCT04879849 · Phase 1 · registry result, not featured evidence · combination 0%0.2 mg NCT04879849 · Phase 1 · registry result, not featured evidence · combination 14.3%280 mg PO BID NCT03229278 · Phase 1 · registry result, not featured evidence · combination 0%140 mg / 280 mg NCT03229278 · Phase 1 · registry result, not featured evidence · combination 66.7%140 mg PO BID NCT03229278 · Phase 1 · registry result, not featured evidence · combination 100%140 mg PO daily NCT03229278 · Phase 1 · registry result, not featured evidence · combination 38.2%100 mg NCT02903914 · Phase 1 · registry result, not featured evidence · combination 35.7%75 mg NCT02903914 · Phase 1 · registry result, not featured evidence · combination 37.5%50 mg NCT02903914 · Phase 1 · registry result, not featured evidence · combination —50 mg NCT02903914 · Phase 1 · registry result, not featured evidence · combination —50 mg NCT02903914 · Phase 1 · registry result, not featured evidence · combination 14.3%20 mg/kg NCT03236935 · Phase 1 · registry result, not featured evidence —12.5 mg/kg NCT03236935 · Phase 1 · registry result, not featured evidence |
| Most frequent reported AEs | 280 mg PO BIDd aspartate aminotransferase increased 14.3% cough 14.3% fatigue 14.3% NCT03229278 · Phase 1 · registry result, not featured evidence · combination show 11 more results140 mg / 280 mg anemia 66.7% back pain 66.7% diarrhea 66.7% NCT03229278 · Phase 1 · registry result, not featured evidence · combination 140 mg PO BID lipase increased 66.7% alkaline phosphatase increased 33.3% anorexia 33.3% NCT03229278 · Phase 1 · registry result, not featured evidence · combination 140 mg PO daily hepatobiliary disorders - other, specify 100% abdominal pain 66.7% back pain 66.7% NCT03229278 · Phase 1 · registry result, not featured evidence · combination 6 mg/kg + 3 mg/kg Q2W fatigue 100% dehydration 83.3% periorbital oedema 83.3% NCT02526017 · Phase 1 · registry result, not featured evidence · combination 6 mg/kg Q2W aspartate aminotransferase increased 60% blood creatine phosphokinase increased 40% fatigue 40% NCT02526017 · Phase 1 · registry result, not featured evidence 4 mg/kg + 3 mg/kg Q2W fatigue 55.8% blood creatine phosphokinase increased 47.2% periorbital oedema 46% NCT02526017 · Phase 1 · registry result, not featured evidence · combination 4 mg/kg + 3 mg/kg Q3W candida infection 40% dizziness 40% fall 40% NCT02526017 · Phase 1 · registry result, not featured evidence · combination 4 mg/kg Q2W abdominal pain 45.5% aspartate aminotransferase increased 45.5% fatigue 45.5% NCT02526017 · Phase 1 · registry result, not featured evidence 2 mg/kg + 3 mg/kg Q2W amylase increased 33.3% arthralgia 33.3% aspartate aminotransferase increased 33.3% NCT02526017 · Phase 1 · registry result, not featured evidence · combination 2 mg/kg Q2W fatigue 66.7% blood alkaline phosphatase increased 33.3% blood bilirubin increased 33.3% NCT02526017 · Phase 1 · registry result, not featured evidence 1 mg/kg + 3 mg/kg Q2W anaemia 50% amylase increased 25% aspartate aminotransferase increased 25% NCT02526017 · Phase 1 · registry result, not featured evidence · combination | 300 mg BID + 200 mg Q3Wd fatigue 65% nausea 55% vomiting 50% NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination show 19 more results100 mg BID + 200 mg Q3W fatigue 50% back pain 38.9% diarrhoea 38.9% NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination 100 mg BID + 200 mg Q3W fatigue 48.4% nausea 30.1% cough 26.2% NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination 50 mg BID + 200 mg Q3W fatigue 65% arthralgia 45% nausea 45% NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination 25 mg BID + 200 mg Q3W arthralgia 100% constipation 75% cough 75% NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination 5.0 mg pain in extremity 50% anaemia 33.3% arthralgia 33.3% NCT04879849 · Phase 1 · registry result, not featured evidence · combination 3.5 mg diarrhoea 50% fatigue 50% chills 33.3% NCT04879849 · Phase 1 · registry result, not featured evidence · combination 2.5 mg fatigue 71.4% constipation 57.1% cough 42.9% NCT04879849 · Phase 1 · registry result, not featured evidence · combination 1.6 mg constipation 33.3% device malfunction 33.3% fatigue 33.3% NCT04879849 · Phase 1 · registry result, not featured evidence · combination 0.8 mg fatigue 75% abdominal distension 25% abdominal pain 25% NCT04879849 · Phase 1 · registry result, not featured evidence · combination 0.4 mg anaemia 50% balance disorder 50% constipation 50% NCT04879849 · Phase 1 · registry result, not featured evidence · combination 0.2 mg cough 50% oesophagitis 50% arthralgia 25% NCT04879849 · Phase 1 · registry result, not featured evidence · combination 280 mg PO BID aspartate aminotransferase increased 14.3% cough 14.3% fatigue 14.3% NCT03229278 · Phase 1 · registry result, not featured evidence · combination 140 mg / 280 mg anemia 66.7% back pain 66.7% diarrhea 66.7% NCT03229278 · Phase 1 · registry result, not featured evidence · combination 140 mg PO BID lipase increased 66.7% alkaline phosphatase increased 33.3% anorexia 33.3% NCT03229278 · Phase 1 · registry result, not featured evidence · combination 140 mg PO daily hepatobiliary disorders - other, specify 100% abdominal pain 66.7% back pain 66.7% NCT03229278 · Phase 1 · registry result, not featured evidence · combination 100 mg diarrhoea 25.2% constipation 23.6% fatigue 23.6% NCT02903914 · Phase 1 · registry result, not featured evidence · combination 75 mg aspartate aminotransferase increased 21.4% back pain 21.4% fatigue 21.4% NCT02903914 · Phase 1 · registry result, not featured evidence · combination 50 mg fatigue 37.5% diarrhoea 25% decreased appetite 18.8% NCT02903914 · Phase 1 · registry result, not featured evidence · combination 20 mg/kg hypertension 28.6% anemia 14.3% arthralgia 14.3% NCT03236935 · Phase 1 · registry result, not featured evidence |
Notes
- aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- bPopulation context differs: registered conditions differ.
- cThe assessment timepoint is not available for both results.
- dPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Nivolumab
show 7 more results
show 7 more results
Pembrolizumab
show 6 more results
show 3 more results
show 3 more results
Renal Cell Carcinoma
Shared mechanism: PD-1 · full Renal Cell Carcinoma pipeline
Nivolumab
Marketed by Bristol-Myers Squibb and partners
NCT02231749 · Phase 3 · completed
The trial was randomized and actively controlled, with 550 patients receiving nivolumab plus ipilimumab and 546 receiving sunitinib, but it was open-label. Its objective clinical endpoints were favorable for the nivolumab combination, with statistically significant comparisons reported for response rate, overall survival, and progression-free survival; however, the registry does not document the power calculation needed to establish adequate powering, so this is moderate evidence rather than strong evidence.
Next expected readout: December 2026 · NCT05263050 (registry estimate)
Reported efficacy
Overall Survival (OS) at Primary Endpoint (Randomization until 398 deaths, up to May 2015 (approximately 30 months)): Overall Survival (OS) at Primary Endpoint (Randomization until 398 deaths, up to May 2015 (approximately 30 months)): Nivolumab 25 months | Everolimus 19.55 months (95% CI 17.64 to 23.06) (met)
Result source: NCT01668784
Pembrolizumab
Marketed by Merck & Co.
NCT02853331 · Phase 3 · completed
The trial randomly assigned 861 participants to open-label pembrolizumab plus axitinib or active-controlled sunitinib monotherapy, with progression assessed by blinded independent central imaging review. Both prespecified primary endpoints favored the combination: progression-free survival was significantly improved (HR 0.69, p=0.00012) and overall survival was significantly improved (HR 0.53, p=0.00005), but the open-label design limits the evidence strength.
Next expected readout: December 2026 · NCT05319015 (registry estimate)
Reported efficacy
Progression-free Survival (PFS) by Independent Imaging Review (IIR) (From the date of randomization to the date of the first documentation of PD or date of death, whichever occurred first or up to data cutoff date 28 Aug 2020 (up to approximately 46 months)): Progression-free Survival (PFS) by Independent Imaging Review (IIR) (From the date of randomization to the date of the first documentation of PD or date of death, whichever occurred first or up to data cutoff date 28 Aug 2020 (up to approximately 46 months)): Lenvatinib 18 mg Plus Everolimus 5 mg 14.7 months (95% CI 11.1 to 16.7) | Lenvatinib 20 mg Plus Pembrolizumab 200 mg 23.9 months (95% CI 20.8 to 27.7) | Sunitinib 50 mg 9.2 months (95% CI 6 to 11) (met)
Result source: NCT02811861
Results for Renal Cell Carcinoma
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
Coverage. Nivolumab: 7 of 8 rows · Pembrolizumab: 8 of 8 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Nivolumab Rows use multiple source trials | Pembrolizumab Rows use multiple source trials |
|---|---|---|
| Duration of Response time to event · months No placebo or comparator arm | NA months30 mga,b,c,d NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination show 2 more doses7.38 months*30 mg NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination · converted to months from 32 weeks as posted 20.63 months*30 mg NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination · converted to months from 89.4 weeks as posted | 12.4 months100 mga,b,c,d NCT02903914 · Phase 1 · registry result, not featured evidence · combination show 2 more dosesNA months75 mg NCT02903914 · Phase 1 · registry result, not featured evidence · combination NA months50 mg NCT02903914 · Phase 1 · registry result, not featured evidence · combination |
| ORR event count · % of participants No placebo or comparator arm | 14.9% (n=429)*0.006 mg/kg q3w + 360 mg q3wa,b,c,d NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination · converted to % from 64 Participants as posted show 1 more dose17.6% (n=17)* NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination · converted to % from 3 Participants as posted | 20% (n=5)*3.2/4 mga,b,c,d NCT02009449 · Phase 1 · registry result, not featured evidence · converted to % from 1 Participants as posted show 19 more doses20% (n=5)*3.2/4 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination · converted to % from 1 Participants as posted 6.3% (n=95)*1.6/2 mg NCT02009449 · Phase 1 · registry result, not featured evidence · converted to % from 6 Participants as posted 10.7% (n=28)*1.6/2 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination · converted to % from 3 Participants as posted 39.6% (n=48)*1.6/2 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination · converted to % from 19 Participants as posted 0% (n=5)*0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · converted to % from 0 Participants as posted 46.7% (n=15)*0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination · converted to % from 7 Participants as posted 0% (n=6)*0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination · converted to % from 0 Participants as posted 16.7% (n=6)*0.8/ 1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination · converted to % from 1 Participants as posted 20% (n=5)*0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination · converted to % from 1 Participants as posted 35.7% (n=14)*0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination · converted to % from 5 Participants as posted 100% (n=1)*0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination · converted to % from 1 Participants as posted 0% (n=5)*0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination · converted to % from 0 Participants as posted 0% (n=6)*0.4/0.5 mg NCT02009449 · Phase 1 · registry result, not featured evidence · converted to % from 0 Participants as posted 33.3% (n=3)*0.4/0.5 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination · converted to % from 1 Participants as posted 20% (n=5)*0.4/ 0.5 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination · converted to % from 1 Participants as posted 0% (n=4)*0.4/0.5 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination · converted to % from 0 Participants as posted 0% (n=5)*0.2/0.25 mg NCT02009449 · Phase 1 · registry result, not featured evidence · converted to % from 0 Participants as posted 25% (n=4)*0.2/0.25 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination · converted to % from 1 Participants as posted 0% (n=4)*0.08/0.1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · converted to % from 0 Participants as posted |
| ORR responder rate · % of participants No placebo or comparator arm | 7% (n=14)280 mg PO BIDe,d NCT03229278 · Phase 1 · registry result, not featured evidence · combination 16 other source trials0% (n=30)4 mg/kg + 3 mg/kg Q2W NCT02526017 · Phase 1 · registry result, not featured evidence · combination 0% (n=30)4 mg/kg + 3 mg/kg Q2W NCT02526017 · Phase 1 · registry result, not featured evidence · combination 9.1% (n=11)4 mg/kg + 3 mg/kg Q2W NCT02526017 · Phase 1 · registry result, not featured evidence · combination 9.1% (n=11)4 mg/kg + 3 mg/kg Q2W NCT02526017 · Phase 1 · registry result, not featured evidence · combination 6.9% (n=29)4 mg/kg + 3 mg/kg Q2W NCT02526017 · Phase 1 · registry result, not featured evidence · combination 3.4% (n=29)4 mg/kg + 3 mg/kg Q2W NCT02526017 · Phase 1 · registry result, not featured evidence · combination 3.2% (n=31)4 mg/kg + 3 mg/kg Q2W NCT02526017 · Phase 1 · registry result, not featured evidence · combination 0% (n=31)4 mg/kg + 3 mg/kg Q2W NCT02526017 · Phase 1 · registry result, not featured evidence · combination 13.3% (n=30)4 mg/kg + 3 mg/kg Q2W NCT02526017 · Phase 1 · registry result, not featured evidence · combination 6.7% (n=30)4 mg/kg + 3 mg/kg Q2W NCT02526017 · Phase 1 · registry result, not featured evidence · combination 5.9% (n=68)4 mg/kg + 3 mg/kg Q2W NCT02526017 · Phase 1 · registry result, not featured evidence · combination 6% (n=67)4 mg/kg + 3 mg/kg Q2W NCT02526017 · Phase 1 · registry result, not featured evidence · combination 6.7% (n=30)4 mg/kg + 3 mg/kg Q2W NCT02526017 · Phase 1 · registry result, not featured evidence · combination 16.7% (n=30)4 mg/kg + 3 mg/kg Q2W NCT02526017 · Phase 1 · registry result, not featured evidence · combination 13.8% (n=29)4 mg/kg + 3 mg/kg Q2W NCT02526017 · Phase 1 · registry result, not featured evidence · combination 10.7% (n=28)4 mg/kg + 3 mg/kg Q2W NCT02526017 · Phase 1 · registry result, not featured evidence · combination | 7% (n=14)280 mg PO BIDe,d NCT03229278 · Phase 1 · registry result, not featured evidence · combination 4 other source trials0% (n=10)100 mg NCT02903914 · Phase 1 · registry result, not featured evidence · combination 10% (n=10)50 mg NCT02903914 · Phase 1 · registry result, not featured evidence · combination 7.7% (n=13)75 mg NCT02903914 · Phase 1 · registry result, not featured evidence · combination 11% (n=118)100 mg NCT02903914 · Phase 1 · registry result, not featured evidence · combination |
| PFS time to event · months No placebo or comparator arm | 18.37 months*30 mga,b,c,d NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination · converted to months from 79.6 weeks as posted show 2 more doses2.33 months*30 mg NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination · converted to months from 10.1 weeks as posted 3.37 months*30 mg NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination · converted to months from 14.6 weeks as posted | 2.1 months100 mga,b,c,d NCT02903914 · Phase 1 · registry result, not featured evidence · combination show 3 more doses3 months100 mg NCT02903914 · Phase 1 · registry result, not featured evidence · combination 2.6 months75 mg NCT02903914 · Phase 1 · registry result, not featured evidence · combination 2.1 months50 mg NCT02903914 · Phase 1 · registry result, not featured evidence · combination |
| Dropout rate | 100%40 mgf NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination show 47 more results100%30 mg NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination 97.5%30 mg NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination 100%20 mg NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination 0%0.009 mg/kg q3w + 360 mg q3w NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 0%0.006 mg/kg q3w + 240 mg q2w NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 33.3%0.006 mg/kg q2w + 240 mg q2w NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 20%0.006 mg/kg q3w + 360 mg q3w NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 17.2%0.006 mg/kg q3w + 360 mg q3w NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 0%0.003 mg/kg q2w + 240 mg q2w NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 0%Part 3 Schedule Finding (Schedule NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 0%Part 3 Schedule Finding (Schedule NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 0%Part 3 Schedule Finding (Schedule NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 10.5%Part 4 Dose Expansion of NKTR-214 NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 100%3.2/4 mg NCT02009449 · Phase 1 · registry result, not featured evidence 100%3.2/4 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 99.1%1.6/2 mg NCT02009449 · Phase 1 · registry result, not featured evidence 100%1.6/2 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 96.5%1.6/2 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 100%0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence 100%0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 100%0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 100%0.8/ 1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination —0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 100%0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 85.7%0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 100%0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 100%0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 100%0.4/0.5 mg NCT02009449 · Phase 1 · registry result, not featured evidence 100%0.4/0.5 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 100%0.4/ 0.5 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination —0.4/0.5 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 100%0.4/0.5 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 100%0.2/0.25 mg NCT02009449 · Phase 1 · registry result, not featured evidence 100%0.2/0.25 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 100%0.08/0.1 mg NCT02009449 · Phase 1 · registry result, not featured evidence 0%280 mg PO BID NCT03229278 · Phase 1 · registry result, not featured evidence · combination 0%140 mg / 280 mg NCT03229278 · Phase 1 · registry result, not featured evidence · combination 0%140 mg PO BID NCT03229278 · Phase 1 · registry result, not featured evidence · combination 0%140 mg PO daily NCT03229278 · Phase 1 · registry result, not featured evidence · combination 0%6 mg/kg + 3 mg/kg Q2W NCT02526017 · Phase 1 · registry result, not featured evidence · combination 0%6 mg/kg Q2W NCT02526017 · Phase 1 · registry result, not featured evidence —4 mg/kg + 3 mg/kg Q2W NCT02526017 · Phase 1 · registry result, not featured evidence · combination 0%4 mg/kg + 3 mg/kg Q3W NCT02526017 · Phase 1 · registry result, not featured evidence · combination 0%4 mg/kg Q2W NCT02526017 · Phase 1 · registry result, not featured evidence 25%2 mg/kg + 3 mg/kg Q2W NCT02526017 · Phase 1 · registry result, not featured evidence · combination 0%2 mg/kg Q2W NCT02526017 · Phase 1 · registry result, not featured evidence —1 mg/kg + 3 mg/kg Q2W NCT02526017 · Phase 1 · registry result, not featured evidence · combination | n/a: no completion milestone300 mg BID + 200 mg Q3Wf NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination show 35 more resultsn/a: no completion milestone100 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination n/a: no completion milestone100 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination n/a: no completion milestone50 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination n/a: no completion milestone25 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination 100%3.2/4 mg NCT02009449 · Phase 1 · registry result, not featured evidence 100%3.2/4 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 99.1%1.6/2 mg NCT02009449 · Phase 1 · registry result, not featured evidence 100%1.6/2 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 96.5%1.6/2 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 100%0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence 100%0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 100%0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 100%0.8/ 1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination —0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 100%0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 85.7%0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 100%0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 100%0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 100%0.4/0.5 mg NCT02009449 · Phase 1 · registry result, not featured evidence 100%0.4/0.5 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 100%0.4/ 0.5 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination —0.4/0.5 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 100%0.4/0.5 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 100%0.2/0.25 mg NCT02009449 · Phase 1 · registry result, not featured evidence 100%0.2/0.25 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 100%0.08/0.1 mg NCT02009449 · Phase 1 · registry result, not featured evidence 0%280 mg PO BID NCT03229278 · Phase 1 · registry result, not featured evidence · combination 0%140 mg / 280 mg NCT03229278 · Phase 1 · registry result, not featured evidence · combination 0%140 mg PO BID NCT03229278 · Phase 1 · registry result, not featured evidence · combination 0%140 mg PO daily NCT03229278 · Phase 1 · registry result, not featured evidence · combination n/a: no completion milestone100 mg NCT02903914 · Phase 1 · registry result, not featured evidence · combination n/a: no completion milestone75 mg NCT02903914 · Phase 1 · registry result, not featured evidence · combination —50 mg NCT02903914 · Phase 1 · registry result, not featured evidence · combination n/a: no completion milestone50 mg NCT02903914 · Phase 1 · registry result, not featured evidence · combination n/a: no completion milestone50 mg NCT02903914 · Phase 1 · registry result, not featured evidence · combination |
| Discontinued due to AEs | —40 mgf NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination show 47 more results—30 mg NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination —30 mg NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination —20 mg NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination —0.009 mg/kg q3w + 360 mg q3w NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination —0.006 mg/kg q3w + 240 mg q2w NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination —0.006 mg/kg q2w + 240 mg q2w NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination —0.006 mg/kg q3w + 360 mg q3w NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination —0.006 mg/kg q3w + 360 mg q3w NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination —0.003 mg/kg q2w + 240 mg q2w NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination —Part 3 Schedule Finding (Schedule NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination —Part 3 Schedule Finding (Schedule NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination —Part 3 Schedule Finding (Schedule NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination —Part 4 Dose Expansion of NKTR-214 NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination —3.2/4 mg NCT02009449 · Phase 1 · registry result, not featured evidence —3.2/4 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination —1.6/2 mg NCT02009449 · Phase 1 · registry result, not featured evidence —1.6/2 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination —1.6/2 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination —0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence —0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination —0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination —0.8/ 1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination —0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination —0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination —0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination —0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination —0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination —0.4/0.5 mg NCT02009449 · Phase 1 · registry result, not featured evidence —0.4/0.5 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination —0.4/ 0.5 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination —0.4/0.5 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination —0.4/0.5 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination —0.2/0.25 mg NCT02009449 · Phase 1 · registry result, not featured evidence —0.2/0.25 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination —0.08/0.1 mg NCT02009449 · Phase 1 · registry result, not featured evidence —280 mg PO BID NCT03229278 · Phase 1 · registry result, not featured evidence · combination —140 mg / 280 mg NCT03229278 · Phase 1 · registry result, not featured evidence · combination —140 mg PO BID NCT03229278 · Phase 1 · registry result, not featured evidence · combination —140 mg PO daily NCT03229278 · Phase 1 · registry result, not featured evidence · combination —6 mg/kg + 3 mg/kg Q2W NCT02526017 · Phase 1 · registry result, not featured evidence · combination —6 mg/kg Q2W NCT02526017 · Phase 1 · registry result, not featured evidence —4 mg/kg + 3 mg/kg Q2W NCT02526017 · Phase 1 · registry result, not featured evidence · combination —4 mg/kg + 3 mg/kg Q3W NCT02526017 · Phase 1 · registry result, not featured evidence · combination —4 mg/kg Q2W NCT02526017 · Phase 1 · registry result, not featured evidence —2 mg/kg + 3 mg/kg Q2W NCT02526017 · Phase 1 · registry result, not featured evidence · combination —2 mg/kg Q2W NCT02526017 · Phase 1 · registry result, not featured evidence —1 mg/kg + 3 mg/kg Q2W NCT02526017 · Phase 1 · registry result, not featured evidence · combination | —300 mg BID + 200 mg Q3Wf NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination show 35 more results—100 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination —100 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination —50 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination —25 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination —3.2/4 mg NCT02009449 · Phase 1 · registry result, not featured evidence —3.2/4 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination —1.6/2 mg NCT02009449 · Phase 1 · registry result, not featured evidence —1.6/2 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination —1.6/2 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination —0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence —0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination —0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination —0.8/ 1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination —0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination —0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination —0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination —0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination —0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination —0.4/0.5 mg NCT02009449 · Phase 1 · registry result, not featured evidence —0.4/0.5 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination —0.4/ 0.5 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination —0.4/0.5 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination —0.4/0.5 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination —0.2/0.25 mg NCT02009449 · Phase 1 · registry result, not featured evidence —0.2/0.25 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination —0.08/0.1 mg NCT02009449 · Phase 1 · registry result, not featured evidence —280 mg PO BID NCT03229278 · Phase 1 · registry result, not featured evidence · combination —140 mg / 280 mg NCT03229278 · Phase 1 · registry result, not featured evidence · combination —140 mg PO BID NCT03229278 · Phase 1 · registry result, not featured evidence · combination —140 mg PO daily NCT03229278 · Phase 1 · registry result, not featured evidence · combination 1.6%100 mg NCT02903914 · Phase 1 · registry result, not featured evidence · combination 0%75 mg NCT02903914 · Phase 1 · registry result, not featured evidence · combination —50 mg NCT02903914 · Phase 1 · registry result, not featured evidence · combination 0%50 mg NCT02903914 · Phase 1 · registry result, not featured evidence · combination 0%50 mg NCT02903914 · Phase 1 · registry result, not featured evidence · combination |
| Serious AEs | 57.1%40 mgf NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination show 47 more results85.7%30 mg NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination 49.4%30 mg NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination 33.3%20 mg NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination 66.7%0.009 mg/kg q3w + 360 mg q3w NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 50%0.006 mg/kg q3w + 240 mg q2w NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 0%0.006 mg/kg q2w + 240 mg q2w NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 36%0.006 mg/kg q3w + 360 mg q3w NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 44.7%0.006 mg/kg q3w + 360 mg q3w NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 33.3%0.003 mg/kg q2w + 240 mg q2w NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 60%Part 3 Schedule Finding (Schedule NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 62.5%Part 3 Schedule Finding (Schedule NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 33.3%Part 3 Schedule Finding (Schedule NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 42.1%Part 4 Dose Expansion of NKTR-214 NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 40%3.2/4 mg NCT02009449 · Phase 1 · registry result, not featured evidence 60%3.2/4 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 51.3%1.6/2 mg NCT02009449 · Phase 1 · registry result, not featured evidence 47.1%1.6/2 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 56.1%1.6/2 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 33.3%0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence 55.6%0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 66.7%0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination —0.8/ 1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 66.7%0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 16.7%0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 57.1%0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 100%0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 20%0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 33.3%0.4/0.5 mg NCT02009449 · Phase 1 · registry result, not featured evidence 33.3%0.4/0.5 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination —0.4/ 0.5 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 33.3%0.4/0.5 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 40%0.4/0.5 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 33.3%0.2/0.25 mg NCT02009449 · Phase 1 · registry result, not featured evidence 0%0.2/0.25 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 75%0.08/0.1 mg NCT02009449 · Phase 1 · registry result, not featured evidence 14.3%280 mg PO BID NCT03229278 · Phase 1 · registry result, not featured evidence · combination 0%140 mg / 280 mg NCT03229278 · Phase 1 · registry result, not featured evidence · combination 66.7%140 mg PO BID NCT03229278 · Phase 1 · registry result, not featured evidence · combination 100%140 mg PO daily NCT03229278 · Phase 1 · registry result, not featured evidence · combination 50%6 mg/kg + 3 mg/kg Q2W NCT02526017 · Phase 1 · registry result, not featured evidence · combination 54.5%6 mg/kg Q2W NCT02526017 · Phase 1 · registry result, not featured evidence 52.1%4 mg/kg + 3 mg/kg Q2W NCT02526017 · Phase 1 · registry result, not featured evidence · combination 50%4 mg/kg + 3 mg/kg Q3W NCT02526017 · Phase 1 · registry result, not featured evidence · combination 10%4 mg/kg Q2W NCT02526017 · Phase 1 · registry result, not featured evidence 33.3%2 mg/kg + 3 mg/kg Q2W NCT02526017 · Phase 1 · registry result, not featured evidence · combination 33.3%2 mg/kg Q2W NCT02526017 · Phase 1 · registry result, not featured evidence 50%1 mg/kg + 3 mg/kg Q2W NCT02526017 · Phase 1 · registry result, not featured evidence · combination | 45%300 mg BID + 200 mg Q3Wf NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination show 35 more results50%100 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination 51%100 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination 40%50 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination 0%25 mg BID + 200 mg Q3W NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination 40%3.2/4 mg NCT02009449 · Phase 1 · registry result, not featured evidence 60%3.2/4 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 51.3%1.6/2 mg NCT02009449 · Phase 1 · registry result, not featured evidence 47.1%1.6/2 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 56.1%1.6/2 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 33.3%0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence 55.6%0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 66.7%0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination —0.8/ 1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 66.7%0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 16.7%0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 57.1%0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 100%0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 20%0.8/1 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 33.3%0.4/0.5 mg NCT02009449 · Phase 1 · registry result, not featured evidence 33.3%0.4/0.5 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination —0.4/ 0.5 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 33.3%0.4/0.5 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 40%0.4/0.5 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 33.3%0.2/0.25 mg NCT02009449 · Phase 1 · registry result, not featured evidence 0%0.2/0.25 mg NCT02009449 · Phase 1 · registry result, not featured evidence · combination 75%0.08/0.1 mg NCT02009449 · Phase 1 · registry result, not featured evidence 14.3%280 mg PO BID NCT03229278 · Phase 1 · registry result, not featured evidence · combination 0%140 mg / 280 mg NCT03229278 · Phase 1 · registry result, not featured evidence · combination 66.7%140 mg PO BID NCT03229278 · Phase 1 · registry result, not featured evidence · combination 100%140 mg PO daily NCT03229278 · Phase 1 · registry result, not featured evidence · combination 38.2%100 mg NCT02903914 · Phase 1 · registry result, not featured evidence · combination 35.7%75 mg NCT02903914 · Phase 1 · registry result, not featured evidence · combination 37.5%50 mg NCT02903914 · Phase 1 · registry result, not featured evidence · combination —50 mg NCT02903914 · Phase 1 · registry result, not featured evidence · combination —50 mg NCT02903914 · Phase 1 · registry result, not featured evidence · combination |
| Most frequent reported AEs | 40 mgf anaemia 57.1% decreased appetite 57.1% contusion 42.9% NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination show 45 more results30 mg fatigue 71.4% weight decreased 71.4% anaemia 57.1% NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination 30 mg fatigue 65.8% nausea 55.7% diarrhoea 53.2% NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination 20 mg diarrhoea 66.7% dyspnoea 66.7% fatigue 66.7% NCT02718066 · Phase 1/2 · registry result, not featured evidence · combination 0.009 mg/kg q3w + 360 mg q3w pyrexia 100% rash 100% chills 66.7% NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 0.006 mg/kg q3w + 240 mg q2w arthralgia 100% fatigue 100% headache 100% NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 0.006 mg/kg q2w + 240 mg q2w chills 100% pyrexia 100% back pain 66.7% NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 0.006 mg/kg q3w + 360 mg q3w fatigue 76% chills 64% cough 60% NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 0.006 mg/kg q3w + 360 mg q3w fatigue 50.6% pyrexia 47.9% nausea 40.1% NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 0.003 mg/kg q2w + 240 mg q2w chills 100% nasal congestion 100% arthralgia 66.7% NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination fatigue 90% diarrhoea 80% nausea 80% NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination diarrhoea 75% influenza like illness 75% pruritus 75% NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination decreased appetite 100% fatigue 100% influenza like illness 100% NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination fatigue 78.9% influenza like illness 68.4% nausea 57.9% NCT02983045 · Phase 1/2 · registry result, not featured evidence · combination 3.2/4 mg anaemia 80% decreased appetite 80% fatigue 80% NCT02009449 · Phase 1 · registry result, not featured evidence 3.2/4 mg fatigue 100% anaemia 80% headache 60% NCT02009449 · Phase 1 · registry result, not featured evidence · combination 1.6/2 mg anaemia 75.2% fatigue 59% thrombocytopenia 59% NCT02009449 · Phase 1 · registry result, not featured evidence 1.6/2 mg fatigue 85.3% anaemia 76.5% thrombocytopenia 58.8% NCT02009449 · Phase 1 · registry result, not featured evidence · combination 1.6/2 mg anaemia 68.4% fatigue 59.6% cough 42.1% NCT02009449 · Phase 1 · registry result, not featured evidence · combination 0.8/1 mg anaemia 83.3% constipation 66.7% decreased appetite 66.7% NCT02009449 · Phase 1 · registry result, not featured evidence 0.8/1 mg fatigue 88.9% nausea 83.3% anaemia 77.8% NCT02009449 · Phase 1 · registry result, not featured evidence · combination 0.8/1 mg anaemia 83.3% thrombocytopenia 66.7% fatigue 50% NCT02009449 · Phase 1 · registry result, not featured evidence · combination 0.8/1 mg anaemia 83.3% fatigue 66.7% thrombocytopenia 66.7% NCT02009449 · Phase 1 · registry result, not featured evidence · combination 0.8/1 mg fatigue 100% decreased appetite 66.7% lipase increased 50% NCT02009449 · Phase 1 · registry result, not featured evidence · combination 0.8/1 mg fatigue 85.7% thrombocytopenia 71.4% anaemia 57.1% NCT02009449 · Phase 1 · registry result, not featured evidence · combination 0.8/1 mg activated partial thromboplastin time prolonged 100% alanine aminotransferase increased 100% anaemia 100% NCT02009449 · Phase 1 · registry result, not featured evidence · combination 0.8/1 mg anaemia 100% fatigue 100% thrombocytopenia 100% NCT02009449 · Phase 1 · registry result, not featured evidence · combination 0.4/0.5 mg anaemia 83.3% fatigue 83.3% nausea 83.3% NCT02009449 · Phase 1 · registry result, not featured evidence 0.4/0.5 mg anaemia 100% dyspnoea 66.7% fatigue 66.7% NCT02009449 · Phase 1 · registry result, not featured evidence · combination 0.4/0.5 mg thrombocytopenia 100% fatigue 66.7% anaemia 33.3% NCT02009449 · Phase 1 · registry result, not featured evidence · combination 0.4/0.5 mg fatigue 100% anaemia 80% hypokalaemia 60% NCT02009449 · Phase 1 · registry result, not featured evidence · combination 0.2/0.25 mg anaemia 50% fatigue 50% injection site erythema 50% NCT02009449 · Phase 1 · registry result, not featured evidence 0.2/0.25 mg asthenia 100% neutropenia 100% spermatic cord disorder 100% NCT02009449 · Phase 1 · registry result, not featured evidence · combination 0.08/0.1 mg injection site erythema 75% abdominal distension 50% abdominal pain 50% NCT02009449 · Phase 1 · registry result, not featured evidence 280 mg PO BID aspartate aminotransferase increased 14.3% cough 14.3% fatigue 14.3% NCT03229278 · Phase 1 · registry result, not featured evidence · combination 140 mg / 280 mg anemia 66.7% back pain 66.7% diarrhea 66.7% NCT03229278 · Phase 1 · registry result, not featured evidence · combination 140 mg PO BID lipase increased 66.7% alkaline phosphatase increased 33.3% anorexia 33.3% NCT03229278 · Phase 1 · registry result, not featured evidence · combination 140 mg PO daily hepatobiliary disorders - other, specify 100% abdominal pain 66.7% back pain 66.7% NCT03229278 · Phase 1 · registry result, not featured evidence · combination 6 mg/kg + 3 mg/kg Q2W fatigue 100% dehydration 83.3% periorbital oedema 83.3% NCT02526017 · Phase 1 · registry result, not featured evidence · combination 6 mg/kg Q2W aspartate aminotransferase increased 60% blood creatine phosphokinase increased 40% fatigue 40% NCT02526017 · Phase 1 · registry result, not featured evidence 4 mg/kg + 3 mg/kg Q2W fatigue 55.8% blood creatine phosphokinase increased 47.2% periorbital oedema 46% NCT02526017 · Phase 1 · registry result, not featured evidence · combination 4 mg/kg + 3 mg/kg Q3W candida infection 40% dizziness 40% fall 40% NCT02526017 · Phase 1 · registry result, not featured evidence · combination 4 mg/kg Q2W abdominal pain 45.5% aspartate aminotransferase increased 45.5% fatigue 45.5% NCT02526017 · Phase 1 · registry result, not featured evidence 2 mg/kg + 3 mg/kg Q2W amylase increased 33.3% arthralgia 33.3% aspartate aminotransferase increased 33.3% NCT02526017 · Phase 1 · registry result, not featured evidence · combination 2 mg/kg Q2W fatigue 66.7% blood alkaline phosphatase increased 33.3% blood bilirubin increased 33.3% NCT02526017 · Phase 1 · registry result, not featured evidence 1 mg/kg + 3 mg/kg Q2W anaemia 50% amylase increased 25% aspartate aminotransferase increased 25% NCT02526017 · Phase 1 · registry result, not featured evidence · combination | 300 mg BID + 200 mg Q3Wf fatigue 65% nausea 55% vomiting 50% NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination show 31 more results100 mg BID + 200 mg Q3W fatigue 50% back pain 38.9% diarrhoea 38.9% NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination 100 mg BID + 200 mg Q3W fatigue 48.4% nausea 30.1% cough 26.2% NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination 50 mg BID + 200 mg Q3W fatigue 65% arthralgia 45% nausea 45% NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination 25 mg BID + 200 mg Q3W arthralgia 100% constipation 75% cough 75% NCT02178722 · Phase 1/2 · registry result, not featured evidence · combination 3.2/4 mg anaemia 80% decreased appetite 80% fatigue 80% NCT02009449 · Phase 1 · registry result, not featured evidence 3.2/4 mg fatigue 100% anaemia 80% headache 60% NCT02009449 · Phase 1 · registry result, not featured evidence · combination 1.6/2 mg anaemia 75.2% fatigue 59% thrombocytopenia 59% NCT02009449 · Phase 1 · registry result, not featured evidence 1.6/2 mg fatigue 85.3% anaemia 76.5% thrombocytopenia 58.8% NCT02009449 · Phase 1 · registry result, not featured evidence · combination 1.6/2 mg anaemia 68.4% fatigue 59.6% cough 42.1% NCT02009449 · Phase 1 · registry result, not featured evidence · combination 0.8/1 mg anaemia 83.3% constipation 66.7% decreased appetite 66.7% NCT02009449 · Phase 1 · registry result, not featured evidence 0.8/1 mg fatigue 88.9% nausea 83.3% anaemia 77.8% NCT02009449 · Phase 1 · registry result, not featured evidence · combination 0.8/1 mg anaemia 83.3% thrombocytopenia 66.7% fatigue 50% NCT02009449 · Phase 1 · registry result, not featured evidence · combination 0.8/1 mg anaemia 83.3% fatigue 66.7% thrombocytopenia 66.7% NCT02009449 · Phase 1 · registry result, not featured evidence · combination 0.8/1 mg fatigue 100% decreased appetite 66.7% lipase increased 50% NCT02009449 · Phase 1 · registry result, not featured evidence · combination 0.8/1 mg fatigue 85.7% thrombocytopenia 71.4% anaemia 57.1% NCT02009449 · Phase 1 · registry result, not featured evidence · combination 0.8/1 mg activated partial thromboplastin time prolonged 100% alanine aminotransferase increased 100% anaemia 100% NCT02009449 · Phase 1 · registry result, not featured evidence · combination 0.8/1 mg anaemia 100% fatigue 100% thrombocytopenia 100% NCT02009449 · Phase 1 · registry result, not featured evidence · combination 0.4/0.5 mg anaemia 83.3% fatigue 83.3% nausea 83.3% NCT02009449 · Phase 1 · registry result, not featured evidence 0.4/0.5 mg anaemia 100% dyspnoea 66.7% fatigue 66.7% NCT02009449 · Phase 1 · registry result, not featured evidence · combination 0.4/0.5 mg thrombocytopenia 100% fatigue 66.7% anaemia 33.3% NCT02009449 · Phase 1 · registry result, not featured evidence · combination 0.4/0.5 mg fatigue 100% anaemia 80% hypokalaemia 60% NCT02009449 · Phase 1 · registry result, not featured evidence · combination 0.2/0.25 mg anaemia 50% fatigue 50% injection site erythema 50% NCT02009449 · Phase 1 · registry result, not featured evidence 0.2/0.25 mg asthenia 100% neutropenia 100% spermatic cord disorder 100% NCT02009449 · Phase 1 · registry result, not featured evidence · combination 0.08/0.1 mg injection site erythema 75% abdominal distension 50% abdominal pain 50% NCT02009449 · Phase 1 · registry result, not featured evidence 280 mg PO BID aspartate aminotransferase increased 14.3% cough 14.3% fatigue 14.3% NCT03229278 · Phase 1 · registry result, not featured evidence · combination 140 mg / 280 mg anemia 66.7% back pain 66.7% diarrhea 66.7% NCT03229278 · Phase 1 · registry result, not featured evidence · combination 140 mg PO BID lipase increased 66.7% alkaline phosphatase increased 33.3% anorexia 33.3% NCT03229278 · Phase 1 · registry result, not featured evidence · combination 140 mg PO daily hepatobiliary disorders - other, specify 100% abdominal pain 66.7% back pain 66.7% NCT03229278 · Phase 1 · registry result, not featured evidence · combination 100 mg diarrhoea 25.2% constipation 23.6% fatigue 23.6% NCT02903914 · Phase 1 · registry result, not featured evidence · combination 75 mg aspartate aminotransferase increased 21.4% back pain 21.4% fatigue 21.4% NCT02903914 · Phase 1 · registry result, not featured evidence · combination 50 mg fatigue 37.5% diarrhoea 25% decreased appetite 18.8% NCT02903914 · Phase 1 · registry result, not featured evidence · combination |
Notes
- aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- bTrial phases differ: Phase 1 versus Phase 1/2.
- cPopulation context differs: registered conditions differ.
- dThe assessment timepoint is not available for both results.
- ePopulation comparability has not been reviewed for both studies.
- fPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Nivolumab
show 2 more results
show 2 more results
show 7 more results
show 7 more results
Pembrolizumab
show 3 more results
show 3 more results
Metastatic Colorectal Cancer
Shared mechanism: PD-1 · full Metastatic Colorectal Cancer pipeline
Nivolumab
Marketed by Bristol-Myers Squibb and partners
NCT02060188 · Phase 2 · completed
The study was non-randomized, unblinded, and had no comparator arm; its 385 participants were distributed across multiple treatment cohorts, including small cohorts. The primary endpoint was investigator-assessed tumor response, and although results were posted, there was no controlled primary comparison to determine whether nivolumab improved outcomes.
Next expected readout: December 2027 · NCT04017650 (registry estimate)
No aligned efficacy figure on record for this race.
Pembrolizumab
Marketed by Merck & Co.
NCT02460198 · Phase 2 · completed
The study treated 124 participants with pembrolizumab in a non-randomized, open-label, single-group design without a placebo or active comparator. Although the primary endpoint was an objective tumor response measure assessed by central imaging, the study had no formal between-group comparison and therefore provides limited evidence of pembrolizumab’s comparative benefit.
Next expected readout: December 2026 · NCT04140526 (registry estimate)
Reported efficacy
Objective Response Rate (ORR) - Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1) Assessed by Central Imaging Vendor (Up to approximately 48 months): Objective Response Rate (ORR) - Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1) Assessed by Central Imaging Vendor (Up to approximately 48 months): Cohort A - Pembrolizumab 200 mg 32.8 Percentage of participants (95% CI 21.3 to 46) | Cohort B - Pembrolizumab 200 mg 34.9 Percentage of participants (95% CI 23.3 to 48) (not_applicable)
Result source: NCT02460198
Results for Metastatic Colorectal Cancer
There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.
Nivolumab: registry results are on file for Metastatic Colorectal Cancer, but their comparison mappings are not yet available.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
Esophageal Squamous Cell Carcinoma
Shared mechanism: PD-1 · full Esophageal Squamous Cell Carcinoma pipeline
Nivolumab
Marketed by Bristol-Myers Squibb and partners
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: February 2027 · NCT06047379 (registry estimate)
No aligned efficacy figure on record for this race.
Pembrolizumab
Marketed by Merck & Co.
NCT03189719 · Phase 3 · completed
KEYNOTE-590 was a randomized, double-blind, placebo-controlled Phase 3 in 749 patients with advanced esophageal or gastroesophageal junction carcinoma. Its primary endpoints, overall and progression-free survival, are clinical outcomes and were met. The benefit was concentrated in PD-L1 CPS >=1 tumours, and the sources read give no power calculation, so the grade is moderate.
Next expected readout: December 2026 · NCT06907602 (registry estimate)
Reported efficacy
Overall Survival (OS) in Participants With Esophageal Squamous Cell Carcinoma (ESCC) Whose Tumors Are Programmed Cell Death-Ligand 1 (PD-L1) Biomarker-Positive (Combined Positive Score [CPS] ≥10) (Up to approximately 34 months); OS in Participants With ESCC (Up to approximately 34 months); OS in Participants Whose Tumors Are PD-L1 Biomarker-Positive (CPS ≥10) (Up to approximately 34 months); OS in All Participants (Up to approximately 34 months); Progression-free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) As Assessed By Investigator in Participants With ESCC (Up to approximately 34 months); PFS Per RECIST 1.1 As Assessed By Investigator in Participants Whose Tumors Are PD-L1 Biomarker-Positive (CPS ≥10) (Up to approximately 34 months); PFS Per RECIST 1.1 As Assessed By Investigator in All Participants (Up to approximately 34 months): Primary endpoints, overall survival and progression-free survival: pembrolizumab plus cisplatin/fluorouracil improved both vs placebo plus chemotherapy; the label restricts use to PD-L1 CPS >=1, as an exploratory CPS <1 analysis showed OS HR 0.96 (KEYTRUDA label, KEYNOTE-590). (met)
Result source: NCT03189719
Results for Esophageal Squamous Cell Carcinoma
There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.
Nivolumab: registry results are on file for Esophageal Squamous Cell Carcinoma, but their comparison mappings are not yet available.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Nivolumab's landscape · Pembrolizumab's landscape